---
document_datetime: 2023-09-21 20:13:24
document_pages: 65
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/darzalex-h-c-4077-ii-0029-epar-assessment-report-variation_en.pdf
document_name: darzalex-h-c-4077-ii-0029-epar-assessment-report-variation_en.pdf
version: success
processing_time: 118.9591085
conversion_datetime: 2025-12-14 23:32:30.011041
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

17 October 2019 EMA/CHMP/622108/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Darzalex

International non-proprietary name: daratumumab

Procedure No. EMEA/H/C/004077/II/0029

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 5                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................5 |                                                                                                            |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................5                                                  |
| 2. Scientific discussion................................................................................                   | 6                                                                                                          |
| 2.1. Introduction                                                                                                          | ........................................................................................................6  |
| 2.2. Non-clinical aspects..............................................................................................7   |                                                                                                            |
| 2.3. Clinical aspects                                                                                                      | ....................................................................................................7      |
| 2.3.1. Introduction......................................................................................................7 |                                                                                                            |
| 2.3.2. Pharmacokinetics                                                                                                    | ..............................................................................................8            |
| 2.3.3. Pharmacodynamics..........................................................................................          | 11                                                                                                         |
| 2.3.4. Discussion on clinical pharmacology...................................................................              | 14                                                                                                         |
| 2.3.5. Conclusions on clinical pharmacology.................................................................               | 15                                                                                                         |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 15      |
| 2.4.1. Dose response study(ies) .................................................................................          | 15                                                                                                         |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 15   |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 35                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................           | 35                                                                                                         |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 35    |
| 2.6. Discussion on clinical safety.................................................................................        | 57                                                                                                         |
| 2.6.1. Conclusions on clinical safety............................................................................          | 58                                                                                                         |
| 2.6.2. PSUR cycle                                                                                                          | ..................................................................................................... 58   |
| 2.7. Risk management plan                                                                                                  | ....................................................................................... 58                 |
| 2.8. Update of the Product information........................................................................             | 62                                                                                                         |
| 2.8.1. User consultation                                                                                                   | ............................................................................................ 62            |
| 3. Benefit-Risk Balance.............................................................................                       | 62                                                                                                         |
| 3.1. Therapeutic Context ...........................................................................................       | 62                                                                                                         |
| 3.1.1. Disease or condition                                                                                                | ........................................................................................ 62                |
| 3.1.2. Available therapies and unmet medical need.......................................................                   | 62                                                                                                         |
| 3.1.3. Main clinical studies.........................................................................................      | 62                                                                                                         |
| 3.2. Favourable effects..............................................................................................      | 62                                                                                                         |
| 3.3. Uncertainties and limitations about favourable effects.............................................                   | 63                                                                                                         |
| 3.4. Unfavourable effects...........................................................................................       | 63                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ......................................... 63                                                               |
| 3.6. Effects Table......................................................................................................   | 63                                                                                                         |
| 3.7. Benefit-risk assessment and discussion.................................................................               | 64                                                                                                         |
| 3.7.1. Importance of favourable and unfavourable effects..............................................                     | 64                                                                                                         |
| 3.7.2. Balance of benefits and risks ............................................................................          | 64                                                                                                         |
| 3.8. Conclusions                                                                                                           | ....................................................................................................... 64 |
| 4. Recommendations.................................................................................                        | 64                                                                                                         |
| 5. EPAR changes                                                                                                            | ....................................................................................... 65                 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADR

adverse drug reaction

ALP

alkaline phosphatase

ALT

alanine aminotransferase

ASCT

autologous stem cell transplant

AST

aspartate aminotransferase

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

CL

clearance

Cmax

maximum concentration

CR

complete response

CRAB

calcium elevation, renal insufficiency, anemia, and bone abnormalities

CrCL

creatinine clearance

DILI

drug-induced liver injury

DOR

duration of response

DRd

daratumumab, lenalidomide, and dexamethasone

DVMP

daratumumab, bortezomib, melphalan, and prednisone

ECOG

Eastern Cooperative Oncology Group

ESMO

European Society for Medical Oncology

FISH

fluorescent in situ hybridization

HDT

high-dose chemotherapy

HR

hazard ratio

HRQoL

health-related quality of life

ICH

International Conference on Harmonisation

IDMC

Independent Data Monitoring Committee

IMiD

immunomodulatory drug

IMWG

International Myeloma Working Group

IRR

infusion-related reaction

ISS

International Staging System

ITT

intent-to-treat

Km

Michaelis-Menten constant

MoA

mechanism of action

MPT

melphalan, thalidomide, and prednisone

MRD

minimal residual disease

NCCN

National Comprehensive Cancer Network

ORR

overall response rate

OS

overall survival

PFS

progression-free survival

PFS2

progression-free survival on next line of therapy

PI

proteasome inhibitor

PRO

patient-reported outcome

Q

intercompartmental clearance

Rd

lenalidomide and dexamethasone

sCR

stringent complete response

SD

standard deviation

SOC

system organ class

SPM

secondary primary malignancies

<div style=\"page-break-after: always\"></div>

| SWOG   | Southwest Oncology Group                             |
|--------|------------------------------------------------------|
| TEAE   | treatment-emergent adverse event                     |
| ULN    | upper limit of normal                                |
| US     | United States                                        |
| V 1    | volume of distribution in the central compartment    |
| V 2    | volume of distribution in the peripheral compartment |
| VAS    | Visual Analogue Scale                                |
| VGPR   | very good partial response                           |
| V max  | maximum velocity of the nonlinear clearance process  |
| VMP    | bortezomib, melphalan, and prednisone                |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Janssen-Cilag International NV submitted to the European Medicines Agency on 22 March 2019 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT) for Darzalex; as a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 6.1 has also been submitted.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

Darzalex was designated as an orphan medicinal product EU/3/13/1153 on 24 May 2016. Darzalex was designated as an orphan medicinal product in the following indication: treatment of plasma cell myeloma.

The new indication, which is the subject of this application, falls within the above mentioned orphan designation.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0264/2017 on the granting of a (product-specific) waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Protocol assistance

The MAH received Protocol Assistance from the CHMP.

## Scientific Advice

The MAH received scientific advice from the CHMP in 2014 (EMEA/H/SA/2456/3/2014/PA/III). The CHMP agreed to study design, treatment regimens and endpoints for the pivotal study MMY3008.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

Jorge Camarero Jiménez

<div style=\"page-break-after: always\"></div>

| Timetable                                                                                                          | Actual dates      |
|--------------------------------------------------------------------------------------------------------------------|-------------------|
| Submission date                                                                                                    | 22 March 2019     |
| Start of procedure:                                                                                                | 27 April 2019     |
| CHMP Co-Rapporteur Assessment Report                                                                               | 3 July 2019       |
| CHMP Rapporteur Assessment Report                                                                                  | 21 June 2019      |
| PRAC Rapporteur Assessment Report                                                                                  | 21 June 2019      |
| Updated PRAC Rapporteur Assessment Report                                                                          | 4 July 2019       |
| PRAC Outcome                                                                                                       | 11 July 2019      |
| CHMP members comments                                                                                              | 15 July 2019      |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                                                               | 19 July 2019      |
| Request for supplementary information (RSI)                                                                        | 25 July 2019      |
| CHMP Rapporteur Assessment Report                                                                                  | 19 September 2019 |
| PRAC Rapporteur Assessment Report                                                                                  | 26 September 2019 |
| PRAC members comments                                                                                              | n/a               |
| Updated PRAC Rapporteur Assessment Report                                                                          | n/a               |
| PRAC Outcome                                                                                                       | 3 October 2019    |
| CHMP members comments                                                                                              | 7 October 2019    |
| Updated CHMP Rapporteur Assessment Report                                                                          | 10 October 2019   |
| Opinion                                                                                                            | 17 October 2019   |
| The CHMP adopted a report on similarity of Darzalex with Imnovid, Farydak, Kyprolis and Ninlaro on 17 October 2019 | 17 October 2019   |

## 2. Scientific discussion

## 2.1. Introduction

Multiple myeloma, a malignant disorder of the plasma cells characterized by uncontrolled and progressive proliferation of a plasma cell clone, is estimated to represent 0.8% of all cancers worldwide. The proliferation of myeloma cells causes displacement of normal bone marrow haematopoietic precursors and the overproduction of M-proteins. Characteristic hallmarks of multiple myeloma include osteolytic lesions, anaemia, increased susceptibility to infections, hypercalcaemia, renal insufficiency or failure, and neurological complications.

While OS rates for multiple myeloma have improved significantly over the last decade due to the availability of effective new therapies, it remains an incurable disease. Based on the revised International Staging System (R-ISS), the 5-year OS is 82% for R-ISS stage I, 62% for R-ISS stage II and 40% for R-ISS stage III. Median OS time was not reached for patients with R-ISS stage I and was of 83 and 43 months for R-ISS stage II and R-ISS stage III patients, respectively 1 . Patients with newly diagnosed multiple myeloma are typically categorized into 2 subpopulations defined by their age, comorbidity and suitability for intensive treatment. For patients who are considered fit, an induction regimen followed by high-dose chemotherapy (HDT) and ASCT is considered the standard of care according to both US (National Comprehensive Cancer

1  Palumbo A,  Avet-Loiseau H,  Oliva S et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015; 33: 2863-2869.

<div style=\"page-break-after: always\"></div>

Network [NCCN]) and European Society for Medical Oncology [ESMO]) guidelines, and this therapeutic approach is customarily limited to younger patients. For patients considered ineligible for HDT and ASCT due to their age, presence of comorbidities, and/or physical status, the treatment approach often favours longer, less intensive/toxic treatments.

The coexistence of different tumor subclones at baseline displaying different drug sensitivities ultimately contributes to the development of drug resistance and disease progression (Barlogie 2014). Because combination regimens comprised of agents with non-overlapping and synergistic mechanisms of action target multiple pathways in multiple myeloma cells, they are more likely to overcome intratumoral clonal heterogeneity than single agent or doublet approaches. Thus, triple or quadruple drug regimens have become standard of care for newly diagnosed multiple myeloma (Kumar 2018; Moreau 2017).

Elderly patients are generally not considered eligible for HDT and ASCT due to increased comorbidities which increase the risk of complications, morbidity and mortality. This is particularly notable as multiple myeloma is disproportionately detected in older adults, the majority of whom are older than 65 years at the time of diagnosis (median age at diagnosis: 72 years). Furthermore, comorbidities such as renal dysfunction are present at initial diagnosis in a significant proportion of patients with multiple myeloma (12% to 30%).

Daratumumab is a targeted immunotherapy that binds with high affinity to tumor cells that overexpress CD38, a transmembrane glycoprotein. Combining daratumumab with Rd in patients with newly diagnosed multiple myeloma who are not eligible for ASCT is supported by the approved use of Rd for this indication as well as the approved use of DRd in the relapsed/refractory setting.

The current submission is supported by the Phase 3 study MMY3008 where DRd was compared to Rd for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for ASCT.

The following new indication is proposed:

DARZALEX is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

<div style=\"page-break-after: always\"></div>

## · Tabular overview of clinical studies

<!-- image -->

| Shudy Idenhification Fist Subject First Visit/ Completion date (Day Month Yer) Shudy Stahus   | Phase Shudy Description/Desig, Study Population Key Objechive()                                                                                                                                                                                                                                                                                                                                              | Shudy Drug(s): Fommulation (Route of Adminishation) Dose Regimen Duuahion of Treatuent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Number of Subjects in the SCS (by Treatment Group)   |
|-----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|
| Phase 3 Study                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                      |
| 54767414MMY300S 24 September 2018 (cutoff for interim analysis) Ongoing                       | Phase 3 Open-label, randomized Subjects with newly diagnosed mltiple myeloma who are ineligible for high dose chemotherapy and ASCT To compare the efficacy (PFS) of DRd coupared with Rd and to evaluate safety/tolerrbility and clinical outcomes of DRd compared with Rd including: TIP, CR rate, MRD negativity rate, OS, and sCR rate (additional objectives are listed in the CSR)(Mod5.3.5.1/MMY3008) | Treahment Group A: LenalidomidePO at 25mg' on Days 1-21 of each 28-day cycle, Dexamethasone PO or IV at 40 mg once a Week (Days 1, 8, 15, 22 ofeach 28·day cycle). Trealment Group B: Darahumumab IV at 16 mg/kg; once every week for 8 weeks (Cycles 1-2), then, every other week for 16 additional doses (Cycles 3-6), and then, every 4 weeks (Cycle 7 and beyond) umhil disease progression or uacceptable toxicity. Lenalidomide PO at 25 mg on Days 1-21 of each 28-day cycle. Dexamethasone PO orIVat 40 mgonce a week (Days 1, 8, 15, 22 of each 28-day cycle). | Rd: 365 DRd: 364                                     |

ASCT=autologous Stem cell transplant: CR=complete response: CSR=clinical shudy report: DRd=darahumumab in combination with lenalidomide and dexamethasone: IV=intravenous; MRD=mininnl residual disease: OS=overall survival: PFS=progression-free suvival: PO=by mouth; Rd=lenalidomide-dexamethasone; sCR=stringent complete response; TTP=time to disease progression

'For subjecis with a creatinine clearance behween 30 and 50 mL/osin, the dose of lenalidomide was recommended to be 10 mg every 24 hous.

* For subjects &gt;75 yeaurs of age or with BMI ~18.5, dexamethasone could be administered at a dose of20 mg weekly.

## 2.3.2. Pharmacokinetics

## Absorption

Absorption  data  are  not  available  because  all  studies  in  this  and  prior  submissions  administered daratumumab as an IV infusion.

## Distribution

The mean±SD volume of distribution in subjects who received 16 mg/kg was 90.19±43.40 mL/kg after the first dose and 59.51±54.68 mL/kg following repeat dosing (Study GEN501); Japanese subjects receiving 16 mg/kg exhibited a similar volume of distribution of 57.97±3.29 mL/kg (Study MMY1002). As described by the monotherapy PPK model, the estimate for the central volume of distribution is 56.98±18.07 mL/kg. Overall, these data suggest that daratumumab is primarily localized to the vascular system with limited extravascular tissue distribution

## Elimination

As shown previously in the monotherapy studies, daratumumab clearance decreased with increasing dose and with multiple doses. After the first infusion, mean clearance decreased from 1.06 mL/h/kg in the 2 mg/kg group to 0.29 mL/h/kg in the 24 mg/kg group; after repeat dosing, clearance decreased from 0.59 mL/h/kg (n=1) in the 2 mg/kg group to 0.16 mL/h/kg in the 24 mg/kg group. Following the first administration at the approved dose of 16 mg/kg, clearance was 0.42±0.42 mL/h/kg and the t1/2 was 216±104 hours (9.0±4.3 days). Following repeated administration of 16 mg/kg, daratumumab clearance decreased to 0.30±0.12 mL/h/kg and t1/2 increased to 255±216 hours (10.6±9.0 days).

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependencies

## Dose proportionality

Following the first administration of daratumumab ranging from 0.005 to 24 mg/kg, Cmax increased in an approximately dose-proportional manner for doses ≥ 1 mg/kg. After repeat dosing, Cmax increased in a greater than dose-proportional manner. AUC also increased in a greater than dose-proportional manner after both the first and last dose. Consistent with the monotherapy data, Cmax following the first infusion increased in approximate proportion to the increasing daratumumab dose of 2 to 16 mg/kg daratumumab and AUClast increased in a greater than dose-proportional manner after the first dose. These findings are consistent with target-mediated clearance.

As reported for monotherapy, mean clearance following the first dose decreased with increasing dose, from 1.50±0.96 mL/h/kg in the 1 mg/kg cohort to 0.29±0.15 mL/h/kg in the 24 mg/kg cohort. This trend for decreasing  clearance  with  increased  dose  was  also  evident  following  repeat  dosing,  from  6.72±6.18 mL/h/kg  in  the  0.5  mg/kg  cohort  to  0.16±0.08  mL/h/kg  in  the  24  mg/kg  cohort.  Following  the  first administration at the approved dose of 16 mg/kg, clearance was 0.32±0.13 mL/h/kg and 0.10 mL/h/kg in the 1 subject with the parameter estimated after repeat dosing.

## Time Dependency

Clearance of daratumumab also decreased with multiple doses in the monotherapy studies: after the first infusion, mean clearance decreased from 1.06 mL/h/kg in the 2 mg/kg group to 0.29 mL/h/kg in the 24 mg/kg group; after the last infusion, mean clearance decreased from 0.59 mL/h/kg in the 2 mg/kg group to 0.16 mL/h/kg in the 24 mg/kg group. Following the first administration at the approved dose of 16 mg/kg, clearance was 0.32±0.13 mL/h/kg (mean±SD) and 0.10 mL/h/kg in the 1 subject with the parameter estimated after repeat dosing.

## Comparison of DRd Combination in MMY3008 and Previous Monotherapy and Combination Therapies

Comparison of Cmax (Cycle 1 Day 1) and Ctrough during every-2-week (Cycle 6 Day 1) and every-4-week (Cycle 12 Day 1) dosing was made between the DRd dose regimen from Study MMY3008 (once weekly for 8 weeks, every 2 weeks for 16 weeks, every 4 weeks thereafter) and similar dose regimens from the monotherapy  Study  MMY2002  and  combination  therapy  Studies  GEN503,  MMY1001,  and  MMY3003. Concentrations after administration of the first dose (Cycle 1 Day 1) were similar across monotherapy and combination  therapies.  The  maximal  trough  concentrations  of  daratumumab  were  also  similar  across studies.

## Special populations

No special population studies for hepatic or renal dysfunction with daratumumab have been presented in this application.

## Pharmacokinetic interaction studies

No dedicated clinical drug-drug interaction studies were presented. Since there is no overlapping pathway of elimination,  no  interactions  are  expected  between  daratumumab  and  small-molecule  drugs  including lenalidomide and dexamethasone. This is considered acceptable.

## Population Pharmacokinetic Analysis

A pop-PK model of daratumumab was used to describe the PK characteristics of daratumumab following IV administration  in  combination  with  Rd  and  to  evaluate  the  influence  of  covariates  on  the  exposure  of daratumumab in subjects with newly diagnosed MM who are ineligible for ASCT. In addition, the PK of daratumumab combined with Rd (D-Rd) was compared with that of daratumumab monotherapy studies and the previous combination therapy studies.

<div style=\"page-break-after: always\"></div>

The pop-PK analysis included combined data from a Phase 3 study (MMY3008) and a Phase 1/2 study (GEN503). GEN503 data were pooled into the analysis dataset to improve the PK parameter estimates because Study GEN503 included a wider dose range (2 to 16 mg/kg) and a more intensive PK sampling scheme.  Both  Studies  MMY3008  and  GEN503  shared  the  same  background  therapy  and  similar concentration-time profiles were observed in these 2 studies.

## Effects of Covariates

Body Weight: When daratumumab was administered on a mg/kg basis, no clinically important differences (ie, &lt;20%) in the exposure to daratumumab were observed in subjects with a low body weight (&lt;65 kg, n=102) or high body weight (≥85 kg, n=92) compared to those with a normal body weight (65 to 85 kg, n=161).

Age: No clinically important influence of age on the exposure to daratumumab was observed. There was a 9% decrease in exposu re to daratumumab in older subjects (age ≥75 years, n=153) compared to younger subjects (age &lt;75 years, n=202).

Sex: No clinically important influence of sex on the exposure to daratumumab was observed. The exposure to daratumumab in males was approximately 1% lower than that in females (n=173).

Race:  Because  92%  of  subjects  were  White  and  there  were  only  limited  sample  sizes  in  other  race categories, the effect of race was evaluated as White (n=325) and Non-white (n=30). No clinically important influence of race on the exposure to daratumumab was observed. The exposure to daratumumab in White subjects was approximately 8% higher than in Non-white subjects.

Region: Approximately 28% of subjects were North American. The effect of region was evaluated in North America (n=98) and other regions (n=257). No clinically important influence of region on the exposure to daratumumab was observed. The exposure to daratumumab in North American subjects was approximately 6% lower than that in subjects from other regions.

Renal Impairment: The effect of renal impairment was evaluated in categories of normal renal function (creatinine clearance [CRCL] ≥90 mL/min, n=60), mild renal impairment (60≤ CRCL &lt;90 mL/min, n=141), moderate renal impairment (30≤ CRCL &lt;60 mL/min, n=147), and severe renal impairment (CRCL &lt;30 mL/min; n=7). No clinically important differences (≤13%) in the exposure to daratumumab were observed between subjects with renal impairment and those with normal renal function.

Hepatic Impairment: No subjects had severe hepatic impairment (TB &gt;3× upper limit of normal [ULN] and any AST). As only 1 subject had moderate hepatic impairment (TB &gt;1.5× to 3.0× ULN, as defined using the National Cancer Institute criteria of hepatic dysfunction), this subject was combined with subjects with mild hepatic impairment (TB 1.0× to 1.5× ULN or AST &gt;ULN) in this analysis. The effect of hepatic impairment was evaluated in categories of normal hepatic function (TB and AST ≤ULN, n=323) and mild/moderate hepatic  impairment  (n=31).  The  exposures  to  daratumumab  in  subjects  with  mild/moderate  hepatic impairment were similar to those in subjects with normal hepatic function and were consistent with the findings based on previous studies. No clinically important differences in the exposure to daratumumab (-3%) were observed between subjects with hepatic impairment and those with normal hepatic function as found in the monotherapy or the previous combination therapy study populations.

Baseline  Albumin:  No  clinically  important  differences  in  the  exposure  to  daratumumab  were  observed between  subjects  with  abnormal  albumin  and  those  with  normal  albumin  level.  The  exposure  to daratumumab was 6% lower in subjects with abnormal albumin level (&lt;35 g/L; n=142) compared with subjects who h ad normal albumin level (≥35 g/L; n=213).

Type  of  Myeloma:  No  clinically  important  differences  in  the  exposure  to  daratumumab  were  observed between  subjects  with  IgG  myeloma  and  non-IgG  myeloma.  The  exposure  to  daratumumab  was approximately 18% lower in subjects with IgG myeloma (n=232) compared with subjects with non-IgG myeloma (n=123), consistent with previous study results.

ECOG Score: No clinically important differences in the exposure to daratumumab (≤7%) were observed between subjects with ECOG score s of 1 (n=170) or ≥2 (n=59) and those with ECOG scores of 0 (n=126).

<div style=\"page-break-after: always\"></div>

Immunogenicity: All  immunogenicity-evaluable subjects (n=338) in the PPK analysis were negative for anti-daratumumab antibodies. Immunogenicity-evaluable subjects were defined as subjects who received at least 1 dose of daratumumab and had at least 1 postinfusion sample for detection of anti-daratumumab antibodies.

## 2.3.3. Pharmacodynamics

## Mechanism of action

No new data on the mechanism of action has been presented in this application.

Daratumumab is a human IgG mAb that binds with high affinity to CD38, a transmembrane glycoprotein expressed on tumor cells, and induces tumor cell death through multiple mechanisms of action. These mechanisms  of  action  include  several  immune-mediated  activities,  including  complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and direct cytotoxicity by induction of apoptosis by Fc gamma receptor mediated crosslinking of tumor-bound mAbs (Overdijk 2016). Translational biomarker studies of samples from subjects treated with daratumumab in Phase  1  and  Phase  2  studies  (Studies  GEN501  and  MMY2002,  respectively)  have  revealed  previously unknown immunomodulatory effects of daratumumab (Krejcik 2016). Daratumumab leads to the rapid and sustained  elimination  of  highly  immunosuppressive  subsets  of  CD38+  regulatory  T  cells,  CD38+ myeloid-derived suppressor cells, and CD38+ regulatory B cells (Krejcik 2016). The elimination of these immunosuppressive  cells,  modulation  of  CD38  enzymatic  activity,  and  destruction  of  the  malignant myeloma  cells  are  thought  to  lead  to  the  clonal  expansion  of  CD8+  and  CD4+  T  cells  (Chiu  2016). Altogether, daratumumab's converging mechanisms of actions are hypothesized to synergistically lead to the deep responses observed in patients.

## Primary and secondary pharmacology

## Primary pharmacology

## Exploratory Exposure-response Analysis

Exposure-response (E-R) relationships were investigated based on the simulated daratumumab exposure metric data from Study MMY3008 using the pop-PK model. Since all subjects in the D-Rd group received the recommended dose of 16 mg/kg, there is limited exposure variation for daratumumab and, therefore, only exploratory and graphic E-R analyses were performed for selected efficacy endpoints and AEs.

## Progression-free Survival

An apparent maximal effect (Emax) relationship was observed between the relative hazard of progression or death and daratumumab systemic exposures. The relative hazard for progression or death decreased rapidly with increasing daratumumab systemic exposure. When the first peak exposures reached the first quartile (Q1) (232 μg/mL), the risk (compared to the control Rd group) was reduced by approximate 50% for PFS, indicating that the maximum effect on PFS had been attained for the majority of the subjects at the 16 mg/kg dose with an acceptable safety profile.

<div style=\"page-break-after: always\"></div>

Figure 1: Relative Hazard of PFS at Different Predicted Exposures

<!-- image -->

Abbreviations:ISS=Intemational StagingSystem

Key:The solidred line is thepoint estimate,and gray shaded areas represent 95%confidence interval. Blue vertical dotted lines separate the quartiles ofmaximal trough concenhation（Ccughm),peak and trough concentations after the first dose (Cand Cu,espectively).The control group in each study was used as the reference (ie, Cuohms=0).Hazard ratio and its 95% confidence interval were estimated based on stratified Cox regression models.The stratification factors included ISS staging (III),region (North Amenica versus other),and age （&lt;75yearsversus≥75years)

The quartiles for Cml were: 1 quaitile（≤1.78E-02μg/mL),2quartile（1.78E-02to25.7μg/mL), 3quatile(25.7 to51.8μg/mL),and4quartile(51.8 to 118μg/mL).

The quartiles for C1 were: 1quartile （232μg/mL), 2quartile (232 to264 μg/mL),3quartile (264 to 290 μg/mL), and 4quartile (290 to 415 μg/mL).

The quartiles for C gm were: 1quartile（≤439 μg/mL),2quartile（439 to570μg/mL),3quartile(570 to 667μg/mL),and 4quartile （667 to 1,030μg/mL).

The improvement in PFS was observed in the majority of the daratumumab-treated subjects (exposure quartiles: Q2-Q4, 75%). In the case-control analysis, the improvement of PFS was apparent in the Q1 DRd match group compared with the Q1 Rd match group for both peak and trough concentrations after the first dose. In addition, the PFS improvement in the Q1 group according to the peak and trough concentration following the first dose appeared comparable to that in the Q2-Q4 groups. The results suggest that, despite trough concentrations following the first dose being close to 0 in Q1 subjects, the PFS improvement in those subjects were similar to that in the Q2-Q4 groups.

<div style=\"page-break-after: always\"></div>

Figure 2 : Kaplan-Meier Curves for the Matched Subgroups (PFS)

<!-- image -->

Abbreviations:DRd=daratumumab-lenalidomide-dexamethasone:Ql=first quartile;

Rd=lenalidomide-dexamethasone.

Note:Maximal troughis theoverallmaximal trough concentration;Firstpeakis end-of-infusionconcentration after thefirst infusion;First trough istroughconcentration afterthefirstinfusion.

In summary, the E-R analysis on efficacy data suggests that the maximum drug effect on PFS had been attained for the majority of the subjects at the studied 16 mg/kg dose and it appears that subjects in the DRd arm of Study MMY3008 benefited from the treatment with daratumumab evidenced by a lower relative risk of disease progression/death across the studied concentration range compared with subjects in the Rd arm.

## Selected Adverse Events

There  was  no  apparent  E-R  relationship  between  Cpeak,  1st  and  IRR,  and  between  Cpeak  max  and thrombocytopenia, anemia, neutropenia, lymphopenia, and infections within the studied drug concentration range. The results were consistent with the clinical analysis where the safety profile is similar between the D-Rd and the Rd arms.

## Secondary pharmacology

## Immunogenicity

No  patients  developed  anti-daratumumab  antibodies  during  Study  MMY3008.  This  confirms  previous findings that the risk of immunogenicity for daratumumab is low.

Table 1 : Summary of Antibody to Daratumumab Status; Immune Response-evaluable Population

|                                                                                                                                             | DRd n (%)                                                                                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis set: immmme response-evaluable                                                                                                     | 338                                                                                                                                         |
| Subjects with appropriate sample                                                                                                            | 338                                                                                                                                         |
| Subjects positive for anthi-darahumumab antibodies be                                                                                       | 0                                                                                                                                           |
| Subjects negahive for anti-darahummumab anhbodies                                                                                           | 338(100.0%)                                                                                                                                 |
| Abbreviations:DRd=darahummumab-lenalidomide-dexamethasone.                                                                                  | Abbreviations:DRd=darahummumab-lenalidomide-dexamethasone.                                                                                  |
| oegsturupe qemmerep tsry naq rege paueiqo sedmes arom ro I peq sdes apeudondde pim salqns. Denominator is subjects with appropniate sample. | oegsturupe qemmerep tsry naq rege paueiqo sedmes arom ro I peq sdes apeudondde pim salqns. Denominator is subjects with appropniate sample. |

<div style=\"page-break-after: always\"></div>

## 2.3.4. Discussion on clinical pharmacology

The clinical pharmacology of daratumumab used as monotherapy is well established. The PK profile for daratumumab when given in combination treatment seems to show a similar pattern to what has been observed in in the monotherapy studies. Clinical pharmacology data for the combination treatment with VMP derive from two clinical studies (MMY3007 and MMY1001) with a total of 353 patients evaluable for PK analyses. Additionally, a pop-PK analysis from Study MMY3008 contributes data. The applied analytical methods for both the statistical analyses and the PK data analysis seem appropriate.

## Pharmacokinetics

Overall, there is no new data with regards to the basic pharmacokinetic properties including absorption, distribution,  metabolism,  elimination  and  excretion.  It  is  supported  that  as  a  mAb,  the  distribution  of daratumumab is primarily localised to the vascular system, and the dose-dependent elimination (nonlinear characteristics) is consistent with target-mediated elimination (where clearance decreases as a function of dose).

The typical pharmacokinetic profile shows similar pattern to what has been observed in in the monotherapy studies. Steady state is reached after approximately 21 weeks (≈5 months) and mean trough concentrations were  375615  μg/mL.  After  approximately  1  yea r,  the  mean  trough  concentrations  dropped  to approximately 250525 μg/mL. The MAH informs that target saturation &gt;90% is maintained at trough concentrations in the majority (&gt;99%) of the patients following the every 4 week dose regimen.

A  logistic  regression  analysis  of  overall  response  rate  and  predicted  maximal  pre-infusion  (trough) daratumumab concentration showed by the initial (monotherapy) PK analysis, that maximal response rate was obtained with daratumumab concentrations around 300 µg/mL and no additional effect was obtained with higher concentrations. The MAH calculated that 90% of the maximal effect on ORR ( )  was achieved when Cpre-infusion,max was 274 µg/mL. From the data presented, it appears that mean trough concentrations are well above the thresholds of 274 µg/mL and 300 µg/mL during the initial 4 weeks' dosing period the first 52 weeks but thereafter, pre-infusion values appear to be slightly lower than the thresholds. Mean concentrations are however well above both thresholds at all time points. Thus, when comparing results  from  the  present  combination  studies  (MMY3007  and  MMY1001)  with  the  results  from  the monotherapy studies, similar mean concentrations after first dose and similar pattern for the subsequent cycles are observed. Therefore, it is concluded that the PK data from the two studies including patients treated with the D-VMP combination are comparable with the data reported from the monotherapy studies. This supports the assumption (based on molecular structures of the agents) that there are no interactions with the combination treatment, and it justifies the use of PK-data from the previous registration studies with daratumumab.

The  pop-PK  analysis  was  based  on  1,635  PK  samples  from  353  PK-evaluable  patients  (all  receiving daratumumab at 16 mg/kg). Initially, the MAH was asked to to discuss the goodness of fit for the updated population PK as several samples are clustered away from the correlation regression line of the population predictions and the conditional weighted residuals showed samples which lie outside the +/- 5 limits. Eta shrinkage was high for V1 and the visual predictive checks showed that the model poorly captured the data variability. In their response, the MAH agreed that the shrinkage on V1 was fairly high (56%), however, the issue will not be pursued. Thus overall, the goodness-of-fit (GOF) plots presented showed an acceptable symmetrical distribution around the unity line, supporting that the applied model is appropriate and the VPCs for the final updated PPK model are considered acceptable and do not indicate any misspecifications.

The impact of covariate effects was analysed using a forest-plot, showing the relative change to reference individual of each selected covariate on pre-infusion levels (trough concentrations). A change greater than ±20% is considered clinically  meaningful.  The impact  of  severe  renal  impairment  versus  normal  renal function patients leads to change between -30% and 9% change in maximal trough concentrations and patients with higher body-weight (85kg) may show an increase in trough concentrations between 11-27% compared to a 65 kg subject. Based on these results, the impact of high body weight and severe renal impairment on trough concentration levels might be of relevance. The MAH was asked to discuss this issue in more detail. Based on their response, it was concluded that the hazard ratio analysis in over-weight patients demonstrates a slight trend in favour of DRd but the 95% CI includes the unity, demonstrating the

<div style=\"page-break-after: always\"></div>

lack of significant effect in this sub-group of population. However, these results seems contradictory with the E-R  analysis  previously  developed,  where  relative  hazard  ratio  was  related  to  maximal  through concentrations, showing that higher through concentrations would lead to a less hazard ratio. The issue will not be pursued. Regarding the patients with severe renal impairment, it is acknowledged that low number of patients with severe renal impairment where recruited in the study and the clinical impact observed in the forest plot could be considered as preliminary.

## Pharmacodynamics

No new data related to mechanism of action or QTc evaluation are presented. This is overall acceptable. No patients developed anti-daratumumab antibodies, which is assuring.

It is reassuring that no patients developed anti-daratumumab antibodies during the present Study MMY3008. This confirms previous findings that the risk of immunogenicity for daratumumab is low. The present combination treatment with D-Rd is not expected to increase the risk of immunogenicity. However, in relation to a Post-Authorisation Measure regarding assay and ADA detection, several concerns regard the adequacy of the assay emerged. The Applicant is encouraged to continue immunogenicity surveillance in coming studies. Especially longer-term exposure could add valuable information to better understand ADA response kinetics by capturing more persistent responses, if any, and to rule out impact on efficacy. The impact of ADA on efficacy will be further investigated in samples from previous studies using a highly sensitive assay.

## 2.3.5. Conclusions on clinical pharmacology

The  new  analyses  presented  do  not  change  the  current  knowledge  on  PK/PD  and  immunogenicity  of daratumumab.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No dedicated dose-response studies were conducted.

In study MMY3008, daratumumab was administered at 16 mg/kg weekly for 8 weeks (for 8 doses), every 2 weeks for 16 weeks (for 8 doses), then every 4 weeks thereafter, which is the approved dose regimen of daratumumab as monotherapy and in combination therapy with Rd in subjects with RRMM.

## 2.4.2. Main study

## Study MMY3008: Randomized, open-label, active controlled, parallel-group, multicentre study in subjects at least 18 years of age with newly diagnosed multiple myeloma who are ineligible for high dose chemotherapy and ASCT

This is a randomized, open-label, active controlled, parallel-group, multicentre study in subjects at least 18 years of age with newly diagnosed multiple myeloma who are not candidates for high dose chemotherapy and ASCT. Approximately 730 subjects were planned to be enrolled in this study with 365 subjects per treatment arm.

<div style=\"page-break-after: always\"></div>

## Methods

Figure 3 : Schematic Overview of Study MMY3008

Screening within 21 days of randomization

<!-- image -->

## Stratificationfactors

- ·Region (NA vs other)

· ISS (I vs II vs II)

- ·Age(&lt;75vs≥75years)

End-of-Treatment Visit (30 days after last dose)  Long Term Follow-up.

BMI=body mass index; CR=complete response; D=daratumumab; d=dexamethasone; ECOG= Eastern Cooperative Oncology Group; ISS=International  Staging  System;  IV=intravenous;  MRD=  minimal  residual  disease;  n=number;  NA=North  America;  NDMM=newly diagnosed  multiple  myeloma;  NGS=next-generation  sequencing;  ORR=overall  response  rate;  OS=overall  survival;  PD=progressive disease;  PFS=progression-free  survival;  PO=per  os;  QW=once  weekly;  Q2W=once  every  2  weeks;  Q4W=once  every  4  weeks; R=lenalidomide; VGPR=very good partial response

- a On days when daratumumab was administered, dexamethasone was administered to patients in the DRd group and served as the treatment dose of steroid for that day, as well as the required pre-infusion medication.
- b For subjects with a creatinine clearance between 30 and 50 mL/min, the dose of lenalidomide was recommended to be 10 mg every 24 hours.
- c For subjects older than 75 years of age or with BMI &lt;18.5, dexamethasone could be administered at a dose of 20 mg weekly.
- d Efficacy endpoints were sequentially tested in the order shown.

## Study participants

Main inclusion criteria for participation in the study were the following:

- Subject must have documented multiple myeloma satisfying the CRAB (calcium elevation, renal insufficiency, anemia and bone abnormalities) criteria, monoclonal plasma cells in the bone marrow ≥ 10% or presence of a biopsy proven plasmacytoma, and measurable disease.
- -Measurable disease, as assessed by central laboratory, defined by any of the following:
- IgG myeloma: Serum monoclonal paraprotein (M-protein) level ≥ 1.0 g/dL or urine M-protein level ≥ 200 mg/24 hours; or

IgA, IgM, IgD, or IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or

Light  chain  multiple  myeloma  without  measurable  disease  in  serum  or  urine:  Serum immunoglobulin free light chain ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio.

- Newly diagnosed and not considered candidate for high-dose chemotherapy with SCT due to:
- -Being age ≥ 65 years, OR
- -In subjects &lt;65 years: presence of important comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation. Sponsor review and approval of subjects under 65 years of age is required before randomization.

Cycle:28 days

<div style=\"page-break-after: always\"></div>

- Subject must have an ECOG performance status score of 0, 1, or 2

Main exclusion criteria were:

- Subject  has  a  diagnosis  of  primary  amyloidosis,  monoclonal  gammopathy  of  undetermined significance, or smoldering multiple myeloma. Monoclonal gammopathy  of undetermined significance is  defined  by  presence of serum M-protein &lt;3 g/dL; absence of lytic bone lesions, anemia,  hypercalcemia,  and  renal  insufficiency  related  to  the  M-protein;  and  (if  determined) proportion of plasma cells in the bone marrow of 10% or less (Kyle 2003).17 Smoldering multiple myeloma is defined as asymptomatic multiple myeloma with absence of related organ or tissue impairment end organ damage (Kyle 2003, Kyle 2007).17,19
- Subject has a diagnosis of Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
- Subject has prior or current systemic therapy or SCT for multiple myeloma, with the exception of an emergency  use  of  a  short  course  (equivalent  of  dexamethasone  40  mg/day  for  4  days)  of corticosteroids before treatment.

## Treatments

- Treatment Arm A (Rd) : Lenalidomide was administered at a dose of 25 mg orally on Days 1 through 21 of each 28-day cycle (for subjects with a creatinine clearance [CrCL] between 30 and 50 mL/min, the dose of lenalidomide was to be 10 mg every 24 hours), and dexamethasone was administered at a dose of 40 mg (oral or IV) once a week (for subjects older than 75 years or underweight [body mass index &lt;18.5], the  dexamethasone  could  be  administered  at  a  dose  of  20  mg  weekly).  Subjects  were  to  continue lenalidomide and dexamethasone until disease progression or unacceptable toxicity.
- Treatment Arm B (DRd): Daratumumab (16 mg/kg IV) was administered weekly for the first 8 weeks (Cycles 1-2) of treatment and then every other week for 16 weeks (Cycles 3-6), then every 4 weeks (from Cycle 7 and beyond). Lenalidomide and dexamethasone were administered as described in Treatment Arm A. Subjects were to continue on DRd until disease progression or unacceptable toxicity.

The Follow-up Phase began once the subject discontinued all study treatments.

Figure 4 : Schematic Overview Study Treatment Administration

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Objectives

## Primary Objective

To compare the efficacy of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival (PFS) in subjects with newly diagnosed multiple myeloma who are not candidates for high dose chemotherapy and autologous stem cell transplant.

## Secondary Objectives

- Time to disease progression (TTP)
- Complete response (CR) rate
- Minimal residual disease (MRD) negativity rate
- PFS2 (defined as time from randomization to progression on the next line of therapy or death, whichever comes first)
- Overall survival (OS)
- Time to next treatment
- Stringent CR (sCR) rate
- Overall response rate (partial response [PR] rate or better)
- Proportion of subjects who achieve very good partial response (VGPR) or better
- Time to response
- Duration of response
- To  evaluate  the  clinical  efficacy  of  daratumumab  combination  with  Rd  in  high-risk  molecular subgroups
- To  evaluate  treatment  effects  on  patient-reported  outcomes  and  heath  economic/resource utilization
- To assess the safety and tolerability of daratumumab when administered in combination with Rd.
- To assess the pharmacokinetics of daratumumab in combination with Rd.
- To assess the immunogenicity of daratumumab.

## Exploratory Objective

- To explore biomarkers predictive of response or resistance to therapy
- To assess durability of MRD negativity

## Outcomes/endpoints

## Primary endpoints

The primary endpoint is PFS , which is defined as the duration from the date of randomization to either progressive disease, or death, whichever occurs first. PFS was determined by the use of a validated computer algorithm that combines laboratory results (eg, monoclonal [M]-protein level) and applicable imaging and generates the outcome according to IMWG criteria (Durie 2006, Rajkumar 2011). Further, sensitivity analyses of PFS were performed, including those using investigator-determined response.

## Secondary endpoints

The secondary efficacy endpoints include:

-Time to disease progression (TTP): is defined as the time from the date of randomization to the date of first documented evidence of PD, as defined in the IMWG criteria. For subjects who have not progressed, data will be censored at the date of the disease evaluation before the start of any subsequent anti-myeloma therapy.

- CR rate , defined as the percentage of subjects achieving CR, as defined:
- Negative immunofixation of serum and urine, and
- Disappearance of any soft tissue plasmacytomas, and

<div style=\"page-break-after: always\"></div>

- &lt;5% plasma cells (PCs) in bone marrow
- For  those  subjects  with  negative  serum  M-protein  quantitation  by  electrophoresis  (SPEP)  and suspected daratumumab interference on immunofixation, a reflex assay using anti-idiotypeantibody will be utilized to confirm daratumumab interference and rule out false positive immunofixation. Patients who have confirmed daratumumab interference, but meet all other clinical criteria for CR or sCR, will be considered CR/sCR.

- MRD negativity rate , defined as the proportion of subjects assessed as MRD negative, at any timepoint after the date of randomization.

-Progression-free Survival on Next line of Therapy (PFS2), defined as the time from randomization to progression on the next line of treatment or death, whichever comes first. Disease progression will be based on investigator judgment. For those subjects who are still alive and not yet progressed on the next line of treatment, they will be censored on the last date of follow-up.

- Overall survival (OS) , measured from the date of randomization to the date of the subject's death. If the subject is alive or the vital status is unknown, then the subject's data will be censored at the date the subject was last known to be alive.

-Time to next treatment , defined as the time from randomization to the start of the next-line treatment.

-sCR rate , defined as the percentage of subjects achieving CR in addition to having a normal free light chain (FLC) ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry

-Overall response rate (ORR), defined as the proportion of subjects who achieve PR or better, according to the IMWG criteria, during or after the study treatment.

-Proportion of subjects who achieve VGPR or better , defined as the proportion of subjects achieving VGPR and CR (including sCR) according to the IMWG criteria during or after the study treatment at the time of data cutoff.

-Time to response , defined as the time between the randomization and the first efficacy evaluation that the subject has met all criteria for PR or better. For subjects without response, data will be censored either at the date of progressive disease or, in the absence of progressive disease, at the last disease evaluation before the start of subsequent anti-myeloma therapy.

-Duration of response , calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria. For subjects who have not progressed, data will be censored at the last disease evaluation before the start of any subsequent anti-myeloma therapy.

- To evaluate clinical efficacy of DRd in high risk molecular subgroups compared to Rd alone.

- To evaluate the impact of DRd compared to Rd on patient-reported perception of global health.

## Sample size

The sample size calculation was based on the assumption that the median PFS for Rd arm is approximately 24 months and the addition of daratumumab would reduce the risk of the disease progression or death by 25%, ie, assuming the hazard ratio (DRd vs Rd) of 0.75, a total of 390 PFS events is needed to achieve a power of 80% to detect this hazard ratio with a log-rank test (two-sided alpha is 0.05).

With a 21-month accrual period and an additional 24-month follow-up, the total sample size needed for the study is approximately 730 (365/arm) subjects.

<div style=\"page-break-after: always\"></div>

The sample size calculation has taken into consideration an annual dropout rate of 5%, and the planned interim efficacy analysis used the O'Brien-Fleming alpha spending function. PFS and responses were derived using the same validated computer algorithm as used in previous daratumumab studies.

## Randomisation

Subjects were randomly assigned (1:1 ratio) to receive either DRd or Rd stratified by International Staging System (ISS, I vs II vs III), region (North America vs Other), and age (&lt;75 vs ≥ 75).

## Blinding (masking)

As this is an open study, blinding procedures are not applicable.

## Statistical methods

Long-term survival follow-up was to continue until 330 deaths had been observed or 7 years after the last subject was randomized, whichever came first. The study was to achieve approximately 80% power to detect  a  27%  reduction  in  the  risk  of  death  (hazard  ratio  [HR]=0.73)  with  a  log-rank  test  (two-sided alpha=0.05).

The primary endpoint of Progression-free survival (PFS) and responses were derived using the validated computer algorithm as used in previous daratumumab studies. For PFS, the primary analysis was to consist of a stratified log rank test for the comparison of the PFS distribution between the 2 treatment arms. The Kaplan-Meier method was to be used to estimate the distribution of overall PFS for each treatment. The treatment effect (hazard ratio) and its two-sided 95% confidence intervals were to be estimated using a stratified  Cox  regression  model  with  treatment  as  the  sole  explanatory  variable.  Other  time-to-event efficacy endpoints, including TTP, PFS2, OS, and time to subsequent anti-myeloma treatment, were to be analysed similarly.

Comparison between the 2 treatment arms of overall response rates, VGPR or better rate, CR or better rate, MRD negativity rate, and other binary endpoints were to be conducted using the stratified Cox regression model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, III), region (North America vs. Other), and age (&lt;75 years vs. ≥ 75 years) as randomized. Other time-to-event efficacy endpoints, including TTP, PFS2, OS, and time to subsequent anti myeloma treatment, were to be analysed similarly. Duration of response were to be analysed descriptively using the Kaplan-Meier method.

For overall survival, the final analysis will occur after 330 deaths have been observed. Earlier analyses, in which overall survival are analyzed will be considered as interim analyses, and the stopping boundary will be determined  using  the  observed  number  of  deaths  at  the  time  of  the  analyses  and  a  modified  linear alpha-spending function per the Lan-DeMets method. At the interim PFS analysis (234 PFS events), a total alpha of 0.0001 (2-sided) will be spent. Cumulative total alpha (2-sided) spent at each subsequent analysis of OS will be the total alpha allocated to OS multiplied by the proportion of the number of deaths observed at the time of the analysis out of the total planned number of deaths (330).

Strong control of familywise Type I error rate will be controlled at a two-sided significance level of 0.05 for the following major secondary endpoints: TTP, CR rate, MRD negativity rate, PFS2 and OS. A hierarchical testing procedure will be used

## Interim analyses

Two interim analyses are planned. The first interim analysis, with a purpose to evaluate safety, will be performed after a total of approximately 100 subjects have been treated for at least 8 weeks or discontinued the study treatment. The second interim analysis will be performed when 234 PFS events, which is 60% of

<div style=\"page-break-after: always\"></div>

the  total  planned  events,  have  been  accumulated.  The  purpose  of  this  interim  analysis  is  to  evaluate cumulative interim safety and efficacy data. The significance level at this interim analysis to establish the superiority of DRd over Rd with regard to PFS will be determined based on the observed number of PFS events at the interim analysis, using the O'Brien-Fleming boundaries as implemented by the Lan-DeMets alpha spending method. If the experimental arm (DRd) is numerically worse than the control arm in terms of PFS (observed hazard ratio &gt;1 favoring the control arm), then the study may be terminated for futility, with a conditional power of less than 20% under the alternative hypothesis given the observed interim data.

## Results

## Participant flow

Figure 5 : Participant flow Study MMY3008

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 2 : Summary of study treatment disposition, Intent-to-treat Analysis Set, Study MMY3008

|                                       | Rd n (%)    | DRd n (%)   | Total n (%)   |
|---------------------------------------|-------------|-------------|---------------|
| Analysis set: intent-to-treat         | 369         | 368         | 737           |
| Subjectsrandomized butnot treateda    | 4 (1.1%)    | 4 (1.1%)    | 8 (1.1%)      |
| Subjects treated ?                    | 365 (98.9%) | 364 (98.9%) | 729 (98.9%)   |
| Subjects who discontinued treatment b | 207 (56.7%) | 118 (32.4%) | 325 (44.6%)   |
| Reason for discontinuation b          |             |             |               |
| Progressive disease                   | 87 (23.8%)  | 53 (14.6%)  | 140 (19.2%)   |
| Adverse event                         | 59 (16.2%)  | 27 (7.4%)   | 86 (11.8%)    |
| Death                                 | 16 (4.4%)   | 21 (5.8%)   | 37 (5.1%)     |
| Non-compliance with study drug        | 23 (6.3%)   | 13 (3.6%)   | 36 (4.9%)     |
| Physician decision                    | 17 (4.7%)   | 2 (0.5%)    | 19 (2.6%)     |
| Lost to follow-up                     | 1 (0.3%)    | 0           | 1 (0.1%)      |
| Withdrawal by subject                 | 4 (1.1%)    | 0           | 4 (0.5%)      |
| Other                                 | 0           | 2 (0.5%)    | 2 (0.3%)      |
| Subjects who discontinued study a     | 93 (25.2%)  | 70 (19.0%)  | 163 (22.1%)   |
| Reason for discontinuation ?          |             |             |               |
| Death                                 | 76 (20.6%)  | 62 (16.8%)  | 138 (18.7%)   |
| Withdrawal by subject                 | 14 (3.8%)   | 7 (1.9%)    | 21 (2.8%)     |
| Lost to follow-up                     | 3 (0.8%)    | 1 (0.3%)    | 4 (0.5%)      |

Key:Rd=lenalidomide-dexamethasone;DRd=daratumumab-lenalidomide-dexamethasone.

? Percentages are based on number of subjects randomized.

Captured as reason éSubject refused further study treatment’ on End of Treatment' CRF page.

## Recruitment

Study Center(s): Austria (4 sites), Australia (9 sites), Belgium (3 sites), Canada (8 sites), Denmark (3 sites), France (45 sites), Germany (14 sites), Ireland (2 sites), Israel (4 sites), Italy (4 sites), Netherlands (3 sites), Sweden (7 sites), United Kingdom (14 sites), United States (56 sites).

Study Period: 10 March 2015 (Date first subject signed informed consent) to 24 September 2018, the data cut-off for the second interim analysis.

## Conduct of the study

The original protocol was dated 14 July 2014, and there were 4 global amendments in addition to country specific amendments for the UK, Germany, and France. The rationale for each amendment is summarized below:

[TSIDS01.RTF] [JNJ-54767414\\MMY3008\\DBR\\_CSRRE\\_CSR\\PROD\\TSIDS01.SAS] 26NOV2018,18:18

<div style=\"page-break-after: always\"></div>

## SummaryofProtocolAmendmentsfor54767414MMY3008

| Amendment INT-1 (29 0ctober 2014; substantial) Amendment INT-1/UK-1 (26 March 2015; substantial)   | Clarificationsweremade toMRDmonitoring andinvestigator feedback was incorporated into the protocol. Revisionmadetoupdatethecriteriafortreatment discontinuation, based on feedback from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment DEU-1                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| (13 April 2015; substantial)                                                                       | Revision made to the exclusion criterion for hepatitis,based on feedback from the German PEI on a related ongoing daratumumab protocol.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Amendment INT-2 (26 August 2015; substantial)                                                      | Revisions made to clarify blood typing assessment during the (Coombs)Testing (IAT) due to therisk of daratumumab interference with blood typing. Also, further defined the exclusion criteria for hepatitis B and C, and HIV.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Amendment INT-2/UK-1 (28 August 2015; substantial)                                                 | Country specific change from UK-1 incorporated into INT-2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Amendment INT-2/FRA-1 (17 February 2016; non-substantial)                                          | Revisionsmade toincorporatefeedbackfrom theFrenchNational Ethics Committee regarding duration of contraceptive use from 4 to 3 months per IB and ICF risk language                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Amendment INT-3 (02 November 2016; substantial)                                                    | Revisions were made to the timepoints for the assessment of MRD-negativity to align with newly defined IMWG categories.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Amendment INT-3/UK-1 (14 November 2016; substantial)                                               | Country specific change from UK-1 incorporated intoINT-3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Amendment INT-4 (22 May 2017; substantial)                                                         | Revision made for subjects in the DRd group to continue treatmentwithlenalidomideanddexamethasoneuntildisease progression or unacceptable toxicitybased on continuous lenalidomide treatment emerging as the standard of care and consistent with the approved lenalidomide prescribing information.Previous versionhadlenalidomide and dexamethasone stopping at 2 years in the DRd group. Two subjects in the DRd group had treatment disruption due to implementing the amendment. One subject had met the 2-year mark while waitingfor IRB approval of the amendment and received one month of treatment with daratumumab alone.The second subject signed the ICF for amendment 4 but Rd was discontinued at the 2-year mark in error. |
| Amendment INT-4.UK-1 (01 June 2017; substantial)                                                   | Country specific change from UK-1 incorporated into INT-4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

During the study, issues were identified involving the collection of unscheduled samples for pharmacokinetic, quantitative immunoglobulins, and exploratory peripheral blood MRD testing from study subjects. A corrective action plan was implemented. The non-compliance did not have an impact on the safety,  physical,  or  mental  integrity  of  the  study  subjects.  Some  of  the  unscheduled  pharmacokinetic samples were tested but the results were not included in the analysis. Additionally, pharmacokinetic samples not tested will be destroyed. The unscheduled peripheral blood MRD samples were not tested and the samples will be destroyed. The unscheduled quantitative immunoglobulin samples were tested, and the data retained in the database.

## Protocol deviations

All protocol deviations of eligibility criteria and those deviations that could impact subject safety or primary endpoints  were  considered  major  protocol  deviations.  Major  protocol  deviations  were  reported  for  68 subjects (9.2%) across both treatment groups: 25 subjects (6.8%) in the DRd group and 43 subjects (11.7%) in the Rd group. One subject in the DRd group had 2 major protocol deviations (entered but did not satisfy criteria and other [M-protein disease evaluation at screening not within protocol defined window]).

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 3 : Summary of baseline disease characteristics - ITT

|                                         | Rd             | DRd            |               |
|-----------------------------------------|----------------|----------------|---------------|
|                                         | n (96)         | n (%)          | n (96)        |
| Analysis set: intent-to-treat           | 369            | 368            | 737           |
| Age, years                              |                |                |               |
| N                                       | 369            | 368            | 737           |
| Category, n (%)                         |                |                |               |
| 65                                      | 4 (1.1%)       | 4 (1.1%)       | 8 (1.1%)      |
| 65 -≤70                                 | 73 (19.8%)     | 74 (20.1%)     | 147 (19.9%)   |
| 70- ≤75                                 | 131 (35.5%)    | 130 (35.396)   | 261 (35.49)   |
| 275                                     | 161 (43.6%)    | 160 (43.5%)    | 321 (43.6%)   |
| Mean (SD)                               | 74.2 (5.66)    | 74.0 (5.44)    | 74.1 (5.55)   |
| Median                                  | 74.0           | 73.0           | 73.0          |
| Range                                   | (45; 89)       | (50; 90)       | (45; 90)      |
| Sex, n (%)                              |                |                |               |
| N                                       | 369            | 368            | 737           |
| Male                                    | 195 (52.896)   | 189 (51.496)   | 384 (52.19)   |
| Female                                  | 174 (47.2%)    | 179 (48.6%)    | 353 (47.9%6)  |
| Ethnicity, n (%6)                       |                |                |               |
| N                                       | 369            | 368            | 737           |
| Hispanic or Latino                      | 12 (3.396)     | 11 (3.0%)      | 23 (3.196)    |
| Not Hispanic or Latino                  | 352 (95.4%)    | 347 (94.396)   | 699 (94.8%)   |
| Unknowu                                 | 3 (0.896)      | (9691)9        | 9 (1.29)      |
| Not Reported                            | 2 (0.596)      | 4 (1.1%)       | 6 (0.896)     |
| Race, n (%)                             |                |                |               |
| N                                       | 369            | 368            | 737           |
| White                                   | 339 (91.9%6)   | 336 (91.396)   | 675 (91.6%6)  |
| BlackorAfnicanAmerican                  | 16 (4.396)     | 12 (3.3%)      | 28 (3.896)    |
| Asian                                   | 2 (0.596)      | 3 (0.8%%)      | 5 (0.7%)      |
| AmericanIndian or Alaska Native         | 0              | 0              | 0             |
| NativeHawaiian or other PacificIslander | 1 (0.396)      | 0              | 1 (0.1%)      |
| Other\"                                  | (969'1) 9      | 6 (1.69%)      | 12 (1.6%)     |
| Unknown                                 | 1 (0.3%)       | 2 (0.59)       | 3 (0.49%)     |
| Not Reported                            | 4 (1.1%6)      | 9 (2.4%)       | 13 (1.8%)     |
| Weight (kg)                             |                |                |               |
|                                         | 369            | 368            | 737           |
| N Category, n (%)                       |                |                |               |
| 50                                      | 13 (3.5%6)     | 9 (2.49)       | 22 (3.0%)     |
| 50-c65                                  | 93 (25.2%)     | 96 (26.1%)     | 189 (25.6%)   |
| 65.c85                                  | 184 (49.996)   | 168 (45.7%6)   | 352 (47.89)   |
| 285                                     | 79 (21.4%)     | 95 (25.8%)     | 174 (23.6%)   |
| Mean (SD)                               | 74.0 (15.21)   | 75.1 (16.66)   | 74.5 (15.95)  |
| Median                                  | 72.9           | 72.1           | 72.3          |
| Range                                   | (39; 140)      | (45; 152)      | (39; 152)     |
| Height (cm)                             |                |                |               |
| N                                       | 369            | 368            | 737           |
| Mean (SD)                               | 166.1 (9.53)   | 166.2 (9.25)   | 166.1 (9.39)  |
| Medinn                                  | 166.0          | 166.0          | 166.0         |
| Range                                   | (144; 192)     | (137; 193)     | (137; 193)    |
| Baveline BSA (m)                        |                |                |               |
| N                                       | 369            | 368            | 737           |
| Mean (SD)                               | 1.840 (0.2224) | 1.854 (0.2326) | 1.847(0.2275) |
| Median                                  | 1.817          | 1.830          | 1.826         |
| Range                                   | (1.27; 2.61)   | (1.34; 2.73)   | (1.27; 2.73)  |
| Baseline ECOG score, n (%)              |                |                |               |
| N                                       | 369            | 368            | 737           |
| 0                                       | 123 (33.3%)    | 127 (34.596)   | 250 (33.9%)   |
| 1                                       | 187 (50.7%)    | 178 (48.496)   | 365 (49.5%)   |
| 22                                      | 59 (16.0%)     | 63 (17.196)    | 122 (16.6%)   |

Key: Rd = lenalidomide-dexamethssone; DRd = daratumumab-lenalidomide-dexamethasone; BSA=Body Suface Ares;

* Subjects reporting multiple races are included umder other.

ECOG=EastemCooperativeOncologyGroup.

Note: Percentages are calculated with the number of subjects in each treamment group with available data as denominator.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

The primary analysis population was the intent-to-treat (ITT) population, which included all randomized subjects. A summary of all subjects per analysis set is presented in the following Table.

Table 4 : Subjects per analysis set

|                            | Rd   | DRd   | Total   |
|----------------------------|------|-------|---------|
| Study population           |      |       |         |
| Subjects screened          |      |       | 952     |
| Intent-to-treat (ITT)      | 369  | 368   | 737     |
| Per-protocol²(PP)          | 360  | 359   | 719     |
| Response-evaluableb        | 356  | 354   | 710     |
| Pharmacokinetic evaluablec |      | 356   | 356     |
| Immunogenicity evaluabled  |      | 338   | 338     |

Key: Rd = lenalidomide-dexamethasone; DRd = daratumumab-lenalidomide-dexamethasone.

Includes subjects who are randomized and meet all eligibility criteria.

b Includes subjects who have a confirmed diagnosis of multiple myeloma and measurable disease at baseline or screening visit.Inaddition, subjects must havereceived at least one component of study treatment and have adequate post-baseline

^ Includes subjects assigned to DRd group who received at least 1 administration of daratumumab and have at least 1 pharmacokinetic sample concentration value after the first infusion.

Includes subjects assigned to DRd group who have at least 1 immunogenicity sample obtained after their first daratumumabadministration.

Modifiedfrom[TSIDS02.RTF][NI-54767414MMY3008DBR\\_CSRRE\\_CSRIPRODITSIDS02.SAS]26NOV2018,18:18

## Outcomes and estimation

## Primary Endpoint:

## PFS (cut-off 24 September 2018)

Table 5 : PFS based on computerised algorithm: ITT

|                                | Rd                   | DRd                  |
|--------------------------------|----------------------|----------------------|
| Analysis set: intent-to-treat  | 369                  | 368                  |
| Progression-free suvival (PFS) |                      |                      |
| Niumber of events (%)          | 143 (38.8%)          | 97 (26.4%)           |
| Niumber of censored (%)        | 226 (61.2%)          | 271 (73.6%)          |
| Kaplan-Meier estimnte (months) |                      |                      |
| 25%quantille(959C1)            | 14.46 (11.56, 16.82) | 25.56 (20.53, 31.08) |
| Median (95% C1)                | 31.87 (28.94, NE)    | NE (NE, NE)          |
| 75%quantile(95% C1)            | 39.23 (35.81, NE)    | NE (NE, NE)          |
| P-value\"                       |                      | <0.0001              |
| Hazard ratio (95% C1)          |                      | 0.56 (0.43, 0.73)    |
| 12-month PFSrate%(95%CI)       | 78.6 (73.8, 82.6)    | 86.2(82.2,89.4)      |
| 24-month PFS rate % (95%CI)    | 62.0 (56.5. 67.1)    | 76.2 (71.4,80.4)     |
| 36-month PFS rate % (959 CI)   | 38.5 (23.0, 53.9)    | 69.5 (63.5, 74.0)    |

Key. Rd =lenalidomide-dexamethasone, DRd= darahumumab-lenalidomide-dexamethasone; CI= confidence interval.

p-value is based on the log-rank test stratified with ISS stoging (IL, I, I), region (North America V5. Other), and age (≤75 years Vc. ≥75 years) as randomized.

Hazsrd rstio snd95%6CI from aCoxproportional hszsrd5model with trestment as thesoleexplanstory vaniable snd stratified with ISS staging (L, II, ml), region (North America Vs. Other), and age (C75 years Vs. ≥75 years) as randomized. A bazard ratio-| indicates an advantage for DRd.

[TEFPFS01.RTF][UNJ-54767414IMMY3008DBR\\_CSRIRE\\_CSRIPRODITEFPFS01.SAS]26NOV2018.19:23

<div style=\"page-break-after: always\"></div>

Figure 6 : Kaplan-Meier plot for PFS - ITT

<!-- image -->

Key: Rd = lenalidomide-dexamethasone; DRd = darahumumab-lenalidomide-dexamethasone.

Table 6 : Summary of reasons for Censoring PFS

|                                                    | Rd n (%6)   | DRd n (%)   |
|----------------------------------------------------|-------------|-------------|
| Analysis set: intent-to-treat                      | 369         | 368         |
| Subjects censored                                  | 226 (61.2%) | 271 (73.6%) |
| Reason for censoring                               |             |             |
| Study cut-off                                      | 178 (78.8%) | 256 (94.5%) |
| Subsequent antimyeloma therapy                     | 34 (15.0%)  | 12 (4.4%)   |
| Withdrawal of consent to study participation       | 13 (5.896)  | 3 (1.1%)    |
| Lost to follow-up                                  | 1 (0.4%)    | 0           |
| Subjects with progression-free swrvival event      | 143 (38.8%) | 97 (26.4%)  |
| Subjects with confirmed progressive disease        | 111 (77.6%) | 64 (66.0%)  |
| Reason for progressive disease'                    |             |             |
| Serum M-protein                                    | 68 (61.3%)  | 32 (50.0%)  |
| Urine M-protein                                    | 20 (18.0%6) | 6 (9.4%6)   |
| Serum FLCd                                         | 6 (5.4%)    | 6 (9.4%)    |
| Bone lesion (increase in size)                     | 11 (9.9%)   | 5 (7.89)    |
| Bone lesion (new bone lesion)                      | 17 (15.3%)  | 11 (17.2%)  |
| Plasmacytomas (increase in size)                   | 0           | 1 (1.6%)    |
| Plasmacytomas (new plasmacytomas)                  | 7 (6.3%)    | 7 (10.9%)   |
| Hypercalcemia                                      | 3 (2.7%)    | 1 (1.6%)    |
| Subjecis died without confimed progressive disease | 32 (22.4%)  | 33 (34.0%)  |
| Death due to progressive disease                   | 2 (6.3%)    | 2 (6.1%)    |
| Other                                              | 30 (93.896) | 31 (93.9%6) |

Key:Rd=1enalidomide-dexamethasone:DRd=darahumumab-lenalidomide-dexamethasone.

Percentages are based on number of subjects censored in each treatment group.

Only applieable to subjects without measurable serum and urine M-protein levels.

Percentages are based on number of subjects with \"death without confirmed PD\" event in each treatment group.

Percentages are based on number of subjects with PD event in each treatment group.

[TEFRFPD01.RTF] [NI-54767414MMY3008IDBR CSRIRE CSRPRODITEFRFPD01.SAS] 26NOV2018, 19:25

<div style=\"page-break-after: always\"></div>

## Updated PFS (cut-off 10 June 2019)

Table 7 : Updated PFS based on computerised algorithm: ITT

|                                 | Rd                   | DRd.                 |
|---------------------------------|----------------------|----------------------|
| Analysis set: intent-to-treat   | 369                  | 368                  |
| Progression-free survival (PFS) |                      |                      |
| Number of events (%)            | 171 (46.3%)          | 120 (32.6%)          |
| Number of censored (%)          | 198 (53.7%)          | 248 (67.4%)          |
| Kaplan-Meier estimate (months)  |                      |                      |
| 25% quantile (95% CI)           | 14.32 (11.50, 16.66) | 24.94 (20.53, 30.36) |
| Median (95% CI)                 | 33.84 (28.94, 39.23) | NE (NE, NE)          |
| 75% quantile (95% CI)           | NE (NE, NE)          | NE (NE, NE)          |
| P-yalue\"                        |                      | <0.0001              |
| Hazard ratio (95% CIb           |                      | 0.56 (0.44, 0.71)    |
| 12-month PFS rate % (95% CI)    | 78.4 (73.6, 82.4)    | 86.2 (82.2, 89.4)    |
| 24-month PFS rate % (95% CI)    | 61.5 (56.0, 66.5)    | 76.0 (71.2, 80.1)    |
| 36-mlonth PFS rate % (95% CI)   | 46.3 (40.3, 52.1)    | 67.7 (62.5, 72.4)    |

Figure 7 : Updated Kaplan-Meier plot for PFS - ITT

<!-- image -->

## Secondary Endpoints:

For key secondary endpoints, pre-specified hierarchical testing, along with alpha spending using group sequential methods, was performed to strongly control the family-wise type I error rate at 0.05 (2-sided).

Rd

---e--.DRd

<div style=\"page-break-after: always\"></div>

The p-values for CR or better rate, VGPR or better rate, MRD negativity rate, and ORR, all crossed the O'Brien-Fleming stopping boundary of 0.0244 as pre-specified.

## Response-related secondary efficacy endpoints

Table 8: Summary of Response related secondary efficacy endpoints - ITT

|                                 | Rd            | DRd               |
|---------------------------------|---------------|-------------------|
| Overallresponse(sCR+CR+VGPR+PR) |               |                   |
| n(%)                            | 300(81.3%)    | 342(92.9%)        |
| (95%CI)                         | (76.9%,85.1%) | (89.8%,95.3%)     |
| OddsRatio(95% CI)               |               | 3.05(1.89,4.94)   |
| P-value\"                        |               | <0.0001           |
| VGPRorbetter(sCR+CR+VGPR)       |               |                   |
| n(%)                            | 196(53.1%)    | 292(79.3%)        |
| (959%CT)                        | (47.9%,58.39) | (74.8%,83.4%)     |
| OddsRatio(95%CI)                |               | 3.40(2.45.4.72)   |
| P-value\"                        |               | <0.0001           |
| CRorbetter(sCR+CR)              |               |                   |
| n(%6)                           | 92(24.9%)     | 175(47.6%)        |
| (95%CI)                         | (20.6%,29.7%) | (42.4%,52.896)    |
| OddsRatio(95%CI)                |               | 2.72(1.99,3.71)   |
| P-value\"                        |               | 1000'0>           |
| SCR                             |               |                   |
| n(%)                            | 46(12.5%)     | 112(30.4%)        |
| (95%CI)                         | (9.3%,16.3%)  | (25.89,35.49)     |
| OddsRatio(95%CI)                |               | 3.09 (2.11, 4.54) |
| P-value\"                        |               | 1000'0>           |
| MRDnegativity rate (10°)        |               |                   |
| n(%)                            | 27 (7.3%)     | 89 (24.2%)        |
| 95%CIof MRDnegativityrate       | (4.9%,10.5%)  | (19.9%6,28.9%)    |
| Oddsratio with95%CI             |               | 4.04(2.55.6.39)   |
| P-valueb                        |               | <0.0001           |

Key:Rd=lenalidomide-dexamethasone:DRd=daratumumab-lenalidomide-dexamethasone;

CI=confidence interval:CR=completeresponse;MRD=minimal residual disease;PR=partialresponse;sCR=stringent

completeresponse:VGPR=very good partial response.

p-value fromFisher's exact test.

'P-valuefrom theCochranMantel-Haenszel Chi-Squared test.

Note:Mantel-Haenszelestimateof the common oddsratio for stratified tablesisused.The stratification factors are:ISs staging (l.Il.Ill).region(North America vs.Other).and age (&lt;75years vs.≥75years)as randomized.An odds ratio&gt;1 indicatesan advantage forDRd.

[TEFRESP01SCERTF][JNJ-54767414MMY3008DBRCSRRECSRPRODTEFRESP01 SCE.SAS]21JAN2019,09:05

## Minimal Residual Disease (MRD)

For the ITT population, the DRd group demonstrated a greater rate of MRD negativity compared with the Rd group. The MRD negativity rate at the sensitivity threshold of 10-5 was more than 3-fold higher in subjects in the DRd group compared with subjects in the Rd group (DRd: 24.2%, Rd: 7.3%; odds ratio=4.04; 95% CI: 2.55, 6.39; p&lt;0.0001).

An important aspect in the assessment of MRD is the identification of tumor sequence from the baseline sample (calibration) that is required to evaluate the residual disease burden at the time of a deep clinical response. The overall calibration success rate was 238 of 267 (91.9%) in subjects with confirmed CR or better response. As an exploratory evaluation, MRD analyses using different thresholds (10-4 and 10-6) were also conducted in the ITT population. The rates of MRD negativity at these threshold levels were also significantly higher for the DRd group compared with the Rd group.

<div style=\"page-break-after: always\"></div>

## Overall Survival (OS)

Table 9: Summary of Overall Survival (unstratified analysis) - ITT

|                                | Rd                 | DRd              |
|--------------------------------|--------------------|------------------|
| Analysis set:intent-to-treat   | 369                | 895              |
| Overallsurvrval                |                    |                  |
| Number of events (%)           | 103(27.9%)         | 83(23.1%)        |
| Number of censored (%)         | 266 (72.1%)        | 283(76.9%)       |
| Kaplan-Meier estimate (months) |                    |                  |
| 25%quantle(95%CI)              | 32.85(27.60,37.39) | 38.64(32.85,NE)  |
| Median (95% CI)                | NE(47.28,NE)       | NE(NE,NE)        |
| 75%guantle(95% CI)             | NE(NE,NE)          | NE(NE,NE)        |
| P-alue\"                        |                    | 0.0775           |
| Hazard ratio (93% CI)          |                    | 0.77(0.58,1.03)  |
| 12-monthsurvivalrate %(95%CI)  | 91.3(87.9,93.8)    | 92.6(89.4,94.9)  |
| 24-monthsurvivalrate%(95%CI)   | 83.4(79.1,86.9)    | 84.3(80.2,87.7)  |
| 36-monthsurvivalrate%(95%CT)   | 72.4 (67.2,76.9)   | 77.3 (72.4,81.4) |
| 48-month survivalrate%(95%CI)  | 53.4(31.8,70.8)    | 70.5(62.8,76.9)  |

Key:Rd =lenalidomide-dexamethasone;DRd =daratumumab-lenalidomide-dexamethasone; CI= confidence interval.

p-value isbased on the umstratifiedlog-rank test.

Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable.A hazard ratiolindicatesanadvantageforDRd

## PFS2

Table 10

## Summary of Progression-free Survival on Next Line of Therapy (PFS2) Based on Investigator Assessment - ITT

|                                                          | Rd                   | DRd                  |
|----------------------------------------------------------|----------------------|----------------------|
| Analysis set: intent-to-treat                            | 369                  | 368                  |
| Progression-free survival on next line of therapy (PFS2) |                      |                      |
| Number of events (%)                                     | 121 (32.8%)          | 96 (26.1%)           |
| Number of censored (%)                                   | 248 (67.2%)          | 272 (73.9%)          |
| Kaplan-Meier estimate (months)                           |                      |                      |
| 25% quantile (95% CI)                                    | 26.02 (21.55, 30.19) | 34.07 (30.29, 41.03) |
| Median (95% CI)                                          | 47.28 (39.62, NE)    | NE (NE, NE)          |
| 75% quantile (95% CI)                                    | NE (47.28, NE)       | NE (NE, NE)          |
| P-value a                                                |                      | 0.0079               |
| Hazard ratio (95% CI) b                                  |                      | 0.69 (0.53, 0.91)    |
| 12-month PFS2 rate %(95% CI)                             | 89.5 (85.8, 92.3)    | 90.7 (87.2, 93.2)    |
| 24-month PFS2 rate %(95% CI)                             | 77.7 (72.9, 81.8)    | 82.5 (78.2, 86.1)    |
| 36-month PFS2 rate %(95% CI)                             | 63.8 (58.0, 69.0)    | 74.3 (69.2, 78.6)    |
| 48-month PFS2 rate %(95% CI)                             | 45.2 (24.4, 63.9)    | 65.4 (56.7, 72.8)    |

Key: Rd = lenalidomide-dexamethasone; DRd = daratumumab-lenalidomide-dexamethasone; CI = confidence interval. a p-value is based on the log-rank test stratified with ISS staging (I, II, III), region (North America vs. Other), and age (&lt;75 years vs. ≥75 years) as ra ndomized.

b  Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, III), region (North America vs. Other), and age (&lt;75 years vs. ≥75 years) as randomized. A hazard ratio &lt; 1 indicates an advantage for DRd.

<div style=\"page-break-after: always\"></div>

## Time to Disease Progression

Table 11

| Summary of Time to Disease Progression - ITT   | Summary of Time to Disease Progression - ITT   | Summary of Time to Disease Progression - ITT   |
|------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                                                | Rd                                             | DRd                                            |
| Analysis set: intent-to-treat                  | 369                                            | 368                                            |
| Time to disease progression a                  |                                                |                                                |
| Number of events (%)                           | 135 (36.6%)                                    | 83 (22.6%)                                     |
| Number of censored (%)                         | 234 (63.4%)                                    | 285 (77.4%)                                    |
| Kaplan-Meier estimate (months)                 |                                                |                                                |
| 25% quantile (95% CI)                          | 17.25 (14.88, 20.93)                           | 37.36 (26.45, NE)                              |
| Median (95% CI)                                | 41.66 (34.50, NE)                              | NE (NE, NE)                                    |
| 75% quantile (95% CI)                          | NE (NE, NE)                                    | NE (NE, NE)                                    |
| P-value b                                      |                                                | <0.0001                                        |
| Hazard ratio (95% CI) c                        |                                                | 0.49 (0.37, 0.64)                              |

Key: Rd = lenalidomide-dexamethasone; DRd = daratumumab-lenalidomide-dexamethasone; CI = confidence interval.

a Time to disease progression is defined as the time from the date of randomization to the date of first observation of PD by IMWG algorithm, or death due to PD (prior to subsequent antimyeloma therapy or withdrawal of consent to study participation).

b p-value is based on the log-rank test stratified with ISS staging (I, II, III), region (North America vs. Other), and age (&lt;75 years vs. ≥75 years) as randomized.

c  Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS staging (I, II, III), region (North America vs. Other), and age (&lt;75 years vs. ≥75 years) as randomized. A hazard ratio &lt; 1 indicates an advantage for DRd.

## Time to Response

The median time to response was rapid, occurring after 1 month of treatment. Median time to best response was longer in the DRd group (8.82 months) compared with the Rd group (5.29 months). Median time to VGPR or better (2.94 vs 4.62 months) and median time to CR or better (10.35 vs 11.22 months) was shorter for the DRd group versus the Rd group, respectively.

<div style=\"page-break-after: always\"></div>

Table 12: Summary of Time to Response

|                                                                | Rd            | DRd           |
|----------------------------------------------------------------|---------------|---------------|
| Analysis set: responders (PR or better) in response- evaluable | 300           | 342           |
| Time to first response ^ (months) N                            | 300           | 342           |
| Mean (SD)                                                      | 1.90 (1.820)  | 1.54 (1.300)  |
| Median                                                         | 1.05          | 1.05          |
| Range                                                          | (0.3; 15.3)   | (0.2; 12.1)   |
| Time to best response ~ (months)                               |               |               |
| N                                                              | 300           | 342           |
| Mean (SD)                                                      | 7.86 (7.153)  | 10.08 (7.767) |
| Median                                                         | 5.29          | 8.82          |
| Range                                                          | (0.9; 29.9)   | (0.9; 38.4)   |
| Time to VGPR or better (months)                                |               |               |
| N                                                              | 196           | 292           |
| Mean (SD)                                                      | 6.20 (5.455)  | 4.89 (4.747)  |
| Median                                                         | 4.62          | 2.94          |
| Range                                                          | (0.9; 27.6)   | (0.9; 24.3)   |
| Time to CR or better (months)                                  |               |               |
| N                                                              | 92            | 175           |
| Mean (SD)                                                      | 12.61 (6.100) | 11.95 (6.416) |
| Median                                                         | 11.22         | 10.35         |
| Range                                                          | (2.8; 29.9)   | (1.0; 35.2)   |

Key: Rd =lenalidomide-dexamethasone; DRd = daratumumab-lenalidomide-dexamethasone; PR =partial response. \"Response PR or better.

Note: Response-evaluable set includes subjects whohave a confirmed diagnosis of multiple myeloma and measurable disease at baseline or screening. In addition, subjects must have received at least one component of study treatment and have adequate post-baseline disease assessments.

## Ancillary analyses

## Sensitivity analysis

## PFS by investigator

Table 13: PFS based on investigator assessment - ITT

|                                | Rd                   | DRd                 |
|--------------------------------|----------------------|---------------------|
| Anslysis set: intent-to-treat  | 369                  | 368                 |
| Progression-free svival (PFS)  |                      |                     |
| Nuumber of events (%)          | 146 (39.6%)          | 97 (26.4%)          |
| Ntumber of censored (%)        | 223 (60.4%)          | 271 (73.6%)         |
| Kaplan-Meier estimate (months) |                      |                     |
| 25% quantile(95% C1)           | 14.09 (11.50, 16.56) | 25.86 (20.73,31.08) |
| Median (95% C1)                | 31.41 (26.94, 39.23) | NE (NE. NE)         |
| 75% quantile (95% C1)          | 39.23 (35.81, NE)    | NE (NE, NE)         |
| P-value\"                       |                      | [000'0-             |
| Hazard raltio (95% C1)b        |                      | 0.54 (0.42.0.70)    |
| 12-month PFS mate %(95% CI)    | 78.3 (73.5,82.3)     | 86.5 (82.5,89.6)    |
| 24-month PFS rate % (95% CI)   | 61.5 (55.9, 66.6)    | 76.5 (71.6, 80.6)   |
| 36-mouth PFSrate %(95%CI)      | 35.1 (18.6, 52.2)    | 68.0 (61.6, 73.7)   |

Key: Rd=lenalidomide-dexamethasone; DRd=daratumumab-lenalidomide-dexamethasone; CI=confidence interval

p-value is bssed on the log-rank test straified with ISS staging (I, IlL, Im), region (North Amenica 15. Other), snd sge (&lt;75 years Vs.≥75years)asrandomized

Hazardratioand 95%6CI fromaCoxproportional hazardsmodel with treatment as the sole explanatory vaniable and stratified with ISS staging (L, II, m). region (North Americn Vs. Other),snd age (&lt;75 years Vs. &gt;75 years) as randomized. A

hazard ratio c] indicates an advantage for DRd.

## Other sensitivity analyses

<div style=\"page-break-after: always\"></div>

A PFS analysis that did not censor data for starting subsequent anti-myeloma therapy, an analysis of PFS that  censored  for  death  or  progression  after  more  than  1  missed  disease  evaluation,  a  PFS  analysis evaluating the per-protocol population, and an un-stratified PFS analysis, all showed results consistent with the primary analysis.

## Subgroup analyses

Figure 8 : Forrest plot of subgroup analyses of PFS; ITT

<!-- image -->

Key:Rd=lenalidomide-dexamethasone;DRd=daratumumab-lenalidomide-dexamethasone;EVT=event. Note:Impaired baseline hepatic function includes mild（total bilirubin≤ULNand AST&gt;ULN)or(ULN&lt; total bilinubin≤1.5ULN;moderate（1.5xULN&lt;total bilirubin3xULN）;and severe （total bilinubin&gt;3xULN）. Note:High nisk cytogenetics is defined as positive for any oft（4;14）),t(14;16),and 17p deletion by FISH or karyotype

Note:Type of MO subgoupanalysis is based on subjecis with measurable disease in serum

## Summary of main study

The following table summarises the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 14 . Summary of Efficacy for Study 54767414MMY3008

| Title: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy   | Title: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy                              | Title: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy                              | Title: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy                                                                                                                                                                                            |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                              | 54767414MMY3008                                                                                                                                                                                                                                          | 54767414MMY3008                                                                                                                                                                                                                                          | 54767414MMY3008                                                                                                                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                        | Phase 3, open-label, multi-center, randomized trial comparing Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy | Phase 3, open-label, multi-center, randomized trial comparing Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy | Phase 3, open-label, multi-center, randomized trial comparing Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy                                                                                                                                                               |
|                                                                                                                                                                                                                               | Duration of main phase: Duration of Run-in phase: Duration of Extension                                                                                                                                                                                  | phase:                                                                                                                                                                                                                                                   | Approx. 3.5 years Study initiation date 10 March 2015 Data cut off 24 September 2018 Ongoing n/a n/a                                                                                                                                                                                                                                                                                                                   |
| Hypothesis                                                                                                                                                                                                                    | Superiority                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                             | D-Rd                                                                                                                                                                                                                                                     | D-Rd                                                                                                                                                                                                                                                     | Daratumumab 16 mg/kg IV (each cycle [C] 28 days) Q 1 week for 8 weeks (C 1-2), Q 2 weeks (C 4-6), Q 4 weeks (C7+), until disease progression or unacceptable toxicity. Rd as below.                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                               | Rd                                                                                                                                                                                                                                                       | Rd                                                                                                                                                                                                                                                       | Lenalidomide 25 mg PO on days 1 through 21 of each 28-day cycle (for subjects with a creatinine clearance between 30 and 50 mL/min, lenalidomide 10 mg PO on days 1 through 21 of each 28-day cycle), and dexamethasone (oral or IV) 40 mg once a week (for subjects older than 75 years or underweight (body mass index [BMI] <18.5), dexamethasone 20 mg weekly) until disease progression or unacceptable toxicity. |
| Endpoints and definitions                                                                                                                                                                                                     | Primary endpoint                                                                                                                                                                                                                                         | Progression free survival (PFS)                                                                                                                                                                                                                          | Progression free survival , defined as the duration from the date of randomization to either progressive disease, based on computerized algorithm according to IMWG criteria, or death, whichever occurred first.                                                                                                                                                                                                      |
|                                                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                                                       | Overall response rate (ORR)                                                                                                                                                                                                                              | Proportion of subjects who achieve a partial response (PR) or better (ie., PR, very good partial response, complete response or stringent complete response), based on computerized algorithm according to IMWG.                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary endpoint                                    | Complete response or better rate (CR or better rate)           | Proportion of subjects with a response of CR or better, based on computerized algorithm according to IMWG.        | Proportion of subjects with a response of CR or better, based on computerized algorithm according to IMWG.        |
|-------------------------------------------------|-------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
|                                                 | Secondary endpoint                                    | Minimal Residual Disease-negativity rate (MRD-negativity rate) | Proportion of subjects assessed as MRD negative, at any timepoint after the date of randomization.                | Proportion of subjects assessed as MRD negative, at any timepoint after the date of randomization.                |
|                                                 | Secondary endpoint                                    | Overall Survival (OS)                                          | Overall survival (OS), defined as the duration from the date of randomization to the date of the subject's death. | Overall survival (OS), defined as the duration from the date of randomization to the date of the subject's death. |
| Database lock 21 November 2018                  | Database lock 21 November 2018                        | Database lock 21 November 2018                                 | Database lock 21 November 2018                                                                                    | Database lock 21 November 2018                                                                                    |
| Results and Analysis                            | Results and Analysis                                  | Results and Analysis                                           | Results and Analysis                                                                                              | Results and Analysis                                                                                              |
| Analysis description                            | Primary Analysis                                      | Primary Analysis                                               | Primary Analysis                                                                                                  | Primary Analysis                                                                                                  |
| Analysis population and time point description  | Intent to treat (ITT)                                 | Intent to treat (ITT)                                          | Intent to treat (ITT)                                                                                             | Intent to treat (ITT)                                                                                             |
| Descriptive statistics and estimate variability | Treatment group                                       | Treatment group                                                | D-Rd                                                                                                              | Rd                                                                                                                |
| Descriptive statistics and estimate variability | Number of subjects                                    | Number of subjects                                             | 368                                                                                                               | 369                                                                                                               |
| Descriptive statistics and estimate variability | Primary endpoint: Median PFS (months)                 | Primary endpoint: Median PFS (months)                          | NE                                                                                                                | 31.9                                                                                                              |
| Descriptive statistics and estimate variability | 95% CI                                                | 95% CI                                                         | (NE, NE)                                                                                                          | (28.9, NE)                                                                                                        |
| Descriptive statistics and estimate variability | Secondary endpoint: ORR                               | Secondary endpoint: ORR                                        | 92.9%                                                                                                             | 81.3%                                                                                                             |
| Descriptive statistics and estimate variability | 95% CI                                                | 95% CI                                                         | (89.8%, 95.3%)                                                                                                    | (76.9%, 85.1%)                                                                                                    |
| Descriptive statistics and estimate variability | Secondary endpoint: CR or better rate                 | Secondary endpoint: CR or better rate                          | 47.6%                                                                                                             | 24.9%                                                                                                             |
| Descriptive statistics and estimate variability | 95% CI                                                | 95% CI                                                         | (42.4%, 52.8%)                                                                                                    | (20.6%, 29.7%)                                                                                                    |
| Descriptive statistics and estimate variability | Secondary endpoint: MRD-negativity -5                 | Secondary endpoint: MRD-negativity -5                          | 24.2%                                                                                                             | 7.3%                                                                                                              |
| Descriptive statistics and estimate variability | 95% CI                                                | 95% CI                                                         | (19.9%, 28.9%)                                                                                                    | (4.9%, 10.5%)                                                                                                     |
| Descriptive statistics and estimate variability | Secondary endpoint: Median OS (months)                | Secondary endpoint: Median OS (months)                         | NE                                                                                                                | NE                                                                                                                |
| Descriptive statistics and estimate variability | 95% CI                                                | 95% CI                                                         | (NE, NE)                                                                                                          | (39.23, NE)                                                                                                       |
| Effect estimate per comparison                  | Primary endpoint: PFS                                 | Primary endpoint: PFS                                          | Comparison groups                                                                                                 | D-Rd vs. Rd                                                                                                       |
| Effect estimate per comparison                  |                                                       |                                                                | Hazard ratio (HR)                                                                                                 | 0.56                                                                                                              |
| Effect estimate per comparison                  |                                                       |                                                                | 95% CI                                                                                                            | 0.43-0.73                                                                                                         |
| Effect estimate per comparison                  |                                                       |                                                                | P-value                                                                                                           | <0.0001                                                                                                           |
| Effect estimate per comparison                  | Secondary endpoint: ORR                               | Secondary endpoint: ORR                                        | Comparison groups                                                                                                 | D-Rd vs. Rd                                                                                                       |
| Effect estimate per comparison                  |                                                       |                                                                | Odds ratio                                                                                                        | 3.05                                                                                                              |
| Effect estimate per comparison                  |                                                       |                                                                | 95% CI                                                                                                            | 1.89-4.94                                                                                                         |
| Effect estimate per comparison                  |                                                       |                                                                | P-value                                                                                                           | <0.0001                                                                                                           |
| Effect estimate per comparison                  | Secondary endpoint: CR or better rate                 | Secondary endpoint: CR or better rate                          | Comparison groups                                                                                                 | D-Rd vs. Rd                                                                                                       |
| Effect estimate per comparison                  |                                                       |                                                                | Odds ratio                                                                                                        | 2.72                                                                                                              |
| Effect estimate per comparison                  |                                                       |                                                                | 95% CI                                                                                                            | 1.99-3.71                                                                                                         |
| Effect estimate per comparison                  |                                                       |                                                                | P-value                                                                                                           | <0.0001                                                                                                           |
| Effect estimate per comparison                  | Secondary endpoint: MRD-negativity rate (NGS, 10 -5 ) | Secondary endpoint: MRD-negativity rate (NGS, 10 -5 )          | Comparison groups                                                                                                 | D-Rd vs. Rd                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                        | Odds ratio        | 4.04        |
|------------------------|-------------------|-------------|
|                        | 95% CI            | 2.55-6.39   |
|                        | P-value           | <0.0001     |
| Secondary endpoint: OS | Comparison groups | D-Rd vs. Rd |
|                        | Hazard ratio      | 0.78        |
|                        | 95% CI            | 0.56-1.10   |
|                        | P-value           | 0.1528      |

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The MAH has provided a randomised phase 3, open-label, active controlled, and multicentre study (MMY3008). The incl/excl criteria clearly define a patient population above 18 years, with newly diagnosed MM ineligible for ASCT and with ECOG 0-2. Sections 4.1 and 5.1 of the SmPC clearly reflect the included patient population. The primary endpoint (PFS) is acceptable in this first-line setting. PFS2, CR and OS are important secondary endpoints.

Overall, the study was well-conducted.

## Efficacy data and additional analyses

The study met its primary endpoint showing a statistically significant and clinically meaningful difference in PFS in favour of DRd (36-month PFS rate % (95% CI) of 69.5 (63.5, 74.6) in DRd arm vs 38.5 (23.0, 53.9) in Rd arm; median PFS not reached in DRd arm and 31.9 months in the Rd arm; HR (955 CI) = 0.56 (0.43, 0.73), p-value &lt; 0.0001).  Several sensitivity analyses have been provided, including PFS by investigator, all showed similar results as the primary analysis. Consistent results were shown across the majority of subgroups. Updated PFS data (cut-off 10th June 2019) with a median follow-up of 36.4 months continue to show statistically significant and clinically meaningful results.

Across all response criteria DRd show statistically significant and clinically relevant results that confirm the primary analysis. The MRD negativity rate is 24.2% vs. 7.3% in favour of DRd.

Overall survival data are still immature. The MAH has committed to present the final clinical study report of study MMY3008 by 4Q2024.

## 2.4.4. Conclusions on the clinical efficacy

Study MMY3008 was well conducted. The study met its primary endpoint and showed statistically significant and clinically relevant results. The results from secondary endpoints and subgroup analysis are by majority consistent with the primary endpoint.

## 2.5. Clinical safety

## Introduction

Summaries of adverse events and other safety data are based on 729 subjects (DRd: 364 subjects, Rd: 365 subjects) who were randomized, received at least 1 dose of any study treatment  and contributed any safety data after the start of study treatment, ie, the Safety Population.

<div style=\"page-break-after: always\"></div>

## Patient exposure

A summary of treatment cycles received by subjects in both treatment groups is presented below.

As of the clinical cutoff, subjects in the DRd group had received a median of 27 cycles and subjects in the Rd group had received 22 cycles of treatment. In addition, 237 subjects (65.1%) in the DRd group and 157 subjects (43.0%) in the Rd group had received more than 24 cycles of treatment. The median duration of treatment was 25.3 months for the DRd group and 21.3 months for the Rd group. Thirty-five subjects in the DRd group discontinued Rd but continued daratumumab and an additional 25 subjects discontinued lenalidomide but continued daratumumab and dexamethasone. Four subjects in DRd discontinued daratumumab but continued Rd.

Table 15 : Summary of treatment cycles; SAS

<!-- image -->

|                                                                   | Rd           | DR.d          |
|-------------------------------------------------------------------|--------------|---------------|
| Analysis set: safety                                              | 365          | 364           |
| Distmibution of subjects treated in and beyond each cycle, n (96) |              |               |
| 2 1 cycle                                                         | 365 (100.0%) | 364 (100.096) |
| ≥2cycles                                                          | 348 (95.396) | 355 (97.596)  |
| 2 3 cycles                                                        | 335 (91.896) | 348 (95.696)  |
| 24cycles                                                          | 326 (89.396) | 342 (94.0%6)  |
| 2 5 cycles                                                        | 318 (87.196) | 339 (93.196)  |
| ≥6 cycles                                                         | 307 (84.196) | 337 (92.6%6)  |
| 2 7 cycles                                                        | 297 (81.49)  | 330 (90.7%)   |
| 2 13 cycles                                                       | 252 (69.096) | 306 (84.1%)   |
| 2 19 cycles                                                       | 210 (57.596) | 284 (78.0%6)  |
| 24 cycles                                                         | 157 (43.096) | 237 (65.196)  |
| > 30 cycles                                                       | 70 (19.2%)   | 125 (34.396)  |
| > 36 cycles                                                       | 13 (3.6%6)   | 30 (8.2%)     |
| Total number of trealment cycles received, n (96)                 |              |               |
| 1                                                                 | 17 (4.7%)    | 9 (2.596)     |
| 2                                                                 | 13 (3.6%)    | 7 (1.9%6)     |
| Cycle 1-2                                                         | 30 (8.2%)    | 16 (4.4%)     |
| 3                                                                 | 9 (2.5%)     | (9691)9       |
| 4                                                                 | 8 (2.296)    | 3 (0.896)     |
| 5                                                                 | 11 (3.0%)    | 2 (0.596)     |
| 6                                                                 | 10 (2.7%)    | 7 (1.9%6)     |
| Cycle 3-6                                                         | 38 (10.4%6)  | 18 (4.9%)     |
| Cyele 7-12                                                        | 45 (12.396)  | 24 (6.6%)     |
| Cycle 13-18                                                       | 42 (11.596)  | 22 (6.0%)     |
| Cycle 19-24                                                       | 53 (14.5%6)  | 47 (12.996)   |
| > 24 cycles                                                       | 157 (43.0%)  | 237 (65.196)  |
| > 30 cyeles                                                       | 70 (19.296)  | 125 (34.396)  |

<div style=\"page-break-after: always\"></div>

| >36 cycles                                     | 13 (3.6%6)   | 30 (8.296)   |
|------------------------------------------------|--------------|--------------|
| Summaryof totalnumberoftreatmentcyclesreceived |              |              |
| N                                              | 365          | t9E          |
| Mean (SD)                                      | 19.8 (11.21) | 25.0 (10.28) |
| Median                                         | 22.0         | 27.0         |
| Range                                          | (1; 43)      | (1; 44)      |

Key:Rd=lenalidomide-dexamethasone;DRd=daratumumab-lenalidomide-dexamethasone.

Note: Percentages are calculated with the number of subjects in each teatment group as denominator.

[TSIEXP01.RTF1(INI-54767414IM0MY3008DBR\\_CSRRECSRIPRODITSIEXP01.SAS]26NOV2018.18:18

Table 16 : Summary of relative dose intensity; SAS

|                                                             | R.d n (%)      | DRd n (%6)     | Total (%)      |
|-------------------------------------------------------------|----------------|----------------|----------------|
| Analysis set. safety                                        | 365            | 196            | 729            |
| Lenalidomide(mg) relative dose intensity (96)               |                |                |                |
| N                                                           | 348            | 339            | 687            |
| Mean (SD)                                                   | 83.49 (29.371) | 73.56 (29.671) | 78.59 (29.913) |
| Median                                                      | 91.43          | 76.22          | 84.54          |
| Range                                                       | (4.8; 234.2)   | (60+76D        | (4.8; 240.9)   |
| Category, n (%)                                             |                |                |                |
| 9%608                                                       | 134 (38.596)   | 181 (53.4%)    | 315 (45.9%)    |
| 280%6 - g120%6                                              | 200 (57.596)   | 149 (44.0%)    | 349 (50.8%)    |
| >120%                                                       | 14 (4.0%)      | 9 (2.7%)       | 23 (3.396)     |
| Dexamethasone(mg) relative dose intensity (%6)              |                |                |                |
| N                                                           | 365            | 364            | 729            |
| Mean (SD)                                                   | 82.61 (20.345) | 78.41 (21.087) | 80.51 (20.811) |
| Median                                                      | 90.71          | 84.21          | 87.44          |
| Range                                                       | (18.9; 154.5)  | (22.9; 110.7)  | (18.9; 154.5)  |
| Darahumumab (mg/kg) relative dose intensity (%6)            |                |                |                |
| N                                                           |                | 364            | 364            |
| Mean (SD)                                                   |                | 95.76 (10.452) | 95.76 (10.452) |
| Median                                                      |                | 98.36          | 98.36          |
| Range                                                       |                | (3.2; 107.0)   | (3.2; 107.0)   |
| Darahumumab (mg/kg) relntive dore intensity (Cycle 1-2, 96) |                |                |                |
| N                                                           |                | 364            | 364            |
| Mean (SD)                                                   |                | 90.74 (13.297) | 90.74 (13.297) |
| Median                                                      |                | 16'16          | 91.91          |
| Range                                                       |                | (3.2; 116.4)   | (3.2; 116.4)   |
| Danhumnmnb (mg/kg) relntive dose intensity (Cycle 3-6. 96)  |                |                |                |
| N                                                           |                | 345            | 345            |
| Mean (SD)                                                   |                | 99.40 (7.531)  | 99.40 (7.531)  |
| Median                                                      |                | 100.76         | 100.76         |
| Range                                                       |                | (48.8; 111.7)  | (48.8; 111.7)  |
| Darahumumab (mg/kg) relative dose intensity (Cycle ≥7, %6)  |                |                |                |
| N                                                           |                | 327            | 327            |
| Mean (SD)                                                   |                | 99.81 (4.015)  | 99.81 (4.015)  |
| Median                                                      |                | 100.00         | 100.00         |
| Range                                                       |                | (71.2; 110.1)  | (71.2; 110.1)  |

<div style=\"page-break-after: always\"></div>

|                                                       | Rd             | DRd            | Total          |
|-------------------------------------------------------|----------------|----------------|----------------|
|                                                       | n(%)           | n(%)           | n(%)           |
| Analysisset:safety                                    | 365            | 364            | 729            |
| Lenalidomide(mg)relative dose intensity(%)            |                |                |                |
| N                                                     | 348            | 339            | 687            |
| Mean(SD)                                              | 83.49 (29.371) | 73.56(29.671)  | 78.59 (29.913) |
| Median                                                | 91.43          | 76.22          | 84.54          |
| Range                                                 | (4.8;234.2)    | (7.9;240.9)    | (4.8;240.9)    |
| Category,n (%)                                        |                |                |                |
| 80%                                                   | 134(38.5%)     | 181(53.4%)     | 315(45.9%)     |
| ≥80%-≤120%                                            | 200 (57.5%)    | 149 (44.0%)    | 349(50.8%)     |
| >120%                                                 | 14(4.0%)       | 9(2.7%)        | 23(3.3%)       |
| Dexamethasone(mg)relativedoseintensity(%)             |                |                |                |
| N                                                     | 365            | 364            | 729            |
| Mean(SD)                                              | 82.61(20.345)  | 78.41 (21.087) | 80.51 (20.811) |
| Median                                                | 90.71          | 84.21          | 87.44          |
| Range                                                 | (18.9;154.5)   | (22.9;110.7)   | (18.9;154.5)   |
| Daratumumab(mg/kg)relative doseintensity(%)           |                |                |                |
| N                                                     |                | 364            | 364            |
| Mean (SD)                                             |                | 95.76(10.452)  | 95.76(10.452)  |
| Median                                                |                | 98.36          | 98.36          |
| Range                                                 |                | (3.2;107.0)    | (3.2;107.0)    |
| Daratumumab(mg/kg)relative doseintensity（Cycle1-2.%)  |                |                |                |
| N                                                     |                | 364            | 364            |
| Mean(SD)                                              |                | 90.74 (13.297) | 90.74(13.297)  |
| Median                                                |                | 1616           | 1616           |
| Range                                                 |                | (3.2:116.4)    | (3.2;116.4)    |
| Daratumumab(mg/kg)relative dose intensity（Cycle3-6,%) |                |                |                |
| N                                                     |                | 345            | 345            |
| Mean(SD)                                              |                | 99.40 (7.531)  | 99.40 (7.531)  |
| Median                                                |                | 100.76         | 100.76         |
| Range                                                 |                | (48.8;111.7)   | (48.8;111.7)   |
| Daratumumab(mg/kg)relative dose intensity（Cycle≥7,%)  |                |                |                |
| N                                                     |                | 327            | 327            |
| Mean(SD)                                              |                | 99.81(4.015)   | 99.81 (4.015)  |
| Median                                                |                | 100.00         | 100.00         |
| Range                                                 |                | (71.2;110.1)   | (71.2;110.1)   |

<div style=\"page-break-after: always\"></div>

## Adverse events

Table 17: Overview of TEAEs; SAS

|                                                    | Rd (%)       | DRd (%)       |
|----------------------------------------------------|--------------|---------------|
| Amalysis set: safety                               | 365          | 364           |
| Any TEAE                                           | 362 (99.296) | 364 (100.0%6) |
| Maximum toxicity grade                             |              |               |
| Gde 1                                              | 6 (1.6%6)    | 0             |
| Grade 2                                            | 53 (14.596)  | 35 (9.6%6)    |
| Gmde 3                                             | 200 (54.896) | 206 (56.696)  |
| Grade4                                             | 80 (21.996)  | 98 (26.9%)    |
| Grade 5                                            | 23 (6.396)   | 25 (6.9%6)    |
| Any serious TEAE                                   | 229 (62.796) | 229 (62.996)  |
| TEAE leading to discondinuation of lenalidomide    | 62 (17.0%)   | 76 (20.9%)    |
| TEAE leading to discondnuation of dexamethasone    | 95 (26.096)  | 88 (24.2%6)   |
| TEAEleading to disconrinuation of daratummab       | 0            | 30 (8.296)    |
| TEAE leading to divcontinualion of shudy treabnent | 58 (15.996)  | 26 (7.196)    |

Key: Rd= lenalidomide-dexamethnvone: DRd = daratumwmab-lenalidomide-dexamethasone: TEAE = trealment-emergent adverse event.

* Includes those subjects indicnted ns having discontinued treatment due to an ndverse event ou the end of treatment CRF

page.

Note: Adverse events sre reported using MedDR A vension 20.0.

Note: Percentages are calculated with the number of subjects in each group as denominator.

Note: Dexamethasone is for dexamethnsone or egwiwlent

Modifed fom [TSFAE01.RTF] (INI-54767414IMMY3008IDBR\\_CSRIRE\\_CSRIPRODTSFAE01.SAS] 26NOV2018, 18:26

<div style=\"page-break-after: always\"></div>

## Common AEs

## Table 18: Most common (at least 10%) TEAEs

|                                                        | Rd                      | DRd                     |
|--------------------------------------------------------|-------------------------|-------------------------|
|                                                        | n(%)                    |                         |
| Analysis set safety Total number of subjects with TEAE | 365 362 (99.2%)         | 364 364 (100.0%)        |
| MedDRAsystem orpan clasw/prefemed tem                  |                         |                         |
| Infectons and infestatons                              | 268 (73.4%)             | 314 (86.3%)             |
| Bronchitis                                             | 74 (20.3%)              | 106 (29.1%)             |
| Upper respiratory tract infection                      | 52(14.2%)               | 83 (22.8%)              |
| Paeumoma                                               | 46 (12.6%6)             | 82 (22.5%)              |
| Urinary tact infection                                 | 38 (10.4%6)             | 64 (17.6%)              |
| Viral upper respiratory toct infection                 | 46(12.6%)               | 56 (15.4%)              |
| Gastrountestinal disorden                              | 290(79.5%)              | 311 (85.4%)             |
| Diarrhoea                                              | 168 (46.0%6)            | 207 (56.9%)             |
| Constipation                                           | 130 (35.696)            | 149 (40.9)              |
| Nausea                                                 | 84 (23.0%6)             | 115 (31.6%)             |
| Vomiting                                               | 45 (12.3%)              | 61(16.8%)               |
| Abdominal pain                                         | 33 (9.0%)               | 43 (11.5%)              |
| General disordens and administration site conditions   | 269 (73.7%)             | 311 (85.4%)             |
| Fatigue                                                | 104 (28.59%)            | 147 (40.4%)             |
| Oedema peripheral                                      | 107 (29.3%)             | 140 (38.5%)             |
| Asthenia                                               | 90 (24.7%)              | 117 (32.19)             |
| Pyrexis                                                | 65 (17.8%6)             | 84 (23.1%)              |
| Chills                                                 | 6(1.6%)                 | 46 (12.6%6)             |
| Musculoskeletal and connective tissue disorders        | 256(70.1%)              | 286(78.6%)              |
| Back pain Muscle spasms                                | 96 (26.3%6) 79 (21.6%6) | 123 (33.8%) 107 (29.4%) |
| Arthralga                                              | 64(17.5%)               | 70 (19.2%)              |
| Pain in extemuty Musculoskeletal pain                  | 50 (13.7%6) 40 (11.0%)  | 60(16.5%) 51 (14.0%6)   |
| Bope pain                                              | (%66）9                  | 37 (10.2%)              |
| Musculoskeletal chest pain                             | 43 (11.8%)              | 27 (7.49)               |
| Blood and lymphatic system disorders                   | 234 (64.1%%)            | 275 (75.5%)             |
| Neutropenia                                            | 154 (42.2%)             | 207 (56.9%)             |
| Ansemia                                                | 138(37.8%)              | 126 (34.696)            |
| Leukopenia                                             | 34 (9.3%)               | 68(18.7%)               |
| Thrombocytopenia                                       | 69 (18.9%)              | 68(18.7%6)              |
| Lymphopenia                                            | 45 (12.3%)              | 66(18.1%)               |
| Nervous system disordens                               | 234 (64.1%)             | 260 (71.4%)             |
| Penphenal sensory neuropathy                           | 54 (14.8%)              | 87 (23.9%)              |
| Dizziness                                              | 58 (15.9%)              | 69 (19.06)              |
| Headache                                               | 39 (10.7%6)             | 69 (19.0%)              |
| Panesthevia                                            | (C8）OE                  | 58 (15.9%)              |
| Tremor                                                 | 51 (14.0%)              | 57 (15.7%)              |
| Dysgeusia                                              | 35 (9.6%)               | 40 (11.0%)              |
| Respiratory.thoracicandmediastinal disorders           | 168 (46.0%)             | 243 (66.8%)             |
| Dyspnoea                                               | 56 (15.39%)             | 101 (27.7%0)            |
| Cough                                                  | 59 (16.2%)              | 100(27.5%)              |
| Metabolum and nutnton disorders                        | 175 (47.9%)             | 228 (62.6%)             |
| Decreased appetite                                     | 55 (15.1%)              | 80 (22.0%)              |
| Hypolalemia                                            | 61 (16.7%6)             | 75 (20.6%)              |
| Hyperglyeaemia                                         | 28 (7.7%)               | 50 (13.7%)              |
| Hvpocalcaemia                                          | 32 (8.8%)               | 50 (13.7%)              |
| Skin and subcutaneous tissue disorders                 | 186 (51.0%)             | 191 (52.59)             |
| Rash                                                   | 43 (11.8%)              | 57 (15.7%6) 179 (49.2%) |
| Psychiatric disordens                                  | 191 (52.3%)             |                         |
| Insomnia                                               | 107(29.39)              | 109 (29.9%) 166 (45.6%) |
| lavestigatons Weight decreaved                         | 116 (31.8%) 63 (17.3%)  | 101 (27.79)             |
| Vascular disorders                                     | 138(37.8%)              | 164 (45.1%)             |

<div style=\"page-break-after: always\"></div>

| Hypertension       | 26 (7.1%)   | 47 (12.9%)   |
|--------------------|-------------|--------------|
| Eye disorders      | 123 (33.7%) | 115 (31.6%)  |
| Cataract           | 59 (16.2%)  | 54 (14.8%)   |
| Cardiacdisorders   | 96 (26.3%)  | 100 (27.5%)  |
| Atrialfibrillation | 37 (10.1%)  | 23 (6.3%)    |

Key:Rd=lenalidomide-dexamethasone;DRd=daratumumab-lenalidomide-dexamethasone;TEAE=treatment-emergent adverseevent.

Note: Adverse events are reported using MedDRA version 20.0.

Note:Percentagesarecalculatedwith thenumberof subjectsineachgroupasdenominator.

[TSFAE02AA.RTF][JNJ-54767414MMY3008DBR\\_CSRIRE\\_CSRIPROD\\TSFAE02AA.SAS]26NOV2018,18:42

Table 19 : Grade 3/4 AEs

Table 22: Most Common (at Least 5%) Grade 3 or 4 Treatment-emergent Adverse Events by MedDRA System Organ Class, Preferred Term and Maximum Toxicity Grade; Safety Analysis Set (Study 54767414MMY3008)

| Analysis set: safety                                     | Total n (%) 365   | Rd Grade 3 n (%)       | Grade 4 n (%)   | Total n (%) 364   | DRd Grade 3 n (%)                 | Grade 4 n (%)   |
|----------------------------------------------------------|-------------------|------------------------|-----------------|-------------------|-----------------------------------|-----------------|
| Total number of subjects with toxicity grade 3 or 4 TEAE |                   |                        |                 |                   |                                   |                 |
| MedDRA system organ class/preferred term                 |                   |                        |                 |                   |                                   |                 |
| Blood and lymphatic system                               |                   |                        |                 |                   |                                   |                 |
| disorders                                                |                   | 189 (51.8%)142 (38.9%) |                 |                   | 47 (12.9%)224 (61.5%) 152 (41.8%) | 72 (19.8%)      |
| Neutropenia                                              | 129 (35.3%)       | 93 (25.5%)             | 36 (9.9%)       |                   | 182 (50.0%) 125 (34.3%)           | 57 (15.7%)      |
| Lymphopenia                                              | 39 (10.7%)        | 35 (9.6%)              | 4 (1.1%)        | 55 (15.1%)        | 42 (11.5%)                        | 13 (3.6%)       |
| Anaemia                                                  | 72 (19.7%)        | 72 (19.7%)             | 0               | 43 (11.8%)        | 43 (11.8%)                        | 0               |
| Leukopenia                                               | 18 (4.9%)         | 16 (4.4%)              | 2 (0.5%)        | 40 (11.0%)        | 35 (9.6%)                         | 5 (1.4%)        |
| Thrombocytopenia                                         | 32 (8.8%)         | 23 (6.3%)              | 9 (2.5%)        | 27 (7.4%)         | 20 (5.5%)                         | 7 (1.9%)        |
| Infections and infestations                              | 85 (23.3%)        | 64 (17.5%)             | 21 (5.8%)       | 117 (32.1%)       | 92 (25.3%)                        | 25 (6.9%)       |
| Pneumonia                                                | 29 (7.9%)         | 24 (6.6%)              | 5 (1.4%)        | 50 (13.7%)        | 45 (12.4%)                        | 5 (1.4%)        |
| Metabolism and nutrition disorders                       | 74 (20.3%)        | 54 (14.8%)             | 20 (5.5%)       | 75 (20.6%)        | 61 (16.8%)                        | 14 (3.8%)       |
| Hypokalaemia                                             | 32 (8.8%)         | 25 (6.8%)              | 7 (1.9%)        | 32 (8.8%)         | 28 (7.7%)                         | 4 (1.1%)        |
| Hyperglycaemia                                           | 14 (3.8%)         | 12 (3.3%)              | 2 (0.5%)        | 26 (7.1%)         | 22 (6.0%)                         | 4 (1.1%)        |
| Gastrointestinal disorders                               | 50 (13.7%)        | 45 (12.3%)             | 5 (1.4%)        | 60 (16.5%)        | 53 (14.6%)                        | 7 (1.9%)        |
| Diarrhoea                                                | 15 (4.1%)         | 15 (4.1%)              | 0               | 24 (6.6%)         | 24 (6.6%)                         | 0               |
| General disorders and                                    |                   |                        |                 |                   |                                   |                 |
| administration site conditions                           | 49 (13.4%)        | 44 (12.1%)             | 5 (1.4%)        | 58 (15.9%)        | 57 (15.7%)                        | 1 (0.3%)        |
| Fatigue                                                  | 14 (3.8%)         | 14 (3.8%)              | 0               | 29 (8.0%)         | 29 (8.0%)                         | 0               |
| Respiratory, thoracic and mediastinal disorders          | 35 (9.6%)         | 29 (7.9%)              | 6 (1.6%)        | 46 (12.6%)        | 40 (11.0%)                        | 6 (1.6%)        |
| Pulmonary embolism                                       | 19 (5.2%)         | 16 (4.4%)              | 3 (0.8%)        | 19 (5.2%)         | 17 (4.7%)                         | 2 (0.5%)        |
| Vascular disorders                                       | 29 (7.9%)         | 26 (7.1%)              | 3 (0.8%)        | 45 (12.4%)        | 41 (11.3%)                        | 4 (1.1%)        |
| Hypertension                                             | 13 (3.6%)         | 13 (3.6%)              | 0               | 24 (6.6%)         | 23 (6.3%)                         | 1 (0.3%)        |
| Eye disorders                                            | 34 (9.3%)         | 34 (9.3%)              | 0               | 28 (7.7%)         | 28 (7.7%)                         | 0               |
| Cataract                                                 | 29 (7.9%)         | 29 (7.9%)              | 0               | 26 (7.1%)         | 26 (7.1%)                         | 0               |

Key: Rd = lenalidomide-dexamethasone; DRd = daratumumab-lenalidomide-dexamethasone: TEAE = treatment-emergent adverse event.

Note: Adverse events are reported using MedDRA version 20.0.

Note: Percentages are calculated with the number of subjects in each group as denominator.

<div style=\"page-break-after: always\"></div>

Table 20 Number of Subjects with 1 or More Toxicity Grade 3 or 4 Treatment-emergent Adverse Events with difference of 2%  Higher in DRd treatment group, by MedDRA System Organ Class, Preferred Term and Maximum Toxicity Grade; Safety Analysis Set (Study 54767414MMY3008)

|                                                          | Rd          | Rd            | Rd            | DRd         | DRd           | DRd           |
|----------------------------------------------------------|-------------|---------------|---------------|-------------|---------------|---------------|
|                                                          | Total n (%) | Grade 3 n (%) | Grade 4 n (%) | Total n (%) | Grade 3 n (%) | Grade 4 n (%) |
| Analysis set: safety                                     | 365         |               |               | 364         |               |               |
| Total number of subjects with toxicity grade 3 or 4 TEAE | 301 (82.5%) | 204 (55.9%)   | 97 (26.6%)    | 327 (89.8%) | 210 (57.7%)   | 117 (32.1%)   |
| MedDRA system organ class/preferred term                 |             |               |               |             |               |               |
| Blood and lymphatic system disorders                     | 189 (51.8%) | 142 (38.9%)   | 47 (12.9%)    | 224 (61.5%) | 152 (41.8%)   | 72 (19.8%)    |
| Neutropenia                                              | 129 (35.3%) | 93 (25.5%)    | 36 (9.9%)     | 182 (50.0%) | 125 (34.3%)   | 57 (15.7%)    |
| Lymphopenia                                              | 39 (10.7%)  | 35 (9.6%)     | 4 (1.1%)      | 55 (15.1%)  | 42 (11.5%)    | 13 (3.6%)     |
| Leukopenia                                               | 18 (4.9%)   | 16 (4.4%)     | 2 (0.5%)      | 40 (11.0%)  | 35 (9.6%)     | 5 (1.4%)      |
| Infections and infestations                              | 85 (23.3%)  | 64 (17.5%)    | 21 (5.8%)     | 117 (32.1%) | 92 (25.3%)    | 25 (6.9%)     |
| Pneumonia                                                | 29 (7.9%)   | 24 (6.6%)     | 5 (1.4%)      | 50 (13.7%)  | 45 (12.4%)    | 5 (1.4%)      |
| Metabolism and nutrition disorders                       | 74 (20.3%)  | 54 (14.8%)    | 20 (5.5%)     | 75 (20.6%)  | 61 (16.8%)    | 14 (3.8%)     |
| Hyperglycaemia                                           | 14 (3.8%)   | 12 (3.3%)     | 2 (0.5%)      | 26 (7.1%)   | 22 (6.0%)     | 4 (1.1%)      |
| Gastrointestinal disorders                               | 50 (13.7%)  | 45 (12.3%)    | 5 (1.4%)      | 60 (16.5%)  | 53 (14.6%)    | 7 (1.9%)      |
| Diarrhoea                                                | 15 (4.1%)   | 15 (4.1%)     | 0             | 24 (6.6%)   | 24 (6.6%)     | 0             |
| General disorders and administration                     |             |               |               |             |               |               |
| site conditions                                          | 49 (13.4%)  | 44 (12.1%)    | 5 (1.4%)      | 58 (15.9%)  | 57 (15.7%)    | 1 (0.3%)      |
| Fatigue                                                  | 14 (3.8%)   | 14 (3.8%)     | 0             | 29 (8.0%)   | 29 (8.0%)     | 0             |
| Respiratory, thoracic and mediastinal                    |             |               |               |             |               |               |
| disorders                                                | 35 (9.6%)   | 29 (7.9%)     | 6 (1.6%)      | 46 (12.6%)  | 40 (11.0%)    | 6 (1.6%)      |
| Dyspnoea                                                 | 4 (1.1%)    | 4 (1.1%)      | 0             | 12 (3.3%)   | 11 (3.0%)     | 1 (0.3%)      |
| Vascular disorders                                       | 29 (7.9%)   | 26 (7.1%)     | 3 (0.8%)      | 45 (12.4%)  | 41 (11.3%)    | 4 (1.1%)      |
| Hypertension                                             | 13 (3.6%)   | 13 (3.6%)     | 0             | 24 (6.6%)   | 23 (6.3%)     | 1 (0.3%)      |

Key: Rd = lenalidomide-dexamethasone; DRd = daratumumab-lenalidomide-dexamethasone; TEAE = treatment-emergent adverse event.

Note: Adverse events are reported using MedDRA version 20.0.

Note: Percentages are calculated with the number of subjects in each group as denominator.

## Drug-related TEAEs

The most frequently reported (≥20%) daratumumab -related TEAE, as assessed by the investigators, was neutropenia (26.4%). The most frequently reported lenalidomiderelated TEAEs (≥20% in either treatment group) in the DRd and Rd groups, respectively, were:

- Neutropenia (54.1% and 40.0%)
- Diarrhea (33.5% and 27.7%)
- Fatigue (29.9% and 21.4%)
- Anemia (23.6% and 26.6%)
- Constipation (18.7% and 20.3%)

The most frequently reported dexamethasonerelated TEAEs (≥20% in either treatment group) in the DRd and Rd groups, respectively, were:

Insomnia (25.5% and 24.4%) Peripheral oedema (20.3% and 15.3%).

A majority of Grade 3 or 4 TEAEs assessed as related to study treatment by the investigators were in the Blood  and  Lymphatic  system  disorders  SOC .  The  most  frequently  reported  (≥10%)  Grade  3  or  4 daratumumabrelated  TEAE  was  neutropenia  (21.2%).  The  most  frequently  reported  (≥10%  in  either

<div style=\"page-break-after: always\"></div>

treatment group) Grade 3 or 4 lenalidomide-related TEAEs in the DRd and Rd groups, respectively, were neutropenia (48.1% and 33.7%), anemia (7.1% and 13.7%), and lymphopenia (10.2% and 6.8%).

The most frequently reported Grade 3 or 4 dexamethasone-related TEAE was pneumonia (9.3% in the DRd group and 4.1% in the Rd group).

## Serious adverse event/deaths/other significant events

Table 21 : Deaths

|                                                                                | Rd n(96)   | DR.d (%6)   | Total (9   |
|--------------------------------------------------------------------------------|------------|-------------|------------|
| Anslysis set: safety                                                           | 365        | 19E         | 729        |
| Total number of subiects who died within 60 davs of firat shudytealmleatdoye   | 7 (1.996)  | 10 (2.796)  | 17 (2.396) |
| Primnrycnsofdeath                                                              |            |             |            |
| Adverse event                                                                  | (991)9     | 9 (2.596)   | 15 (2.1%)  |
| Disease progression                                                            | 0          | 1 (0.396)   | 1 (0.1%)   |
| Other                                                                          | 1 (0.3%)   | 0           | 1 (0.19%)  |
| Total nuumber of subjects who died within 30 days of last shudy treabmeut dose | 24 (6.696) | 25 (6.996)  | 49 (6.796) |
| Primnry cnuse of death                                                         |            |             |            |
| Advorwe event                                                                  | 22 (6.0%6) | (9669) 62   | 45 (6.296) |
| Disense progrewsion                                                            | 1 (0.396)  | 1 (0.396)   | 2 (0.396)  |
| Other                                                                          | 1 (0.3%6)  | 1 (0.396)   | 2 (0.396)  |

Key: Rd =lenalidomide-dexamethasone; DRd = daratumwmab-lenalidomide-dexametbssone.

<div style=\"page-break-after: always\"></div>

Table 22: TEAEs with outcome Death

<!-- image -->

|                                                 |           | R.d ()       |                |                  | PaO ()           | PaO ()             |               |
|-------------------------------------------------|-----------|--------------|----------------|------------------|------------------|--------------------|---------------|
| Ansyvis wt afey                                 | Total 365 | Reliedto LEN | Relased to DEX | Total 364        | Relaed DARA      | Relaed toLEN       | Relatedto DEX |
| Totl oumber ofubjectu wih TeAE wih outcome denh |           |              |                | （）（DS（）StD9（DLC） |                  | 10                 | 3 (0.8)       |
| MedDRA sytem crpan clawpfend                    |           |              |                |                  |                  |                    |               |
| Cudiac dnorden                                  | 10 (2.7)  | 2 (0.596)    | (6EO)1         | 7(1.910)         |                  | 1(0.396)3(0.896)   |               |
| Acute myocardal iafarctee                       | 1(03)     |              | 0              | 1(0.396)         | 1(0.316)1(0.346) |                    | 0             |
| Arteriosclerosis coroaary anery                 |           |              |                | 1(0.3)           |                  | 1 (0.396)          |               |
| Crdiac falue acute                              | 0         |              | 0              | (EO)1            | 0                | 1(0.36)            | 0             |
| Crdinc amyleidonis                              | 1(03)     |              | 0              | 0                |                  |                    |               |
| Curdinc aet                                     | 2 (0.596) | (6EO)1       | 1(0.396)       |                  |                  |                    | 0             |
| Cudinc biue                                     | 1(03)     |              | 0              |                  | 0                |                    |               |
| Curdioreeic sbock                               | 1(034)    |              |                | 0                |                  |                    |               |
| Hypertesive beast diseave                       | 0         |              |                |                  | 0                |                    |               |
| Myocardinl infucnion                            | 3(0.00)   | 1(0.39)      | 0              | 1 (0.3%6)        |                  |                    |               |
| Myocardal iscbaemin                             | 1(03)     |              | 0              | 1 (0.396)        | 0                |                    | 0             |
| Lafections and infntadions                      | 61.)      | 3 (0.896)    | 3 (0.896)      | 8(2.296)         |                  | 3 (0.896)3 (0.896) | 3 (0.896)     |
| Neutopenk wpis                                  |           |              | 0              | (EO)1            |                  | 1(0.396)1(0.396)   | 0             |
| Nocardosis                                      |           |              |                |                  | 1(0.396)1(0.316) |                    | 1(0.3%5)      |
| Urosepsis                                       |           |              | 0              | 1 (0.36)         |                  | 1 (0.316)1(0.396)  | 1(0.3%)       |
| Klebuiella infecton                             |           |              | 0              |                  |                  |                    | 0             |
| Lower repinatory tract infecon                  |           |              | 0              | 1(0.396)         |                  |                    |               |
| Parumosis                                       | 3(0.80)   | 2 (0.590)    | 2 (0.596)      |                  |                  |                    | 1 (0.3%)      |
| Sapts                                           | 2(0.5)    |              |                | 0                |                  |                    |               |
| Saptic sbock                                    | 1(03%)    | (Eo)1        | 1 (0.396)      | (EO1             | 0                | 0                  |               |
| Neoplm balomalonst ed                           |           |              |                |                  |                  |                    |               |
| specifed (od cyit aed pohps)                    | 1(0.3%)   |              | 0              | 2 (0.596)        | (90)1            | (9650)2            |               |
| Adenocarcioms pastc                             |           |              | 0              |                  |                  | 1(0.396)           |               |
| Dittave larpe B-cell lympboma                   |           |              | 0              | 1(0.39)          | (0)1             | 1(0.396)           |               |
| Small cel logcaacer                             | 1(03)     |              |                | 0                |                  |                    |               |
| Nenvous system disordern                        | 0         |              |                | 3 (0.896)        |                  | 2(0.5%)            |               |
| Cerebronascuir accideat                         |           |              | 0              | 1(0.3%)          | 0                | 1(0.396)           |               |
| Haemonhapic stroke                              | 0         |              | 0              | 1(0.396)         |                  | 1(0.396)           |               |
| Hepatic eocepbnlopatby                          |           |              | 0              | 1(0.39)          |                  |                    | 0             |
| Gastrolntetiasl dserden                         | 2 (0.5)   |              | 1 (0.36)       | 0                |                  |                    |               |
| Gantrointestiaal haemorbape                     | 1(03%)    |              | 1 (0.3%6)      |                  | 0                | 0                  |               |
| Paeumopenitoorum                                | 1(0.3)    | 0            | 0              | 0                | 0                | 0                  |               |
| Graeral diworden and administadon               |           |              |                |                  |                  |                    |               |
| ie condinoas                                    | 3(0.0)    |              | 1(0.396)       |                  | 0                | 0                  | 0             |
| Geseral pbyical health                          | 2(0.5%6)  |              | 0              | 1 (0.3%6)        | 0                |                    | 0             |
| detenioraboa Muldple orp dyfmctioa syadrome     | 0         |              | 0              | 1(0.3%)          | 0                | 0                  |               |
| Sadden cardinc deah                             | 1(0.30)   | 1 (0.39)     | 1(0.396)       | 0                |                  | 0                  |               |
| Suddeo deno                                     |           | 心            | 0              |                  |                  |                    |               |
| Lajuy.podnoaiapasdprocedual                     |           |              |                |                  |                  |                    |               |
| compbcatioas                                    | 0         |              |                | 2(0.596)         | 0                |                    |               |
| Accident                                        |           |              | 0              | 1(0.3)           | 0                |                    |               |
| Subdunl boreutoon                               | 0         |              | 0              | 1 (0.396)        |                  |                    |               |
| Reptatory,borxcic and medimtinal                |           |              |                |                  |                  |                    |               |
| dierden                                         | 1(03)     |              |                |                  |                  |                    |               |
| Pulmoaury ebolim                                | 1(0.3%)   | 1(0.3)       | 0              | 0                | 0                |                    | 0             |

There were 3 Grade 5 TEAEs related to nervous system disorder that occurred in DRd subjects.

- One subject was a 79-year-old male with an ongoing medical history including hepatic cirrhosis and increased blood bilirubin levels. Several episodes of hyperammonemia were reported during the study.  The  investigator  considered  these  events  to  be  not  related  to  any  component  of  study treatment.

<div style=\"page-break-after: always\"></div>

On Study Day 416, a Grade 2 serious adverse event (SAE) of hepatic encephalopathy was reported. The investigator considered this event to be doubtfully related to daratumumab and lenalidomide, and not related to dexamethasone. The subject discontinued daratumumab on Study Day 407 and dexamethasone on Study Day 484 and continued lenalidomide monotherapy.

On Study Day 711, which was 304 days after the last daratumumab dose, 227 days after the last dexamethasone  dose,  and  6  days  after  the  last  lenalidomide  dose,  a  Grade  4  SAE  of  hepatic encephalopathy was also reported. The investigator considered this event to be not related to any component of study treatment.

On Study Day 717, the subject died due to Grade 5 hepatic encephalopathy. No autopsy was performed. The subject had last received the lenalidomide dose on Study Day 705, which was 298 days after the last daratumumab dose.

- A second subject was an 81-year-old male with an ongoing medical history including hypertension, type 1 diabetes mellitus, mitral valve incompetence, ventricular hypertrophy, and tobacco abuse and a prior medical history of infectious pneumonia. The subject was on prophylactic antithrombotic treatment (heparin calcium) from study entry. At diagnosis, 91% of the subject's bone marrow nucleated cells were plasma cells and platelet count at screening (Study Day -3) was 58×10 9 /L.

On Study Day 40, a Grade 3 SAE of pneumonia was reported and the subject was hospitalized. Treatment included amoxicillin/clavulanate (Augmentin), amoxicillin, and levofloxacin. The dose of dexamethasone was reduced to 20 mg from Study Day 50 due to the Grade 3 SAE of pneumonia and a Grade 2 nonserious adverse event of urinary tract infection.

Since Cycle 1 Day 1, the subject had intermittent Grade 3 thrombocytopenia that worsened to Grade 4 thrombocytopenia on Study Day 45. On Study Day 51, the subject died of Grade 5 hemorrhagic stroke in relation to Grade 4 thrombocytopenia (platelet count was 22×10 9 /L). The investigator considered the event of hemorrhagic stroke as probably related to lenalidomide, doubtfully related to daratumumab, and not related to dexamethasone. The subject had last received the lenalidomide dose on Study Day 45, and daratumumab and dexamethasone doses on Study Day 50.

- A third subject was a 76-year-old male with an ongoing medical history including atrial fibrillation and  hypertension  and  prior  medical  history  of  coronary  arterial  stent  insertion  and  myocardial infarction.

On Study Day 697, the subject underwent spinal surgery. During the hospitalization, the subject developed  an  arterial  embolism  of  the  lower  limb  and  Grade  4  SAEs  of  atrial  fibrillation, cerebrovascular accident, intestinal ischemia, multiple organ dysfunction syndrome, and peripheral ischemia. The investigator considered these events to be possibly related to lenalidomide and not related  to  daratumumab or prednisolone. On Study Day 710, the subject died due to Grade 5 cerebrovascular  accident.  An  autopsy  was  not  performed.  The  subject  had  last  received  the daratumumab, prednisolone, and lenalidomide dose on Study Days 686, 693, and 696, respectively.

All three subjects had contributing medical histories that predisposed them to the Grade 5 neurological events that occurred and therefore, it is difficult to isolate the impact that treatment had on the fatal neurologic events. The first subject had ongoing hepatic cirrhosis at the time of study entry which worsened while on study, but the subject had not received daratumumab for almost 10 months prior to the fatal event. The second subject had low bone marrow reserve and therefore, thrombocytopenia complicated treatment. The  final  subject  had  a  history  of  atrial  fibrillation  and  myocardial  infarction  prior  to  developing  a post-operative thrombotic event that cascaded to multi-organ dysfunction and a Grade 5 cerebrovascular accident.

Three  subjects  (0.8%)  in  the  DRd  group  died  due  to  treatment-emergent  hemorrhage  or  stroke.  Two subjects died due to hemorrhagic stroke and cerebrovascular accident. The remaining subject died due to subdural hematoma and is summarized below.

- The subject was a 63-year-old male who had an ongoing medical history of hypertension, type 2 diabetes mellitus chronic obstructive pulmonary disease, chronic kidney disease, depression, and prior medical history of smoking and alcohol use.

<div style=\"page-break-after: always\"></div>

On Study Day -10, a Grade 3 SAE of subdural hematoma occurred. On the same day, platele t function lab results showed an abnormal platelet function.

On Study Day 8, accidental head trauma was reported and the SAE of subdural hematoma worsened to Grade 4. The investigator considered this event to be not related to any of the study medications. The subject underwent a craniotomy on Study Day 8 and received a transfusion of 4 units of fresh frozen plasma. The subject died of subdural hemorrhage on Study Day 10. The subject had last received the daratumumab, lenalidomide, and dexamethasone doses on Study Days 1, 7, and 8, respectively.

One  subject  (0.3%)  in  the  Rd  group  died  due  to  TEAEs  related  to  hemorrhage  or  stroke  (due  to gastrointestinal hemorrhage).

- The subject was an 83-year-old white female who had an ongoing medical history of hypertension, hypercholesterolemia and had a prior medical history of bilateral pulmonary embolism.

The subject was on prophylactic antithrombotic treatment (tinzaparin sodium) from study entry.

On  Study  Day  51,  a  Grade  4  SAE  of  gastrointestinal  hemorrhage  was  reported.  An  upper gastrointestinal  endoscopy  showed  esophagitis  and  confirmed  the  diagnosis  of  gastrointestinal hemorrhage.  On  the  same  day,  the  subject  received  packed  red  blood  cell  transfusion  and esomeprazole.  The  investigator  considered  the  event  of  gastrointestinal  hemorrhage  to  be doubtfully related to lenalidomide and very likely related to dexamethasone. On Study Day 58, the subject  died  of  the  SAE  of  gastrointestinal  hemorrhage.  The  subject  had  last  received  the lenalidomide and dexamethasone dose on Study Days 50 and 51, respectively.

## Serious Adverse Events

Table 23: SAEs

|                                                     | Rd (6)       | DRd  (%6)    |
|-----------------------------------------------------|--------------|--------------|
| Anslysis set: afety                                 | 365          | 364          |
| Totl oumber of subjects with serious TEAE           | 229 (62.796) | 229 (62.946) |
| MedDRA system organ class/preferred temm            |              |              |
| Infections and infestations                         | 79 (21.6%)   | 120 (33.096) |
| Pueumonia                                           | 27 (7.496)   | 48 (13.296)  |
| Bronchitis                                          | 5 (1.4%)     | 12 (3.396)   |
| Influenza                                           | 6 (1.6%6)    | 11 (3.0%6)   |
| Lower respiratory tact infection                    | 11 (3.0%)    | 10 (2.796)   |
| Sepsis                                              | 7 (1.9%)     | 9 (2.5%)     |
| Urinary tact infection                              | 5 (1.49)     | 8 (2.296)    |
| Musculoskeletal and comnective tissue disorders     | 33 (9.0%6)   | 40 (11.0%6)  |
| Badk pain                                           | 8 (2.2%6)    | 12 (3.396)   |
| Gastrointestinal disorders                          | 35 (9.6%6)   | 39 (10.796)  |
| Dianhoea                                            | 6 (1.6%6)    | 9 (2.5%)     |
| Cardiac disorders                                   | 39 (10.7%6)  | 35 (9.6%6)   |
| Auisl fibrillation                                  | 12 (3.396)   | 8 (2.2%6)    |
| Cardiac failure                                     | 9 (2.5%)     | 5 (1.4%)     |
| Generl disorders and administration site conditions | 36 (9.996)   | 31 (8.596)   |
| Pyrexia                                             | 11 (3.0%)    | 16 (4.4%6)   |
| Geneml phywical hoalth deleriontion                 | 10 (2.796)   | 2 (0.5%)     |
| Respirstory, thoracic snd mediastinal disorders     | 29 (7.9%)    | 30 (8.296)   |
| Pulmonary embolism                                  | 14 (3.8%6)   | 11 (3.096)   |
| Renal and winary disorders                          | 23 (6.3%0)   | 22 (6.096)   |
| Acute kidney injury                                 | 14 (3.896)   | 11 (3.096)   |
| Vascular disorders                                  | 18 (4.9%)    | 19 (5.296)   |
| Deep vein thrombosis                                | 8 (2.296)    | 5 (1.498)    |
| Blood and lymphatic system disorders                | 23 (6.3%6)   | 18 (4.996)   |
| Febrile neutropenia                                 | 9 (2.5%)     | 9 (2.590)    |
| Anaemia                                             | 12 (3.396)   | 6(1.696)     |

<div style=\"page-break-after: always\"></div>

## Adverse Events of Special Interest (AESI)

## IRR

Infusion-related  reactions  (IRRs)  associated  with  daratumumab  administration  were  reported  in  149 subjects (40.9%) . The most frequently reported (≥5% of subjects) preferred terms for IRRs were dyspnea (9.3%), cough (7.4%), and chills (7.4%). Of the subjects with IRRs, most (139 of 149 subjects) had Grade 1 or 2 events; 2.5% of subjects had Grade 3 IRRs; 1 subject (0.3%) had a Grade 4 IRR; no Grade 5 IRR was reported. One subject discontinued treatment with daratumumab due to IRRs (preferred terms of Grade 4 hypertension and Grade 3 tachycardia, dyspnea, and non-cardiac chest pain).

Most subjects with an IRR experienced the IRR during the first infusion of daratumumab (146 of 149 subjects), a pattern consistent with previous daratumumab studies. Six (1.7%) and 14 subjects (3.9%) had an IRR during the second or subsequent infusions, respectively. Fifteen subjects (4.1%) experienced an IRR in more than 1 infusion.

The median onset time for IRRs was 90 minutes into the first infusion, 111 minutes for the second infusion, and 68.5 minutes for the subsequent infusions, which is consistent with previous daratumumab studies.

## Cytopenias

Table 24: Number of Subjects with 1 or more treatment emerged cytopenia AEs

|                                  | Al Godn        | GndeJo            | )   | Lendiap DI      | AI Gnd               | DR4 Gnde3or 4   | Lediap Grade5   |
|----------------------------------|----------------|-------------------|-----|-----------------|----------------------|-----------------|-----------------|
| Aolyh ut ufy                     | 345            |                   |     |                 |                      |                 |                 |
| Sebjeh waey tutme!               | 233 (6.1)      | 119 (51.81)       |     | 4(1.14)         | 273 (75.010)         | 220 (60.4)      | 1(03)2(05)      |
| MeDRA Pd Hneopah' Netopeah       | 154 (42.7) 154 | EL 059) 129 0530) |     | 1(03)           | 208 (57.196) 207     | (50.0*6)        | coreco1         |
| Fehrhonoopel                     | (42) 110.0)    | 11(.0)            |     | 1(03)           | (54.90) 11(.0)       | (50.06) 11 (.0) | 心               |
| Neatopak upu                     |                |                   |     |                 | o1                   |                 | 5co16co1        |
| Hebopeak alhcdea AoME            | 1(0.3) 139     | 1(0)              |     |                 | 127                  |                 |                 |
| AnMmla                           | (.1) 134       | 72 (19.76)        |     | 1(0.3)          | S)                   | 0(11.)          |                 |
|                                  | (37.51)        |                   |     |                 | 126 (.)              |                 |                 |
| Anma mscrocydc                   |                | 72 (19.76)        |     | 1(03)           |                      | 0(11.1)         |                 |
|                                  | 2(0.59)        | 1(0.3)            |     |                 | 1(0.3)               |                 | 心               |
| Mcrocyec aaMedn                  | 口              |                   |     |                 | 1(03%)               |                 | 1(035)          |
| Trembecytopeia\" Theoubecytepauln | P(L) P()       | 32() 3()          |     | 2(0.546) 2(0.5) | 68 (10.7) 68 (15.71) | 270.4 27 (0.)   | 10)             |
| Lyupbopaain\"                     | 45(12.3)       | 30(10.76)         |     |                 | 4 (L19)              | 55 (15.15)      |                 |
|                                  | 450230         | 39(10.710)        |     | 心               | 401                  | 55051)          | 心               |

Ky.R4oarldomide-deumAnvorDRdodnhumh-hulidemide-duerbnoerDhcdccolusoe: TeAE

NotAhu muehenpondoripMeDAwnie2o.o

Note Penceapge a be toal cohs nod toukciy pode cehun ce calcudwd uih be obr of ubjech ceated a cch

mootpm deoaimter

<div style=\"page-break-after: always\"></div>

## Secondary malignancies

Table 25 : Summary of Second Primary Malignancies

<!-- image -->

|                                   |           | DR        | Tol      |
|-----------------------------------|-----------|-----------|----------|
| Anabiu wet uadeey                 | 365       |           | 720      |
| Tealoumberofrbjectaidecoodpraunry | 26 (7.11) | 32 (1.%)  | 54(1.0)  |
| Caace gpel dkdioean-darivd om     |           |           |          |
|                                   | 130.00)   | 216.%)    | H(4.715) |
| Bodl ocaciooo                     | 122)      | 12 0.3)   | 20 (.71) |
| Sumoa coll crciaoea of dia        |           |           | 3(1.8)   |
| Boaeh dvae                        | 1(03)     | 3(0.80)   | 4(0.590) |
| Kentoncebomn                      | 1(035)    |           | 1(0.19)  |
| Porocucinoen                      |           | 1(0)      | 1(0.1)   |
| lnative Setd Mahparacy            | 11(.0%)   | 10 G.716) | 21G)     |
| Pretate caacer                    | 2(0.5)    | 2(0.5)    | 4(0.56)  |
| Adporiom ptnk                     | 1(03)     | 1(0.)     | 2(0)     |
| Adrsoorrcipomu ofcolca            |           | 1(0.)     | 1(01)    |
| Brast caaces                      | 1(0.3)    |           | 1(01)    |
| Breat aroplum                     |           | 1(0)      | 1(0.19)  |
| Colerkctl adraocarcisoma          |           | 10.)      | 1(0.19)  |
| Gmboatntonlotoplnm                | 1(0.3%)   |           | 1(0.1)   |
| Gaooat talno                      |           | 1(0.4)    | 1(011)   |
| Lvasive lebalar beemt caecioomn   |           | 1(0.3)    | 1(0.190) |
| Leoayoutrccen                     | 1(03%)    |           | 1(0.1)   |
| seehpe mvedor lenT                | 1(0.3)    |           | 1(0.19)  |
| Meapeea                           |           | 1(0.5)    | 1(0.1)   |
| Neuoeadocriaecncioeu ofdehia      | 1(03)     |           | 1(9.19)  |
| Pasceatic carcisomn               | 1(0.36)   |           | 1(011)   |
| Pasceatic carcisoa mrtststc       |           | 1(0.39)   | 1(0.19)  |
| Seall car cascer                  | 1(03)     |           | 1(0.1)   |
| Tnasicoaal cell carcisomn         | 1(03)     |           | 1(0.1)   |
| leatho HemuolopcMolpiacy          | 2(051)    | 2(0.)     | 4(0.50)  |
| Duheu lrpe B-ce lyapbomr          | 1(0.3%)   | 1(0.%)    | 2(0.396) |
| reqtqroopek                       |           | 1(0.3)    | 1(01)    |
| Mvlodnplnnc wndroo                | 103961    |           | 1(0.196) |

Ke. Rd-larlilomide drumrdoroor DRd-dantuumab-labidoaude-deumebatoen

## Haemorrhage

The incidence of hemorrhage events (all grades) was balanced across the 2 treatment groups (DRd: 29.4%, Rd: 26.3%) and the majority of events were Grades 1 or 2. One subject in the Rd group discontinued study treatment due to a TEAE of intracranial hemorrhage. Two subjects in the DRd group died due to TEAEs of hemorrhagic stroke and subdural hematoma and 1 subject in the Rd group died due to a TEAE of gastrointestinal hemorrhage.

Four subjects (1.1%) in the DRd group and 1 subject in the Rd group (0.3%) received fresh frozen plasma transfusions. The median time to first onset of hemorrhage events was similar between treatment groups, 31.0 and 29.1 weeks in the DRd and Rd groups, respectively. In both treatment groups, more subjects with hemorrhage events had the first onset during the first (Cycle 1-12) and second (Cycle 13-24) year with fewer first onset events occurring at year 3.

## Infections and Infestations

Overall, the incidence of infections and infestations was higher in the DRd group (86.3%) compared to the Rd group (73.4%). The difference was primarily driven by bronchitis (DRd: 29.1%, Rd: 20.3%), upper respiratory tract infection (DRd: 22.8%, Rd: 14.2%), pneumonia (DRd: 22.5%, Rd: 12.6%), and urinary tract infection (DRd: 17.6%, Rd: 10.4%).

The incidence of Grade 3 or 4 infections was higher in the DRd group (32.1%) compared with the Rd group (23.3%). This was largely due to a higher incidence of Grade 3 or 4 pneumonia in the DRd group (13.7%)

<div style=\"page-break-after: always\"></div>

compared with the Rd group (7.9%). Additionally, the incidence of serious TEAEs of infection were also higher in the DRd group (33.0%) compared with the Rd group (21.6%). This was also due to a higher incidence of serious TEAEs of pneumonia in the DRd group (13.2%) compared with the Rd group (7.4%). For all other Grade 3 or 4 and serious TEAEs of infection, the difference between treatment groups was &lt;2%.

Although infections were reported by a higher percentage of subjects in the DRd treatment group compared with the Rd treatment group, infections were manageable and rarely led to study discontinuation or death. Discontinuation of study treatments due to infection and infestation TEAEs was low in both groups; DRd group (2 subjects [0.5%]) and Rd group (5 subjects [1.4%]). Deaths due to infection were low and balanced between groups (DRd: 2.2%, Rd: 1.6%).

Among subjects in the DRd group who experienced Grade ≥3 pneumonia, 45 subjects had Grade 3, 5 subjects had Grade 4, and 2 subjects had Grade 5 pneumonia. One subject in the DRd group who died due to hemorrhagic stroke had ongoing Grade 3 pneumonia at the time of death. Among the subjects in the Rd group who experienced Grade ≥3 pneumonia, 24 subjects had Grade 3, 5 subjects had Grade 4, and 3 subjects had Grade 5 pneumonia.

The median time to first onset of treatment emergent infections and infestations was similar between treatment groups, 14.1 weeks and 13.6 weeks in the DRd and Rd groups, respectively.

## Viral Infections

The most frequently reported (≥2% in either treatment group) treatment emergent viral infections in the DRd and Rd groups, respectively, were viral upper respiratory infection (15.4% and 12.6%), influenza (9.3% and 5.8%), oral herpes (2.2% and 3.0%), and herpes zoster (1.4% and 3.6%).

The Grade 3 or 4 treatment-emergent viral infections were balanced across treatment groups (12 events in each group). In the DRd group influenza (8 subjects) was the only Grade 3 or 4 viral infection reported in more than 1 subject. In the Rd group influenza (8 subjects) and respiratory syncytial virus infection (2 subjects) were the only Grade 3 or 4 viral infections reported in more than 1 subject. One subject in the Rd group discontinued study treatment due to a TEAE of influenza . The review of TEAE viral infections is limited to those adverse events where a virus was identified and reported; it is possible that some infectious TEAEs are not classified as viral if the pathogen was not identified or reported.

Prophylactic antiviral therapy for herpes infection was administered to 65.2% of subjects in the DRd group and 45.5% of subjects in the Rd group. Systemic antiviral therapy (the majority of which was for prophylactic treatment) was administered to 69.8% of subjects in the DRd group and 52.3% of subjects in the Rd group. The median time to first onset of viral infections was longer in the DRd group (36.8 weeks) compared with the Rd group (32.4 weeks). In both treatment groups, a greater proportion of subjects with viral infections had the first onset during the first year (Cycle 1-12) with fewer first onset events occurring at year 2 or 3.

## Hepatitis B Reactivation

No subject in this study had reactivation of hepatitis B. Five subjects (4 in the DRd group and 1 in the Rd group) had baseline serologies consistent with prior exposure to hepatitis B, only 1 subject (DRd group) was HBSAg positive. Three subjects of the 5 subjects received prophylaxis against hepatitis B reactivation with either tenofovir (2 subjects in the DRd group) or lamivudine (1 subject in the Rd group).

## Opportunistic Infections

History of herpes virus infections was balanced across treatment groups, 15 subjects in each treatment group (preferred terms of herpes zoster, ophthalmic herpes zoster, oral herpes, genital herpes, herpes simplex).

<div style=\"page-break-after: always\"></div>

The most frequently reported (≥2% in eit her treatment group) opportunistic infections in the DRd and Rd groups, respectively, were oral candidiasis (4.1% and 5.2%), oral herpes (2.2% and 3.0%), and herpes zoster (1.4% and 3.6%). Five Grade 3 or 4 treatment-emergent opportunistic infections (cytomegalovirus viremia, nocardiosis, pneumocystis jirovecii infection, pneumocystis jirovecii pneumonia, and pulmonary mycosis) were reported for subjects in the DRd group and 1 Grade 3 or 4 treatment-emergent opportunistic infection (varicella zoster virus infection) for 1 subject in the Rd group. No individual Grade 3 or 4 opportunistic infection was reported in more than 1 subject. No subject discontinued study treatment due to an opportunistic infection. One subject in the DRd group died due to a TEAE of nocardiosis.

The median time to first onset of opportunistic infections was shorter in the DRd group (14.0 weeks) compared with the Rd group (21.6 weeks). In both treatment groups, most subjects with opportunistic infections had the first onset during the first year (Cycle 1-12) with few first onset events occurring at year 2 or 3.

Tumor Lysis Syndrome

There were no reports of tumor lysis syndrome in either treatment group during the study.

Intravascular Haemolysis

There were no reports of intravascular hemolysis in either treatment group during the study.

Treatment-emergent Interferences for Blood Typing

No subject had treatment-emergent interference for blood typing reported during the study.

## Other Adverse Events

## Thrombotic Events

The incidence of thrombotic events was balanced between the DRd and Rd groups. The occurrence of events by individual preferred terms were as follows:

- Deep vein thrombosis (DRd: 8.5%; Rd: 9.6%)
- Pulmonary embolism (DRd: 5.2%; Rd: 5.5%)

Prophylactic use of antithrombotic agents was balanced across the 2 treatment groups (DRd: 64.4%, Rd: 66.9%).

## Laboratory findings

## Table 26 : Haematology

<!-- image -->

|                                 |             |             |              |              |             | Rd Toxicity Grade, n (%) Toxicity Grade,n(%)   | Rd Toxicity Grade, n (%) Toxicity Grade,n(%)   | Rd Toxicity Grade, n (%) Toxicity Grade,n(%)   | Rd Toxicity Grade, n (%) Toxicity Grade,n(%)   | Rd Toxicity Grade, n (%) Toxicity Grade,n(%)   | Rd Toxicity Grade, n (%) Toxicity Grade,n(%)   | Rd Toxicity Grade, n (%) Toxicity Grade,n(%)   |
|---------------------------------|-------------|-------------|--------------|--------------|-------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Anslysis set: safery            | Total 365   | 0           | 1            | 2            |             |                                                | Total 364                                      | 0                                              | 1                                              | 2                                              |                                                |                                                |
| Hematology                      |             |             |              |              |             |                                                |                                                |                                                |                                                |                                                |                                                |                                                |
| WBC low (Leukopenia)            | 364 (99.7%) | 38 (10.4%)  | 123 (33.8%)  | 113 (31.0%)  | 74 (20.3%)  | 16 (4.4%)                                      | 362 (99.5%)                                    | 15 (4.1%)                                      | 78 (21.5%)                                     | 141 (39.0%)                                    | 109 (30.1%)                                    | 19 (5.2%)                                      |
| Hemoglobin low (Anemia)         | 363 (99.5%) | 9(2.5%)     | 108 (29.896) | 157 (43.3%6) | 89 (24.5%)  | 0                                              | 362 (99.5%)                                    | 7(1.9%)                                        | 115 (31.8%6)                                   | 188 (%66 I9)                                   | 52 (14.4%6)                                    | 0                                              |
| Platelets low(Thrombocytopenia) | 363 (99.5%) | 125 (34.4%) | 169 (46.696) | (8.0%)       | 27 (7.4%)   | 13 (3.6%)                                      | 362 (%%5'66)                                   | 95 (26.2%)                                     | 208 (57.59)                                    | 28 (7.7%)                                      | 21 (5.8%)                                      | 10 (2.8%)                                      |
| Neutrophilslow(Neutropenina)    | 362 (99.2%) | 69 (19.19%) | 52 (14.496)  | 96 (26.596)  | 106 (29.3%) | 39 (10.8%)                                     | 362 (99.5%)                                    | 25 (6.996)                                     | 47 (13.0%6)                                    | 83 (22.996)                                    | 144 (39.8%6)                                   | 63 (17.4%)                                     |
| Lymphocytes low (Lymphopenia)   | 362 (%7'66) | 77 (21.3%)  | 0            | 129 (35.6%6) | 135 (37.3%) | 21 (5.8%)                                      | 362 (%65'66)                                   | 51 (14.1%)                                     | 0                                              | 121 (33.49)                                    | 151 (41.7%6)                                   | 39 (%801)                                      |

Key:Rd=lenalidomide-dexamethasone:DRd=daratmumab-lenalidomide-dexamethasone:WBC=WhiteBlood Cell Note: The laboratory toxicity grades atre derived based on the NCI CTCAE (National Cancer Imstiute Common Temminology Cnteria for Adverse Events) Version 4.03. Grade 0 mesns nommal. Subjectsreported as Grnde O are subjects with nonmsl values or a Value in the opposite direchion (forlaboratory tests with bidirectional toxicities defined). Note: For ench parnmeter, the totnl column includes all subjects with available dntn at both baseline snd post-baseline, including those whose toxicity grnde did not worsen during treabment; parcenages in the total columm are calculated wich the mumber of teated subjects in each group as denominator. Percentages for toxicity grde columws are calcnated with the number of subjecis in the total colmm as denominator. For each subject and each parameter, the worst toxicity gade is selected

<div style=\"page-break-after: always\"></div>

## Table 27 : Chemistry

<!-- image -->

|                                       |              | Rd           | Rd                      | Rd          | Rd        | Rd             | DRd          | DRd          | DRd                      | DRd         | DRd        | DRd      |
|---------------------------------------|--------------|--------------|-------------------------|-------------|-----------|----------------|--------------|--------------|--------------------------|-------------|------------|----------|
|                                       |              |              | Toxicity Grade, n(%6) 1 | 2           |           |                | Total        | 0            | Toxicity Grade, n (%6) 1 | 2           |            |          |
| Analysis set: safety                  | 365          |              |                         |             |           |                | 364          |              |                          |             |            |          |
| Biochenisty ALThigh                   | 357 (97.8%6) | 235 (65.896) | 106 (29.796)            | 8(2.2%)     |           | 5(1.49)3(0.8%) | 355 (97.596) | 228 (64.296) | 107 (30.1%6)             | 11 (3.1%)   | 9 (2.5%)   | D        |
| ASThigh                               | 356 (97.5%)  | 265 (74.496) | 79 (22.296)             | 6 (1.7%)    | 5(1.4%)   | 1(0.3%)        | 355 (97.5%)  | 259 (73.0%6) | 87 (24.596)              | 5(1.4%)     | 4(1.1%)    | 0        |
| Crestinine high                       | 361 (%6*86)  | 183 (50.796) | 122 (33.8%6)            | 45 (12.5%)  | 11 (3.0%) | 0              | 358 (%+*36)  | 164 (45.8%)  | 136 (38.0%6)             | 45 (96971)  | 11 (3.1%)  | 2 (0.6%) |
| Sodim high(Hypemntremin)              | 352 (96.4%)  | 302 (85.896) | 49 (13.9%6)             | 0           | 1(0.3%)   | 0              | 350 (96.2%6) | 283 (80.996) | 63 (18.096)              | 1(0.3%)     | 2 (0.6%)   | 1 (0.3%) |
| Sodum low (Hyponstemia)               | 352 (96.4%)  | 203 (57.796) | 122 (34.7%)             | 0           | 25 (%1'D) | 2 (0.6%)       | 350 (96.29%) | 187 (53.4%)  | 131 (37.496)             | 0           | 30 (8.6%)  | 2 (0.6%) |
| Potassiumhigh(Hyperkalemia)           | 352 (96.496) | 250 (71.096) | 80 (22.796)             | 13 (3.7%)   | 8 (2.3%)  | 1 (0.3%)       | 348 (95.6%)  | 243 (69.896) | 89 (25.696)              | 10 (2.9%6)  | 5 (1.4%)   | 1(0.3%)  |
| Potassiumlow(Hypokalemia)             | 352 (96.4%)  | 217 (61.696) | 0                       | t6 (26.7%)  | 32 (%1'6) | 9 (2.6%)       | 348 (95.696) | 196 (56.3%)  | 0                        | 106 (30.5%) | 42 (12.1%) | 4(1.1%)  |
| Bilinubin bigh                        | 357 (97.8%)  | 288 (80.7%6) | 42 (11.8%)              | 25 (%0'D)   | 1 (0.3%)  | 1 (0.3%)       | 356 (97.8%)  | 290 (81.5%)  | 40 (112%)                | 22 (6.2%)   | 4 (1.1%)   | 0        |
| Alkaline pbosphstase high             | 356 (97.5%)  | 210 (59.0%6) | 139 (39.0%6)            | 6 (1.7%)    | 1(0.3%)   | 0              | 353 (97.0%)  | 173 (49.0%6) | 162 (45.9%6)             | 14 (4.0%)   | 4(1.1%)    | 0        |
| Unicacid high(Hypenuricemia)          | 344 (94.2%)  | 267 (77.696) | 68 (%%86D)              | 0           | 0         | 9 (2.6%)       | 336 (92.39)  | 265 (%68L)   | 63 (18.8%6)              | 0           | 0          | 8 (2.4%) |
| Conecled calcium high (Hypercalcemia) | 362 (99.296) | 257 (71.096) | 88 (24.396)             | 8 (2.2%6)   | 3 (0.8%6) | 6 (1.796)      | 358 (98.4%)  | 277 (77.4%)  | 71 (19.896)              | 4 (1.1%)    | 4(1.1%)    | 2 (0.6%) |
| Corrected calcim low (Hypocalcemis)   | 362 (99.2%)  | 220 (60.896) | 85 (23.596)             | 45 (12.4%)  | 7(1.9%)   | 5(1.4%)        | 358 (98.4%)  | 142 (39.7%6) | 131 (36.6%6)             | 60 (968'91) | 18 (5.0%6) | 7 (2.0%) |
| Albuminlow(Hypoabumminemia)           | 361 (98.996) | 77 (21396)   | 134 (37.196)            | 137 (38.0%) | 13 (3.6%) | 0              | 358 (98.4%)  | 65 (18.296)  | 135 (37.796)             | 145 (40.5%) | 13 (3.6%)  | 0        |
| Glucose hizh (Hypergiycemia)          | 353 (96.796) | 325 (92.1%)  | 0                       | 0           | 26 (7.4%) | 2 (0.6%6)      | 341 (93.796) | 296 (86.8%)  | 0                        | 0           | 40 (11.7%) | 5(1.5%)  |
| Glucose low (Hypoglycemia)            | 353 (96.796) | 265 (75.196) | 81 (22.9%)              | 5 (1.4%)    | 1(0.39)   | 1 (0.3%6)      | 341 (93.796) | 266 (78.0%6) | 63 (18.596)              | 10 (2.996)  | 1 (0.3%)   | 1(0.3%)  |

Key.Rd=lennlidomide-dexnmethasone;DRd=daratmumsb-lenalidomide-dexamethasone;ALT=AlanineAminotansferase;AST=AspartateAminotransferase meant nonmal. Subjects reponed as Grade O are subjects with nonmal values or a value im the opposite direchon (for laboratory tests with bidirectional toxicifies defned). Note: For each parameter, the total colum includes all subjects with available data at both baseline and post-baseline, including those whose toxicity grade did not worsen curing treatment, percentages in the total cojumn are calculated with the number of treated subjects in esch group as denominator. Percentages for toxicity grade columms are calculated with the number of subjects in the total colmn as denominator.For each subject andench parameter, the worst toxicity grade is selected

## Table 28 : Vital signs

| Analysis set:safety                       | Rd 365        | DRd 364     |
|-------------------------------------------|---------------|-------------|
| Maximum Weight loss from bsseline, n (%6) |               |             |
| 5-≤10%                                    | 92 (25.29)    | 105 (28.8%) |
| 10-209                                    | 100 (27.49%%) | 101 (27.79) |
| =20%                                      | 24 (6.696)    | 19 (5.2%)   |

Key:Rd=lenalidomide-dexamethasone:DRd=darahmwumab-lenalidomide-dexamethasone.

Note: Percenteges calculated with the number of subjects in each treamment group as denominator.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Table 29 : Age

Overview of Treatment emergent Adverse Events by Age - SAS

| Analysis set safery                               | <75years 206   | Rd (）u ≥75years 159   | Total 365   | 75years 207   | DRd n (%) ≥75years 157   | Total 364   |
|---------------------------------------------------|----------------|-----------------------|-------------|---------------|--------------------------|-------------|
| Any TEAE                                          |                |                       |             |               |                          | 364         |
|                                                   | 203 (98.5%)    | 159 (100.0%)          | 362(99.2%)  | 207(100.0%)   | 157(100.0%)              | (100.0%)    |
| At least one related\"                             | 192 (93.2%)    | 153 (96.2%)           | 345(94.5%)  | 205 (99.0%)   | 156 (99.4%)              | 361(99.2%)  |
| Maximum toxicity grade                            |                |                       |             |               |                          |             |
| Grade 1                                           | 5(2.4%)        | 1(0.6%)               | 6(1.6%)     | 0             | 0                        | 0           |
| Grade2                                            | 37(18.0%)      | 16(10.1%)             | 53(14.5%)   | 27(13.09)     | 8 (5.1%)                 | 35(9.6%)    |
| Grade3                                            | 113 (54.9%)    | 87(54.7%)             | 200(54.8%)  | 119 (57.5%)   | 87(55.4%)                | 206(56.6%)  |
| Grade4                                            | 38(18.4%)      | 42(26.4%)             | (%1)08      | 51(24.6%)     | 47(29.9%)                | 98 (26.9%)  |
| Grades                                            | 10 (4.9%)      | 13 (8.2%)             | 23(6.3%)    | 10 (4.8%)     | 15 (9.6%)                | 25(6.9%)    |
| Any serious TEAE                                  | 117 (56.8%)    | 112(70.4%)            | 229 (62.7%) | 126(60.9%)    | 103(65.6%)               | 229 (62.9%) |
| At least one related                              | 69 (33.5%)     | 72(45.3%)             | 141(38.6%)  | 80 (38.6%)    | 68(43.3%)                | 148 (40.7%) |
| TEAE leading to discontinuation of                |                |                       |             |               |                          |             |
| lenalidomide                                      | 27 (13.1%)     | 35 (22.0%)            | 62 (17.0%)  | 30 (145%)     | 46 (29.3%)               | 76 (20.9%)  |
| At least one related to lenalidomide              | 20 (9.7%)      | 24 (15.1%)            | 44 (12.1%)  | 26(12.6%)     | 34 (21.7%)               | 60 (16.5%)  |
| TEAE leading todiscontinuation of                 |                |                       |             |               |                          |             |
| devamethasone                                     | 45 (21.8%)     | 50 (31.4%)            | 95 (26.0%)  | 46 (22.2%)    | 42(26.8%)                | 88(242%)    |
| At least one related to dexamethasone             | 22 (10.7%)     | 26 (16.4%)            | 48 (13.2%)  | 40 (193%)     | 22 (14.0%)               | 62 (17.0%)  |
| TEAEleading todiscontinuation of daratumumab      | 0              | 0                     | 0           | 12 (5.8%)     | 18 (11.5%)               | 30(8.2%)    |
| At least one related to daranmmab                 | 0              | 0                     | 0           | 8(3.9%)       | 7(4.5%)                  | 15(4.1%)    |
| TEAE leadingto discontinuationof study treatusenr | 25 (12.19)     | 33(20.8%)             | 58(15.9%)   | 10 (4.8%)     | 16(10.2%)                | 26(7.19)    |

Key:Rd =lenalidomide-dexamethasone:DRd =daratumamab-lenalidomide-dexamethasone:TEAE=treatment-energent adverse event.

Inciudes those subjects indicated as having discontinued treatment due to an adverse event on the end of treatment CRF page.

TEAEs related to at least 1 of the 3 components of study treatuent:lenalidomide,dexamethasone or daratumumab.

Note:Devamethasoneis fordevamethasone orequivalent.

Note:Adverse events are Ieported usingMedDRAversion20.0.

Note:Percentages in the total column were calculated with the mumberof subjects im eachzroup as denominator.Percenta zes of subzroups were calculated with thenumberofsubjects ineach subgroup as denoninator.

<div style=\"page-break-after: always\"></div>

Table 30 : Sex

| TSFAE01D: Overview of Treatment-emergent Adverse Erents by Sex; Safety AnalysisSet (Study 54767414AfMfY3008)   | TSFAE01D: Overview of Treatment-emergent Adverse Erents by Sex; Safety AnalysisSet (Study 54767414AfMfY3008)   | TSFAE01D: Overview of Treatment-emergent Adverse Erents by Sex; Safety AnalysisSet (Study 54767414AfMfY3008)   | TSFAE01D: Overview of Treatment-emergent Adverse Erents by Sex; Safety AnalysisSet (Study 54767414AfMfY3008)   | TSFAE01D: Overview of Treatment-emergent Adverse Erents by Sex; Safety AnalysisSet (Study 54767414AfMfY3008)   | TSFAE01D: Overview of Treatment-emergent Adverse Erents by Sex; Safety AnalysisSet (Study 54767414AfMfY3008)   | TSFAE01D: Overview of Treatment-emergent Adverse Erents by Sex; Safety AnalysisSet (Study 54767414AfMfY3008)   |
|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
|                                                                                                                |                                                                                                                | Rd n(%)                                                                                                        |                                                                                                                |                                                                                                                | DRd (%6)                                                                                                       | Total                                                                                                          |
|                                                                                                                | Male                                                                                                           | Female                                                                                                         | Total                                                                                                          | Male                                                                                                           | Feale                                                                                                          |                                                                                                                |
| Amalysis set: safery                                                                                           | 193                                                                                                            | 172                                                                                                            | 365                                                                                                            | 188                                                                                                            | 176                                                                                                            | 364                                                                                                            |
| Any TEAE                                                                                                       | 190 (98.4%)                                                                                                    | 172 (100.0%)                                                                                                   | 362 (99.296)                                                                                                   | 188 (100.0%)                                                                                                   | 176 (100.0%)                                                                                                   | 364 (100.0%)                                                                                                   |
| Atleast one related'                                                                                           | 178 (92.2%)                                                                                                    | 167 (97.1%)                                                                                                    | 345 (94.5%6)                                                                                                   | 187 (99.5%)                                                                                                    | 174 (98.9%)                                                                                                    | 361 (99.2%)                                                                                                    |
| Maximum toxicity grade                                                                                         |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |
| Grade 1                                                                                                        | 5 (2.696)                                                                                                      | 1 (0.6%)                                                                                                       | 6 (1.6%)                                                                                                       | 0                                                                                                              | 0                                                                                                              | 0                                                                                                              |
| Grade 2                                                                                                        | (%6601)17                                                                                                      | 32 (18.6%)                                                                                                     | 53 (14.5%)                                                                                                     | 18 (9.6%)                                                                                                      | 17 (9.7%)                                                                                                      | 35 (9.6%)                                                                                                      |
| Grade 3                                                                                                        | 115 (59.6%)                                                                                                    | 85 (49.496)                                                                                                    | 200 (54.8%)                                                                                                    | 98 (52.1%)                                                                                                     | 108 (61.4%)                                                                                                    | 206 (56.6%6)                                                                                                   |
| Grade 4                                                                                                        | 38 (19.7%)                                                                                                     | 42 (24.4%)                                                                                                     | (%610)08                                                                                                       | 51 (27.1%)                                                                                                     | 47 (26.7%)                                                                                                     | 98 (26.9%)                                                                                                     |
| Grade 5                                                                                                        | 11 (5.7%)                                                                                                      | 12 (7.0%)                                                                                                      | 23 (6.3%)                                                                                                      | 21 (11.2%)                                                                                                     | 4 (2.3%)                                                                                                       | 25 (6.9%)                                                                                                      |
| Any senous TEAE                                                                                                | 123 (63.7%)                                                                                                    | 106 (61.6%)                                                                                                    | 229 (62.7%6)                                                                                                   | 121 (64.4%6)                                                                                                   | 108 (61.4%)                                                                                                    | 229 (62.9%6)                                                                                                   |
| Atleast one related\"                                                                                           | 68 (35.2%)                                                                                                     | 73 (42.4%)                                                                                                     | 141 (38.6%)                                                                                                    | 80 (42.6%)                                                                                                     | 68 (38.6%)                                                                                                     | 148 (40.7%)                                                                                                    |
| TEAEleadingtodiscontinuationoflenalidomide                                                                     | 30 (15.5%)                                                                                                     | 32 (18.6%)                                                                                                     | 62 (17.0%)                                                                                                     | 40 (21.3%)                                                                                                     | 36 (20.5%)                                                                                                     | 76 (20.9%)                                                                                                     |
| Atleast onerelated tolenalidomide                                                                              | 18 (9.3%)                                                                                                      | 26 (15.1%)                                                                                                     | 44 (12.1%)                                                                                                     | 28 (14.9%)                                                                                                     | 32 (18.2%)                                                                                                     | 60 (16.5%)                                                                                                     |
| TEAE leading to discontinuation of                                                                             |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |
| dexamethasone                                                                                                  | 43 (22.3%)                                                                                                     | 52 (30.2%)                                                                                                     | 95 (26.0%)                                                                                                     | 45 (23.9%)                                                                                                     | 43 (24.4%)                                                                                                     | 88 (24.2%)                                                                                                     |
| At least one related to dexamethasone                                                                          | %60112                                                                                                         | 27 (15.7%)                                                                                                     | 48 (13.2%)                                                                                                     | 28 (14.9%6)                                                                                                    | 34 (19.3%)                                                                                                     | 62 (17.0%)                                                                                                     |
| TEAEleadingtodiscontinuation of                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |                                                                                                                |
| daratumumab                                                                                                    | 0                                                                                                              | 0                                                                                                              | 0                                                                                                              | 15 (8.0%)                                                                                                      | 15 (8.5%)                                                                                                      | 30 (8.2%)                                                                                                      |
| Atleastonerelatedtodaratumumab                                                                                 | 0                                                                                                              | 0                                                                                                              | 0                                                                                                              | 4 (2.1%)                                                                                                       | 11 (6.3%)                                                                                                      | 15 (4.1%)                                                                                                      |
| TEAEleadingtodiscontinuationofstudy treatment                                                                  | 27 (14.0%)                                                                                                     | 31 (18.0%)                                                                                                     | 58 (15.9%6)                                                                                                    | 13 (6.9%)                                                                                                      | 13 (7.4%)                                                                                                      | 26 (7.1%)                                                                                                      |

Key.Rd=lenalidomide-dexamethasone;DRd = daratumumab-lenalidomide-dexamethasone; TEAE = treatment-emergent adverse event.

Includes those subjects indicated as having discontinued treatment due to an adverse event on the end of trea mment CRF page.

TEAEs related to at least 1 of the 3 components of study treatment: lenalidomide, dexamethasone or daranumumab.

Note:Dexamethasone is for dexnmethasone orequivalent.

Note: Adverse events are reported using MedDRA version 20.0.

Note: Percentages in the total column were calculated with the number of subjects in each group as denominator. Percentages of subgroups were calculated with the number of subjectsineachsubgroup asdenominator.

Table 31 : Race

| TSFAE01E:Overview of Treatment-emergentAdverseEvents by Racey Safety AnalysisSet(Study 54767414NNIY3008)   | TSFAE01E:Overview of Treatment-emergentAdverseEvents by Racey Safety AnalysisSet(Study 54767414NNIY3008)   | TSFAE01E:Overview of Treatment-emergentAdverseEvents by Racey Safety AnalysisSet(Study 54767414NNIY3008)   | TSFAE01E:Overview of Treatment-emergentAdverseEvents by Racey Safety AnalysisSet(Study 54767414NNIY3008)   | TSFAE01E:Overview of Treatment-emergentAdverseEvents by Racey Safety AnalysisSet(Study 54767414NNIY3008)   | TSFAE01E:Overview of Treatment-emergentAdverseEvents by Racey Safety AnalysisSet(Study 54767414NNIY3008)   | TSFAE01E:Overview of Treatment-emergentAdverseEvents by Racey Safety AnalysisSet(Study 54767414NNIY3008)   |
|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
|                                                                                                            | White                                                                                                      | Rd (%) Other                                                                                               | Total                                                                                                      | White                                                                                                      | DRd (%) Other*                                                                                             | Total                                                                                                      |
| Analysis set: snfety                                                                                       | 335                                                                                                        | 30                                                                                                         | 365                                                                                                        | 334                                                                                                        | 30                                                                                                         | 364                                                                                                        |
| Any TEAE                                                                                                   | 332 (99.19)                                                                                                | 30 (100.0%)                                                                                                | 362 (99.296)                                                                                               | 334 (100.0%)                                                                                               | 30 (100.0%)                                                                                                | 364 (100.0%)                                                                                               |
| Atleast one related\"                                                                                       | 317 (94.6%)                                                                                                | 28 (93.3%)                                                                                                 | 345 (94.596)                                                                                               | 331 (99.1%)                                                                                                | 30 (100.0%)                                                                                                | 361 (99.296)                                                                                               |
| Maximum toxicity giade                                                                                     |                                                                                                            |                                                                                                            |                                                                                                            |                                                                                                            |                                                                                                            |                                                                                                            |
| Grade 1                                                                                                    | 5 (1.5%)                                                                                                   | 1 (3.3%)                                                                                                   | (%91) 9                                                                                                    | 0                                                                                                          | 0                                                                                                          | 0                                                                                                          |
| Grade 2                                                                                                    | 51 (15.29)                                                                                                 | 2 (6.7%)                                                                                                   | 53 (14.5%)                                                                                                 | 35 (10.596)                                                                                                | 0                                                                                                          | 35 (9.6%)                                                                                                  |
| Grade3                                                                                                     | 177 (52.8%)                                                                                                | 23 (76.7%)                                                                                                 | 200 (54.8%6)                                                                                               | 185 (55.4%)                                                                                                | 21 (70.0%)                                                                                                 | 206 (56.6%)                                                                                                |
| Grade 4                                                                                                    | 77 (23.0%)                                                                                                 | 3 (10.0%)                                                                                                  | 80 (21.9%)                                                                                                 | 92 (27.59)                                                                                                 | 6 (20.0%)                                                                                                  | 98 (26.9%6)                                                                                                |
| Grade 5                                                                                                    | 22 (6.6%)                                                                                                  | 1 (3.3%)                                                                                                   | 23 (6.3%)                                                                                                  | 22 (6.6%)                                                                                                  | 3 (10.0%)                                                                                                  | 25 (6.9%)                                                                                                  |
| Any serious TEAE                                                                                           | 213 (63.696)                                                                                               | 16 (53.396)                                                                                                | 229 (62.796)                                                                                               | 210 (62.9%)                                                                                                | 19 (63.3%)                                                                                                 | 229 (62.9%6)                                                                                               |
| Atleast one related\"                                                                                       | 133 (39.7%6)                                                                                               | 8 (26.7%)                                                                                                  | 141 (38.6%)                                                                                                | 132 (39.596)                                                                                               | 16 (53.3%)                                                                                                 | 148 (40.796)                                                                                               |
| TEAEleadingtodiscontinuationoflenalidomide                                                                 | 56 (16.7%6)                                                                                                | 6 (20.0%)                                                                                                  | 62 (17.0%)                                                                                                 | 69 (20.7%6)                                                                                                | 7 (23.3%)                                                                                                  | 76 (20.9%6)                                                                                                |
| Atleast one relsted tolennlidomide                                                                         | 40 (11.9%)                                                                                                 | 4 (13.3%)                                                                                                  | 44 (12.1%)                                                                                                 | 54 (16.2%)                                                                                                 | 6 (20.0%)                                                                                                  | 60 (16.5%6)                                                                                                |
| TEAEleading to discontinuation of                                                                          |                                                                                                            |                                                                                                            |                                                                                                            |                                                                                                            |                                                                                                            |                                                                                                            |
| dexamethasone                                                                                              | 86 (25.796)                                                                                                | 9 (30.0%)                                                                                                  | 95 (26.0%6)                                                                                                | 80 (24.0%)                                                                                                 | 8 (26.7%)                                                                                                  | 88 (24.2%)                                                                                                 |
| Atleast onerelated to dexnmethasone                                                                        | 43 (12.8%)                                                                                                 | 5 (16.7%)                                                                                                  | 48 (13.2%)                                                                                                 | 57 (17.1%)                                                                                                 | 5 (16.7%)                                                                                                  | 62 (17.0%)                                                                                                 |
| TEAEleading to discontinuation of                                                                          |                                                                                                            |                                                                                                            |                                                                                                            |                                                                                                            |                                                                                                            |                                                                                                            |
| dararumumab                                                                                                | 0                                                                                                          | 0                                                                                                          | 0                                                                                                          | 26 (7.8%)                                                                                                  | 4 (13.3%)                                                                                                  | 30 (8.2%)                                                                                                  |
| Atleast onerelated to darahummab                                                                           | 0                                                                                                          | 0                                                                                                          | 0                                                                                                          | 12 (3.6%)                                                                                                  | 3 (10.0%)                                                                                                  | 15 (4.1%)                                                                                                  |
| TEAE lesding to discontinuation of sudy trenmen                                                            | 52 (15.596)                                                                                                | 6 (20.0%)                                                                                                  | 58 (15.9%6)                                                                                                | 22 (6.6%6)                                                                                                 | 4 (13.39)                                                                                                  | 26 (7.1%)                                                                                                  |

Key: Rd= lenalidomide-dexamethasone;DRd=daratumumab-lenalidomide-dexamethasone;TEAE=treatment-emergent adverse event.

Inciudes those subjects indicated as having disconinued treatment due to an sdverse etent on the end of trea ment CRF page.

TEAEs related to atleast 1 of the 3 components of study treatment: lenalidomide, dexamethssone or daratumumab.

Note: Dexamethnsone is for dexamethasone or equivalent.

Note. Percentages in the total columm were calculated with the number of subjecls in each group as denominator. Percentages of subgroups Were calculated with the number of subjects in eech subgroup as denominator.

Note: Adverse events are reported using MedDRA version 20.0.

Inciudes subjects with race other than white, umknown or notreported.

<div style=\"page-break-after: always\"></div>

## Table 32 : Region

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 33 : Baseline renal function

| TSFAEolG:Overview of Treatmtat-mergentAdverse Ereat:by Baseine Resal(Creatinise Clearance)Fuaction StatusSafetyAaalytis Set (SudyE7674140An0S)   | TSFAEolG:Overview of Treatmtat-mergentAdverse Ereat:by Baseine Resal(Creatinise Clearance)Fuaction StatusSafetyAaalytis Set (SudyE7674140An0S)   | TSFAEolG:Overview of Treatmtat-mergentAdverse Ereat:by Baseine Resal(Creatinise Clearance)Fuaction StatusSafetyAaalytis Set (SudyE7674140An0S)   | TSFAEolG:Overview of Treatmtat-mergentAdverse Ereat:by Baseine Resal(Creatinise Clearance)Fuaction StatusSafetyAaalytis Set (SudyE7674140An0S)   | TSFAEolG:Overview of Treatmtat-mergentAdverse Ereat:by Baseine Resal(Creatinise Clearance)Fuaction StatusSafetyAaalytis Set (SudyE7674140An0S)   | TSFAEolG:Overview of Treatmtat-mergentAdverse Ereat:by Baseine Resal(Creatinise Clearance)Fuaction StatusSafetyAaalytis Set (SudyE7674140An0S)   | TSFAEolG:Overview of Treatmtat-mergentAdverse Ereat:by Baseine Resal(Creatinise Clearance)Fuaction StatusSafetyAaalytis Set (SudyE7674140An0S)   | TSFAEolG:Overview of Treatmtat-mergentAdverse Ereat:by Baseine Resal(Creatinise Clearance)Fuaction StatusSafetyAaalytis Set (SudyE7674140An0S)   | TSFAEolG:Overview of Treatmtat-mergentAdverse Ereat:by Baseine Resal(Creatinise Clearance)Fuaction StatusSafetyAaalytis Set (SudyE7674140An0S)   | TSFAEolG:Overview of Treatmtat-mergentAdverse Ereat:by Baseine Resal(Creatinise Clearance)Fuaction StatusSafetyAaalytis Set (SudyE7674140An0S)   | TSFAEolG:Overview of Treatmtat-mergentAdverse Ereat:by Baseine Resal(Creatinise Clearance)Fuaction StatusSafetyAaalytis Set (SudyE7674140An0S)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Asalhis t: safery                                                                                                                                | <0                                                                                                                                               | 3010c60 134                                                                                                                                      | R.4 () 500<90 167                                                                                                                                | 20 60                                                                                                                                            | Tecal 365                                                                                                                                        | <30                                                                                                                                              | 30c60                                                                                                                                            | DR4 () 60100 145                                                                                                                                 | 20                                                                                                                                               | Toa! 364                                                                                                                                         |
| Asy TEAE At lest ee reled\"                                                                                                                       | (100.09) 4 (100.0%)                                                                                                                              | EET (99.3%) 621 (96.3%6)                                                                                                                         | 165 (91.0) 154 (92.2)                                                                                                                            | 50 (100.0%) 58 (96.716)                                                                                                                          | 362 (99.2) 345 (94.596)                                                                                                                          | 7 （000D 7 (100.0)                                                                                                                                | 151 (100.0) 149 (98.76)                                                                                                                          | 145 (100.0%) 144 (99.396)                                                                                                                        | 51 (100.0%) 61 (100.0%)                                                                                                                          | 364 (100.09) 361 (9.2)                                                                                                                           |
| Maxies Doociy pad Gmdel Gade? Grde3                                                                                                              | 0 3 (75.0)                                                                                                                                       | 1(0.79) 15 (112) 77 (57.5%)                                                                                                                      | 4(2.4) 29 (17.44) ()                                                                                                                             | 1(1.7) 9(15.0*4) tf (517)                                                                                                                        | 6(1.0) 53 (14.56) 200 (54.5*6)                                                                                                                   | 0 221)                                                                                                                                           | 14(9.3%) H (55.9)                                                                                                                                | 18 (124) 87 (50.0*)                                                                                                                              | 3(.9) 33 (54.19)                                                                                                                                 | 0 35 (9.6) 206 (54.6)                                                                                                                            |
| Gnde 5 Aay senious TEAE                                                                                                                          | 1(25.0) 2 (50.0) 2 (54.05)                                                                                                                       | (224) 10 (7.5%) (65.796) 59                                                                                                                      | t(4.8%) 105 (62.9%6) 62 (7.1%)                                                                                                                   | (3.3) 5(13) 34 (56.796) 18                                                                                                                       | (21.946) 23 (6.3%) 229 (62.76) 141                                                                                                               | 3(42.9) 2GL 4(57.1) 3(29)                                                                                                                        | (27.8) 11(7.3%) H4 (62.396) 59 (39.15)                                                                                                           | (2.8) 7(4.) 91 (62.896) 56 (4.6)                                                                                                                 | (32.89) 5(1.2) 40 (65.6%) 30 (49.2%)                                                                                                             | (4.91a) 25 (5.9%) 229 (52.946) 148 (40.7%)                                                                                                       |
| Atlat ese nbid                                                                                                                                   |                                                                                                                                                  | (4.0)                                                                                                                                            |                                                                                                                                                  | (30.05)                                                                                                                                          | (4.6)                                                                                                                                            |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |
| TEAE leadng to dscourisutioa o leenlideeida Alt lenst epe nelated to leaabdomide                                                                 | 0                                                                                                                                                | 26 (19.4*) 19 (14.2)                                                                                                                             | 19 (114) 12(7.2%)                                                                                                                                | 17 GL) 13 (1.71)                                                                                                                                 | 62 (17.0) 4 (2.11)                                                                                                                               | 1(14.3) 0                                                                                                                                        | 40 (26.5%) 32 (2121)                                                                                                                             | 24 (16.6N) 21 (14.5)                                                                                                                             | 11 (18.0*) 7(1154)                                                                                                                               | 74 CO.Pa) 00 (16.5)                                                                                                                              |
| TEAE leading to dscoetis deumehaoaa At least eoe relned to dessmed TEAEladogo dsce dannumnmsb At lest ooe mbted to dantuss                       | 2 (50.06) 125.0) 0 0                                                                                                                             | (29.9) 22 (16.4)                                                                                                                                 | (9) 20 (12.0)                                                                                                                                    | 20 (3.3) 3(5) 0                                                                                                                                  | 95 (25.06) 4 (13.2) 0                                                                                                                            |                                                                                                                                                  | 37 (24546) 25 (16.6**)                                                                                                                           | 39 G26.946) 29 (20.0) 10 (5.946)                                                                                                                 | 12 (19.716) (13.19) 6(.) 3(4.90)                                                                                                                 | G4.2) (17.0*)                                                                                                                                    |
|                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  | 0                                                                                                                                                |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  | 14(9.3%) 5030                                                                                                                                    | 7(4.0                                                                                                                                            |                                                                                                                                                  | 30 (3.2) 15 (4.19)                                                                                                                               |
| TEAE lendingto dsccerisuucica ofsoudy                                                                                                            |                                                                                                                                                  | 26 (19.4%)                                                                                                                                       | 16(9.6)                                                                                                                                          | 16 (26.796)                                                                                                                                      | (15.946)                                                                                                                                         |                                                                                                                                                  | 12(7.9%).10 (5.96）4（5.66)26(0.1%)                                                                                                                |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |

Key.Rdleudoide-dmeoo,DRd=dnh uub-leanlidomide-dexxmechasooeTEAEtestmeal-emergeatadvene ereat

Lacades ose bects indicatedshaningdiscotiedtat doe tomadere eentoa eod efmest CRFpag

TEAEmatt1ee]c peeah efndy tueolet lendemil druorcon er dcanmub

Notn Fer Oe ebjec bo buwlsi saal foctee (Cntnioe Chrrocn) nun le a 3oLinGn vabon oe scalap viit as pte hnn No ml h

Note:Daumuduscoa is for deumtancor or equialeet

Note.Perceatages i be tol colu were calcdted wi e nwber ef sabjecs Laesdhpoup as desomiaator Perceaages ef subgoups wete caloabied wi be a ofubiechienchbpoupn deos

No:Adn sts e repned sia MedDrA ers20.0

<div style=\"page-break-after: always\"></div>

Table 34 : Baseline hepatic function

| TSFAEoiH: Overview of Treatneut-emergest Adverse Eveats by Bsseline Hepatic Functiou Status Safety Asalysis Set (Study 647674143A0Y5008)   | TSFAEoiH: Overview of Treatneut-emergest Adverse Eveats by Bsseline Hepatic Functiou Status Safety Asalysis Set (Study 647674143A0Y5008)   | TSFAEoiH: Overview of Treatneut-emergest Adverse Eveats by Bsseline Hepatic Functiou Status Safety Asalysis Set (Study 647674143A0Y5008)   | TSFAEoiH: Overview of Treatneut-emergest Adverse Eveats by Bsseline Hepatic Functiou Status Safety Asalysis Set (Study 647674143A0Y5008)   | TSFAEoiH: Overview of Treatneut-emergest Adverse Eveats by Bsseline Hepatic Functiou Status Safety Asalysis Set (Study 647674143A0Y5008)   | TSFAEoiH: Overview of Treatneut-emergest Adverse Eveats by Bsseline Hepatic Functiou Status Safety Asalysis Set (Study 647674143A0Y5008)   | TSFAEoiH: Overview of Treatneut-emergest Adverse Eveats by Bsseline Hepatic Functiou Status Safety Asalysis Set (Study 647674143A0Y5008)   |
|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                            |                                                                                                                                            | lupsted                                                                                                                                    | Tetl                                                                                                                                       |                                                                                                                                            | DRA (%)                                                                                                                                    | Teal                                                                                                                                       |
| Aaalysis wt: sadey                                                                                                                         | 334                                                                                                                                        | 29                                                                                                                                         | 365                                                                                                                                        |                                                                                                                                            | If                                                                                                                                         | 364                                                                                                                                        |
| Asy TEAE                                                                                                                                   |                                                                                                                                            | 29 (100.0%)                                                                                                                                | 142 (99.25)                                                                                                                                | 332 (100.0%)                                                                                                                               | 31 (100.0%)                                                                                                                                | 344 (100.0%)                                                                                                                               |
| At least eoe releted                                                                                                                       |                                                                                                                                            | 24 (94.6)                                                                                                                                  | H5 (H.5%)                                                                                                                                  | 329 (99.1%)                                                                                                                                | 31(100.0%)                                                                                                                                 | 31 (9.25)                                                                                                                                  |
| tedciy p                                                                                                                                   |                                                                                                                                            |                                                                                                                                            |                                                                                                                                            |                                                                                                                                            |                                                                                                                                            |                                                                                                                                            |
| Cesde1                                                                                                                                     |                                                                                                                                            |                                                                                                                                            | 6(1.N)                                                                                                                                     |                                                                                                                                            |                                                                                                                                            |                                                                                                                                            |
| Gesle2                                                                                                                                     | 51 (15.2)                                                                                                                                  | 2(69)                                                                                                                                      | 5(145%)                                                                                                                                    |                                                                                                                                            | 4(12)                                                                                                                                      | 15(.)                                                                                                                                      |
| Gede3                                                                                                                                      | 184 (54.8%)                                                                                                                                | 16(55.2)                                                                                                                                   | 200(54.8)                                                                                                                                  | 192 (57.89)                                                                                                                                | 14(45.2)                                                                                                                                   | 206(56.6)                                                                                                                                  |
| Gde4                                                                                                                                       | 71G11)                                                                                                                                     | 9GLO)                                                                                                                                      | $0G1.9)                                                                                                                                    | $7 G6.26)                                                                                                                                  | 10G2.5                                                                                                                                     | 快8(26.99)                                                                                                                                  |
| Gmde 5                                                                                                                                     | 21 (6.3)                                                                                                                                   | 2(6.9)                                                                                                                                     | 23 (6.3)                                                                                                                                   | 22(6.6)                                                                                                                                    | 3(9.7)                                                                                                                                     | 25 (6.9)                                                                                                                                   |
| Aay senious TEAE                                                                                                                           | 210 (62.5)                                                                                                                                 | 19 (65.5)                                                                                                                                  | (290622                                                                                                                                    | （%0E9）60C                                                                                                                                  | 20 (64.59)                                                                                                                                 | (96529)622                                                                                                                                 |
| At lest eoe seloted                                                                                                                        |                                                                                                                                            | 14(4%)                                                                                                                                     | 141(08.)                                                                                                                                   | 135 (40.7%)                                                                                                                                | 13(41.5)                                                                                                                                   | 148 (40.7%)                                                                                                                                |
| TEAE leing tsc ef lx At leant eon related to leuslsdemid                                                                                   | 55(16.4) 40(11.9*)                                                                                                                         | 4(13%)                                                                                                                                     | 620700 H(121)                                                                                                                              | 65 (19.0) 53(16.0%)                                                                                                                        | 1105.) 7220                                                                                                                                | 70(20.9) 60(16.5%)                                                                                                                         |
| TEAE lending to discorismtion ef                                                                                                           | 87 (25.9%)                                                                                                                                 | 8(27.)                                                                                                                                     |                                                                                                                                            |                                                                                                                                            |                                                                                                                                            | 88 (24.296)                                                                                                                                |
| dertmethnsone                                                                                                                              | 45(13.716)                                                                                                                                 | 2(654)                                                                                                                                     | 95 (26.0%) 41(3.2)                                                                                                                         | 80 (24.15) 57 (17.24)                                                                                                                      | 8(25.896) 5(6.1)                                                                                                                           | 62(17.04)                                                                                                                                  |
| Arlet co ledo deurnc                                                                                                                       | 0                                                                                                                                          |                                                                                                                                            |                                                                                                                                            |                                                                                                                                            |                                                                                                                                            |                                                                                                                                            |
| TEAE ledagscotis ef                                                                                                                        |                                                                                                                                            | 0                                                                                                                                          |                                                                                                                                            | 23 (6.9%)                                                                                                                                  |                                                                                                                                            | 30(1.2）                                                                                                                                    |
| At least coe elted to dat                                                                                                                  | 0                                                                                                                                          | 0                                                                                                                                          |                                                                                                                                            |                                                                                                                                            | 3(9.7)                                                                                                                                     | 15(4.1%)                                                                                                                                   |
| TEAE leulog e dscoarwtion ef sdy                                                                                                           | 51(15.2)                                                                                                                                   | 7G41)                                                                                                                                      | 580590                                                                                                                                     | 20 (6.0.)                                                                                                                                  | 60940                                                                                                                                      | 24 (.15)                                                                                                                                   |

Cy.Rd=ebdomd-demeasDRd =dantb-lebdod-decmeso TEAE =ett dvee eot

ppopp

TEAEreed  a lst1 of3 co otas of shsdy teiteat leanlidomide,deumthnoee er damnusumub

NotnDeunethasooe i for deumeasoce ot equivaleut

Note:Perceatages ia be totl cob ene calcsced wih be susber of vobjects is esch po n deateistor Paeceutape efvabproups wee calcdeed ih Ce wsber ef sabjech io eac subpoep e deocisstor opedap

| TEAE leadingto discontinuation of daratumumab    | 0          | 27 (14.29)   |
|--------------------------------------------------|------------|--------------|
| Atleastonerelated todaratumumab                  | 0          | 11 (5.8%)    |
| TEAE leadingtodiscontinuation of study treatment | 35 (18.5%) | 21 (11.19%)  |

Key.Rd =lenalidomide-dexamethasone; DRd = daratumumab-lenalidomide-dexamethasone; TEAE = treatment-emergent adverse event.

*Subjects considered mfit for transplant inclndes:subjects65years old with significant comorbidity or ECOG PS=2; subjects 65-74yearsold with ECOGPS=2;or subjects atleast75yearsold

TEAEs related to at least l of the 3 components of study teatnent: lenalidomide,dexamethasone or darahmumab.

Includes those subjects indicated as having discontinued treatment due to an adverse event on the end of treatment CRF page.

Note: Adverse events are reported using MedDR.A version 20.0.

Note:Percentages arecalculatedwith thenumber of subjecisineachgoup as denominator.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

Table 35 : No of subjects with 1 or more TEAEs leading to Discontinuation with a frequency of at least 1% in either treatment group

|                                                                                   | Rd             | Rd               | Rd          | DRd            | DRd              | DRd          |
|-----------------------------------------------------------------------------------|----------------|------------------|-------------|----------------|------------------|--------------|
|                                                                                   | All Grades (9) | Grade 3 or 4 (%) | Gmde 5 n(6) | All Gnades (%) | Grade 3 or 4 (9) | Grade 5 n(%) |
| Analysis set: safety                                                              | 365            |                  |             | +9E            |                  |              |
| Total nwmber of subjects with TEAE leading to discontiuuation of study treabment\" | 58 (15.9%6)    | 48 (13.296)      | 0           | 26 (7.196)     | 17 (4.7%6)       | 0            |
| MedDRA system orgon class/prefemred temm                                          |                |                  |             |                |                  |              |
| General disorders and administration site conditions                              | 7 (1.9%)       | 6 (1.6%)         | 0           | 5 (1.496)      | 1(0.3%)          | 0            |
| Fatigue                                                                           | 0              | 0                | 0           | 4 (1.1%)       | 1 (0.396)        | 0            |
| Asthenia                                                                          | 4 (1.1%)       | 4 (1.1%)         | 0           | 1 (0.396)      | 0                | 0            |

Key: Rd =leualidomide-dexamethnsoue: DRd = darahumwmnb-leualidomide-dexamethasone: TEAE = teatment-emerzent adverse event.

* Includes those subjects indicated as having discontinued trenbment due to an adverse event on the end of treatment CRF page.

Note: Adverse events are reported using MedDRA version 20.0.

Note: Percentages are calcuated with the number of subjects in each group as denominator.

## Post marketing experience

The proposed indication is not marketed.

## 2.6. Discussion on clinical safety

The evaluation of the DRd safety comes from one single pivotal phase 3 study. Overall, a significant number of patients have been exposed to a sufficient number of cycles of DRd for a substantial period of time. This should enable a thorough safety assessment of DRd.

In general, there are slightly more Grade 4 AEs in the DRd arm, 26.9% vs. 21.9%, and looking at common AEs there seems to be more AEs in the DRd arm across all SOCs. The higher number of AEs in DRd reflects the safety profile of daratumumab.

Overall, there are more Grade 3-4 AEs in the DRd arm. Looking at Grade 3-4 AEs a significant difference is seen in neutropenia, lymphopenia and leukopenia. This is also reflected in Grade 3 pneumonia, 12.4% vs. 6.6% in favour of Rd. There is no difference in terms of Grade 4 pneumonias. The higher risk of neutropenia and infections is known with daratumumab and is clearly reflected in sections 4.4 and 4.8 of the SmPC.

Looking at AEs judged to be drug-related by the investigators, differences were seen in terms of neutropenia, diarrhoea and fatigue.

There is no relevant difference in terms of deaths within 60 days of the first dose and within 30 days of the last dose. Overall, no differences could be seen in total number of deaths, 6.3% vs. 6.9%, Rd and DRd respectively.

Cytopenia is commonly associated with daratumumab, however, more importantly there were no relevant differences between Rd and DRd in terms of febrile neutropenia, neutropenic sepsis or neutropenic infection.

There are no significant differences in terms of Grade 3-4 viral infections. However, viral re-activation is a serious risk in relation to daratumumab. The SmPC clearly reflects that prophylaxis for herpes zoster should be considered. There has been cases of fatal hepatitis B reactivation in other studies. This issue is currently

<div style=\"page-break-after: always\"></div>

being addressed in a different procedure (EMEA/H/C/004077/II/0027).Opportunistic infections (Grade 3 or 4) were reported more frequently in the DRd group [5 subjects (cytomegalovirus viremia, nocardiosis, pneumocystis jirovecii infection, pneumocystis jirovecii pneumonia, and pulmonary mycosis)] than in the Rd group (1 subject: varicella zoster virus infection). No individual Grade 3 or 4 opportunistic infection was reported in more than 1 subject. No subject discontinued study treatment due to an opportunistic infection. One subject in the DRd group died due to a TEAE of nocardiosis. The median time to first onset of opportunistic infections was shorter in the DRd group (14 weeks) compared with the Rd group (21.6 weeks). In both treatment groups, most subjects with opportunistic infections had the first onset during the first year (Cycle 1-12) with few first onset events occurring at year 2 or 3.

More patients in the Rd arm discontinued treatment due to AEs, 15.8% vs 7.1%, however, many patients could continue daratumumab monotherapy despite AEs leading to discontinuation of the Rd.

Overall, the observed safety profile is as expected and in line with the safety profile of daratumumab.

## 2.6.1. Conclusions on clinical safety

Overall, the safety profile of DRd is worse than Rd. The additional toxicity clearly reflects the known safety profile of daratumumab. However, the majority of the AEs are clinically manageable, and no new safety findings were observed during this study.

## 2.6.2. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 6.2 is acceptable. In addition, minor revisions were recommended to be taken into account with the next RMP update.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 6.2 with the following content:

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                     |
|------------------------------|--------------------------------------------------------------------------------|
| Important identified risks   | Interference for blood typing (minor antigen) (positive indirect Coombs' test) |
| Important potential risks    | Tumour lysis syndrome Immunogenicity                                           |
| Missing information          | Use in pregnancy and lactation Reproductive and developmental toxicity         |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

| Study Status                                                                                                                                                                                                               | Summary of Objectives                                                                                                                                                                                                      | Safety Concerns Addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due Dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| Not applicable                                                                                                                                                                                                             |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| Not applicable                                                                                                                                                                                                             |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| RRA-19284: Survey of the effectiveness of the DARZALEX ® educational materials regarding the minimization of risk of interference of blood typing Ongoing                                                                  | To assess knowledge and understanding for handling interference with blood typing, in accordance with the educational materials.                                                                                           | Interference for blood typing (minor antigen) (positive indirect Coombs' test)                                                                                                                                             | Final report presented in the next PSUR after survey conclusion                                                                                                                                                            | 3 rd Quarter 2019                                                                                                                                                                                                          |
| Investigate new method for detecting antidrug antibodies Ongoing                                                                                                                                                           | Improve the immunogenicity method's ability to detect anti-daratumumab antibodies in the presence of high trough levels of daratumumab.                                                                                    | Immunogenicity                                                                                                                                                                                                             | Final report                                                                                                                                                                                                               | 4 th Quarter 2018                                                                                                                                                                                                          |

Key: PSUR = Periodic Safety Update Report.

## Risk minimisation measures

| Safety Concern                                                                 | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                            | Pharmacovigilance Activities                                                                                                                                                                                                                                                                         |
|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Interference for blood typing (minor antigen) (positive indirect Coombs' test) | Routine risk minimization measures: SmPC Section 4.4, which advises that patients should be typed and screened and phenotyping or genotyping be considered prior to starting daratumumab treatment; SmPC Sections 4.4, which advises HCPs to notify blood transfusion centers of this interference with indirect antiglobulin tests in the event of a planned transfusion; SmPC Section 4.4, which recommends that if | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: A guided targeted follow-up questionnaire to collect additional information concerning adverse events associated with interference and transfusion reactions. Additional pharmacovigilance activities: |

<div style=\"page-break-after: always\"></div>

| Safety Concern                 | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pharmacovigilance Activities                                                                                                                                                                                                                                                                     |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                | an emergency transfusion is required, non-cross-matched ABO/RhD compatible RBCs can be given per local blood bank practices; SmPC Section 4.5, which recommends to mitigate daratumumab interference by treating reagent RBCs with DTT to disrupt daratumumab binding or other locally validated methods, and that Kell negative units should be supplied after ruling out or identifying alloantibodies using DTT treated RBCs; PL Section 2, which instructs patients to inform the person doing the blood test to match blood type that they are receiving treatment with daratumumab. Additional risk minimization measures: Distribution of educational materials and Patient Alert Cards to HCPs and blood banks as described in the PL, in Annex II, D.                                                                                                                                                                    | Participation of targeted HCPs and blood banks in a survey to evaluate the effectiveness of educational materials distributed to raise awareness and understanding for handling interference for blood typing in accordance with the educational program. Final report due by 3 rd Quarter 2019. |
| Hepatitis B virus reactivation | Routine risk minimization measures: SmPC Section 4.4 and PL Section 2, which advise HBV screening before initiation of treatment with daratumumab and to monitor for clinical and laboratory signs of HBV reactivation during, and for at least 6 months following the end of daratumumab treatment for patients with evidence of positive HBV serology; SmPC Section 4.4, which advises to manage patients according to current clinical guidelines, and to consider consulting a hepatitis disease expert as clinically indicated; SmPC Section 4.4, which advises to suspend treatment with daratumumab and to institute appropriate treatment in patients who develop reactivation of HBV while on daratumumab. Resumption of daratumumab treatment in patients whose HBV reactivation is adequately controlled should be discussed with physicians with expertise in managing HBV; PL Section 2, which includes a warning to | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: None.                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Safety Concern                          | Risk Minimization Measures                                                                                                                                                                                                                                                        | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                              |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                         | patients with history or current HBV infection. SmPC Section 4.8 and PL Section 4, which lists hepatitis B virus reactivation (hepatitis) as an adverse reaction; Additional risk minimization measures: Distribution of a DHPC to HCPs who prescribe daratumumab.                |                                                                                                                                                                                                                                                                                                                                                                           |
| Immunogenicity                          | Routine risk minimization measures: SmPC Section 5.1, which describes results of evaluation and detection of anti-daratumumab antibodies in patients treated with daratumumab alone and patients treated with combination therapies. Additional risk minimization measures: None. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: Investigation of a new method for detecting antidrug antibodies to improve the immunogenicity method's ability to detect anti-daratumumab antibodies in the presence of high trough levels of daratumumab. Final report 4 th |
| Use in pregnancy and lactation          | Routine risk minimization measures: SmPC Section 4.6 and PL Section 2. Additional risk minimization measures: None.                                                                                                                                                               | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities:                                                                                                                                                                                                                              |
| Reproductive and developmental toxicity | Routine risk communication: SmPC Section 5.3. Additional risk minimization measures: None.                                                                                                                                                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None. Additional pharmacovigilance activities: None.                                                                                                                                                                                                                        |

Key: DHPC = Direct Healthcare Professional Communication; DTT = dithiothreitol; HBC = hepatitis B virus;

HCP = healthcare professional; PL = package leaflet; RBC = red blood cell; SmPC = Summary of Product Characteristics.

<div style=\"page-break-after: always\"></div>

## 2.8. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the current QRD template, which were accepted by the CHMP.

## 2.8.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The changes to the package leaflet are minimal and do not require user consultation with target patient groups.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Multiple myeloma (MM) is a malignant clonal plasma cells disorder, that represents approximately a 0.8% of all  cancers  worldwide  (Ferlay  2015).  The  proliferation  of  the  malignant  clonal  plasma  cells  leads  to subsequent  replacement  of  normal  bone  marrow  hematopoietic  precursors  and  overproduction  of M-proteins, progressive morbidity and eventual mortality. Characteristic MM hallmarks include osteolytic lesions,  anaemia  (due  to  bone  marrow  dysfunction),  increased  susceptibility  to  infections  (due  to immunosuppression), hypercalcemia, renal insufficiency/failure, and neurological complications (Palumbo 2011).

## 3.1.2. Available therapies and unmet medical need

Patients with newly diagnosed multiple myeloma are typically categorized into 2 subpopulations defined by their age and suitability for intensive treatment. For patients who are considered fit, an induction regimen followed by high-dose chemotherapy (HDT) and ASCT is considered the standard of care. For patients considered ineligible for HDT and ASCT due to their age, presence of comorbidities, and/or physical status, the treatment approach often favors longer, less intensive/toxic treatments, including most commonly a proteasome inhibitor, an immunomodulatory drug, and a corticosteroid in toxicity-adapted fashions.

## 3.1.3. Main clinical studies

The current submission is based on data from the Phase 3 study, MMY3008 (clinical cut-off, 10 June 2019). This study is a randomized, open-label, active controlled, parallel-group, multicentre study in subjects at least 18 years of age with newly diagnosed multiple myeloma who are ineligible for high dose chemotherapy and ASCT, to evaluate the efficacy (PFS) of DRd compared with Rd and to evaluate the safety/tolerability and clinical outcomes of DRd compared to Rd.

## 3.2. Favourable effects

- The  study  met  is  primary  endpoint  showing  a  statistically  significant  and  clinically  meaningful difference in favour of DRd (median PFS was not reached in DRd, but was 31.9 months in the Rd arm. HR (95% CI) = 0.56 (0.43, 0.73), p-value &lt; 0.0001).

<div style=\"page-break-after: always\"></div>

- Secondary  endpoints  (time  to  PD,  time  to  subsequent  therapy  and  PFS2)  all  show  consistent favourable effects, confirming the primary analysis.
- Across all response criteria DRd show statistically significant and clinically relevant results that confirm the primary analysis.
- The MRD negativity rate was 24.2% vs. 7.3% at 3 years in favour of DRd.

## 3.3. Uncertainties and limitations about favourable effects

OS data are immature. The MAH has committed to providing the final CSR post-authorisation.

Additionally, it should be noted that since the response rates in D-Rd are better, with a higher rate of CR and also with a greater depth of response (MRD negativity), continuing with a long-term maintenance treatment with daratumumab could be questioned, especially in those patients who achieve an optimal response. However, addressing this question would require a new clinical study, which is currently out of the scope of this application.

## 3.4. Unfavourable effects

In general, there are slightly more Grade 4 AEs in the DRd arm, 26.9% vs. 21.9%, and looking at common AEs there seems to be more AEs in the DRd arm across all SOCs. The higher number of AEs in DRd reflects the safety profile of daratumumab.

Looking at Grade 3-4 AEs, a significant increase with daratumumab is seen in neutropenia, lymphopenia and leukopenia. This is also reflected in Grade 3 pneumonia, 12.4% for DRd vs. 6.6% for Rd. There is no difference in terms of Grade 4 pneumonias. The higher risk of neutropenia and infections is known with daratumumab and is reflected in the SmPC.

Cytopenia is commonly associated with daratumumab; however, there were no relevant differences between Rd and DRd in terms of febrile neutropenia, neutropenic sepsis or neutropenic infection.

There are no significant differences in terms of Grade 3-4 viral infections. However, viral re-activation is a serious risk in relation to daratumumab. The SmPC clearly reflects that prophylaxis for herpes zoster should be considered. There have been cases of fatal hepatitis B reactivation in other studies. This issue is currently being addressed in a different procedure (EMEA/H/C/004077/II/0027).

## 3.5. Uncertainties and limitations about unfavourable effects

There are no major uncertainties or limitations about unfavourable effects.

## 3.6. Effects Table

Table 36 . Effects Table for DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone for the treatment of adult patients with NDMM who are ineligible for autologous stem cell transplant (data cut-off:10 June 2019)

| Effect             | Short description         | Unit               | Treat ment         | Contro l           | Uncertainties / Strength of evidence                              | References         |
|--------------------|---------------------------|--------------------|--------------------|--------------------|-------------------------------------------------------------------|--------------------|
| Favourable Effects | Favourable Effects        | Favourable Effects | Favourable Effects | Favourable Effects | Favourable Effects                                                | Favourable Effects |
| PFS                | Progression-free survival | months             | NE                 | 33.8               |                                                                   |                    |
|                    |                           | HR                 | 0.56               | 1                  | p-value <0.00001 HR = 0.56 (95% confidence interval (0.44, 0.71)) |                    |

<div style=\"page-break-after: always\"></div>

| Effect                 | Short description    | Unit                 | Treat ment           | Contro l             | Uncertainties / Strength of evidence   | References           |
|------------------------|----------------------|----------------------|----------------------|----------------------|----------------------------------------|----------------------|
| Unfavourable Effects   | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                   | Unfavourable Effects |
| Grade 4 AEs            |                      | %                    | 32.1%                | 26.6%                |                                        |                      |
| infections             |                      | %                    | 87.6%                | 76.4%                |                                        |                      |
| cytopenia (all grades) |                      | %                    | 77.2%                | 66.0%                |                                        |                      |

NE cannot yet be estimated

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

In Study MMY3008, DRd now showed clinically relevant improvements in terms of PFS and response rates in patients newly-diagnosed with a multiple myeloma who are ineligible for ASCT. These results are highly relevant in this population with a dismal prognosis. A sCR rate of 30.4% is clinically very encouraging.

Overall, the safety profile of daratumumab in combination with Rd seems generally consistent with the known safety profile of daratumumab and the respective combination agents and it seems to be manageable with dosing modifications, and is reasonably tolerated, as suggested by the relatively low proportion of discontinuations due to AEs.

## 3.7.2. Balance of benefits and risks

The B/R balance of DRd in the proposed patient population is considered positive, since the demonstrated benefits of DRd for the treatment of adult patients with NDMM that are ineligible for ASCT are considered to outweigh the toxicity of the combination, which is considered generally acceptable and manageable in the current clinical setting.

## 3.8. Conclusions

The overall B/R of Darzalex in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult

<div style=\"page-break-after: always\"></div>

patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT) for Darzalex; as a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP has been updated accordingly (finally agreed version 6.2). Furthermore, the Annex II is brought in line with the latest QRD template version 10.1.

The variation leads to amendments to the Summary of Product Characteristics, Annex II, Package Leaflet and to the Risk Management Plan (RMP).

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Darzalex is not similar to Imnovid (pomalidomide), Farydak (panabinostat), Kyprolis (carfilzomib) and Ninlaro (ixazomib) within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of indication in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT) for Darzalex; as a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP has been updated accordingly (finally agreed version 6.2). Furthermore, the Annex II is brought in line with the latest QRD template version 10.1. Furthermore, Annex II is brought in line with the latest QRD template version 10.1.

## Summary

Please refer to the Scientific Discussion Darzalex-H-C-4077-II-0029.